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Abstract 
Fibromyalgia syndrome (FMS), a common chronic pain condition, is often incompletely 
treated by conventional medical therapies. It can cause disability, psychological distress, 
work-related absenteeism, increased use of healthcare resources, and result in the 
inability to carry out the tasks of daily living. The purpose of this quantitative, 
correlational study was to investigate the potential influence of laughter on affect and 
pain in individuals with FMS. Laughter produces beneficial effects on acute pain and on 
chronic pain in general and has been found to improve temporary affective states, but 
there have been no studies testing the effects of laughter on the pain and affect of 
fibromyalgia patients. Informing this study were the gate control and neuromatrix 
theories of pain, as well as the dynamic model of affect theory. The research questions 
addressed whether laughter frequency is associated with affect and or with perceived 
chronic pain levels in these individuals. Forty-one adult fibromyalgia patients 
documented all laughter episodes daily and assessed their pain and affective states 3 
times per day for 14 days. Hierarchical regressions revealed that increased overall 
laughter frequency was significantly associated with decreases in overall pain and 
increases in overall positive affect but was not associated with measures of negative 
affect. Also, morning laughter frequency was predictive of increased afternoon and 
evening positive affect ratings, as well as with decreased afternoon pain ratings, but was 
not significantly associated with evening pain ratings. The knowledge gained from these 
results may have positive social change implications at the individual level, within those 
individuals’ larger social networks, and within the research and medical communities.  
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Chapter 1: Introduction to the Study  
Fibromyalgia syndrome (FMS) is a medical condition characterized by chronic 
musculoskeletal pain in multiple body regions and a set of other frequently occurring 
signs and symptoms. FMS is one of the most commonly observed pain conditions in 
medical settings and is thought to impact between 2% and 6% of people worldwide. This 
estimate includes roughly 10 million people in the United States alone (Lawrence et al., 
2008; National Fibromyalgia Association [NFA], 2009).   
The pain associated with FMS may move from site to site in the body and varies 
in its intensity (American College of Rheumatology [ACR], 2010; NFA, 2009). 
Individuals with FMS may show evidence of pain processing dysregulation and may also 
experience other symptoms such as fatigue, sleep disorders, or psychological distress 
(NFA, 2009). Also commonly observed with FMS are memory problems, cognitive 
dysfunction, and co-occurring disorders such as migraines or irritable bowel disorder. As 
of yet, researchers have not uncovered a particular cause for FMS, and there is no known 
cure. As such, medical treatments typically provide incomplete relief (ACR, 2010; NFA, 
2009). 
 If symptoms escalate, this can result in disabling conditions and a decreased 
ability to carry out the tasks of daily living (ACR, 2010). This symptom escalation also 
leads to increased use of healthcare resources (and the associated economic burden), 
increased absenteeism from occupational activities, and increased psychosocial distress 
(Howard et al., 2010; Kleinman et al., 2009; Lachaine, Beauchemin, & Landry, 2010; 
Merskey, 2008; Sicras-Mainar et al., 2009; Spaeth, 2009).  
2 
 
Because of the limited relief from medical interventions alone, goals of managing 
fibromyalgia typically include managing pain, assisting with illness adjustment, 
increasing feelings of well-being, and enhancing productivity (Peterson, 2007; Turk, 
Swanson, & Tunks, 2008). To help with meeting those goals, patients are typically 
encouraged to adopt healthy lifestyle behaviors and pursue alternative additive therapies 
(such as yoga or acupuncture) to complement their medical interventions and to perhaps 
assist them with gaining increased relief from symptoms (ACR, 2010; NFA, 2009). 
 It is important, therefore, to have safe, effective alternative interventions 
available to enhance treatment outcomes. The primary goal of this research was to 
investigate one such potential option—laughter. Laughter, unlike other alternative 
treatments, does not require any specific equipment, there is no cost associated with it, it 
does not require agility or athleticism, it does not require large amounts of time (Bennett 
& Lengacher, 2006; Mora-Ripoll, 2010), and there are minimal side effects (Kong, Shin, 
Lee, & Yun, 2014). Specifically of interest in this study was to learn whether increased 
laughter frequency is associated with improvements in affect and or with reductions in 
pain severity in patients with FMS.  
Background of the Study 
Affect 
Fibromyalgia patients have been shown to experience frequent episodes of 
negative affect and reduced incidence of positive affective states. They also appear to 
have difficulty regulating their emotions. Compared to patients with osteoarthritis (OA; 
also a chronic pain disorder), individuals with FMS evidence increased positive affect 
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dysregulation (Bartley, Rhudy, & Williams, 2009; Zautra, Fasman et al., 2005). FMS 
patients also experience greater difficulty with holding on to a positive affective state 
when in pain (Finan, Zautra, & Davis, 2009). As pain worsens, negative emotions tend to 
become predominant. However, the incidence of positive affect appears to moderate the 
effects of negative affect as well as perceived pain levels (Zautra, Smith, Affleck, & 
Tennen, 2001). This suggests that interventions that “focus on improving positive 
affective resources” may be especially beneficial with FMS patients (Zautra, Fasman et 
al., 2005, p. 147).  
There is little research about the use of laughter to influence affect in chronic 
pain/FMS patients. However, humor therapy has been shown to improve affect/mood and 
quality of life perceptions in older adults with depression or Alzheimer’s disease (Walter 
et al., 2007).  Forced laughter (laughing in the absence of a humorous stimulus) has also 
been shown to significantly improve affect ratings in undergraduate students (Foley, 
Matheis, & Schaefer, 2002; Neuhoff & Schaefer, 2002). 
Alexithymia 
 Alexithymia has been defined as a state of having reduced emotional awareness, 
such as having difficulty with identifying and describing emotional states (Sifneos, 
1973), and is frequently observed in patients with FMS (Evren, Evren, & Guler, 2006). 
For instance, Evren et al. (2006) found that 39.2% of their FMS sample and Steinweg, 
Dallas and Rea (2011) found that 44% of their FMS participants had alexithymia. 
Alexithymia has also been shown to be positively correlated with increased pain intensity 
and with negative affect (Tooyserkani, Besharat, & Koochi, 2011) and has been shown to 
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be associated with pain interference (how much the pain impacts the tasks of daily living) 
and pain catastrophizing (Makino et al., 2013). Because alexithymia appears to be so 
prevalent among this population, excluding participants with alexithymia from study 
participation could make it difficult to obtain enough participants to carry out the study. 
However, because of its potential influence on pain ratings and affect, participants in this 
study were screened for the presence of alexithymia through the use of the Toronto 
Alexithymia Scale-20 (TAS-20; Bagby, Ayearst, Morariu, Watters, & Taylor, 2013; 
Bagby, Parker, & Taylor, 1993; Bagby, Taylor, & Parker, 1994), and those measures 
were held constant in the statistical analyses.  
Depression 
 Depression, a disorder of mood, is associated with higher levels of negative affect 
(Anas & Akhouri, 2013). It is also associated with increased ratings of pain severity in 
those with chronic pain conditions (Aguglia, Salvi, Maina, Rossetto, & Aguglia, 2011; 
Baker, Buchanan, & Corson, 2008). Compared to an estimated 7% in the general 
population having depression (American Psychiatric Association, 2013), FMS patients 
tend to evidence much higher rates—ranging from 14.6% to 46% in literature reviewed 
for this study (see Aguglia et al., 2011; dos Santos, Quintans, Fraga, Macieira, & 
Bonjardim, 2012; Hassett, Cone, Patella, & Sigal, 2000; Ozcetin et al., 2007; Uguz et al., 
2010; Wolfe & Michaud, 2009). Based on these findings, it was expected that this sample 
might also evidence increased ratings of depression. As such, participants were assessed 
for symptoms of depression through the use of the Beck Depression Inventory—Second 
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Edition (BDI-II; Beck, Steer, & Brown, 1996), and those measures were also held 
constant in the statistical analyses.   
Laughter and Pain 
In various studies, laughter has been shown to have positive influences—both 
physiologically and psychologically (Mora-Ripoll, 2011). One area of study that shows 
promise is through the implementation of laughter in order to alter an individual’s pain 
experience (Bennett, 2003). For instance, laughter has been shown to increase acute pain 
tolerance (Stuber et al., 2009; Zweyer, Velker, & Ruch, 2004) and is also associated with 
elevations in acute pain thresholds (Dunbar et al., 2011; Mahony, Burroughs, & Hieatt, 
2001). Though the research involving laughter and chronic pain is limited, focused 
laughter therapy has been found to be beneficial with a small sample of patients with 
rheumatoid arthritis (RA; Herschenhorn, 1994). Following Herschenhorn’s study, 
participants reported improvements in the intensity of the pain experiences and reported 
the pain as being less bothersome. In another study, older adult chronic pain patients 
participated in 8 weeks of humor therapy (Tse et al., 2010). At the conclusion of the 
study, participants reported significantly reduced pain and significantly improved ratings 
of subjective well-being (Tse et al., 2010). The studies discussed above, as well as others, 
will be detailed further in the following chapter.   
Problem Statement 
FMS is a chronic, potentially disabling syndrome with no specifically identified 
cause and no cure, and medical interventions only offer partial relief from symptoms 
(ACR, 2010; NFA, 2009). FMS patients also tend to experience increased incidence of 
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negative affect and reduced positive affect and tend to experience difficulty with affect 
regulation (Bartley et al., 2009; Zautra et al., 2005). The problem is that individuals with 
FMS need safe, alternative treatment options to target symptoms that may not be 
addressed by traditional medical treatments. Laughter has been shown to increase acute 
pain tolerance (Stuber et al., 2009; Zweyer et al., 2004), increase pain thresholds (Dunbar 
et al., 2011; Mahony et al., 2001), produce decreases in pain severity of chronic pain 
(Herschenhorn, 1994; Tse et al., 2010), and improve temporary mood states (Foley et al., 
2002; Neuhoff & Schaefer, 2002; Walter et al., 2007). However, it is not known whether 
laughter is related to reductions in perceived pain severity levels and improvements in 
affect in individuals with FMS.  
Although there have been several studies about the role of affect dysregulation in 
patients with FMS, the specific role laughter may play in the affective states of these 
patients has not been investigated. Of the few studies found detailing the influence of 
laughter on affect and or mood, most are older studies. For instance, Young (1937) found 
that more frequent laughter was associated with higher ratings of cheerfulness in 
undergraduate students. Elicited laughter (from watching funny videos) has been 
associated with significant mood improvements in undergraduate students (Sakuragi, 
Sugiyama, & Takeuchi, 2002); forced (simulated) laughter has also been associated with 
significant improvement in temporary mood states in undergraduates (Foley et al., 2002); 
and in a more recent investigation, laughter therapy has been shown to significantly 
improve affect in cancer patients undergoing radiation therapy (Kim et al., 2015).  It is 
important to discover if the findings discussed can be observed as well with a sample of 
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FMS patients. What sets this study apart from other laughter studies that have been 
conducted is that, instead of eliciting or forcing laughter, actual laughter incidence was 
recorded as participants went about their daily lives. In this way, it was possible to 
observe whether naturally occurring laughter is associated with pain and affect.   
Purpose of the Study 
The purpose of this study was to investigate the potential role laughter frequency 
plays in modulating perceived pain and affect in individuals with FMS. If laughter 
frequency is related to a reduction in perceived pain and or an improvement in affect, it 
can then be implemented as an additional tool in more effectively managing FMS 
symptoms.  
Nature of the Study 
In this correlational study, participants first completed demographic 
questionnaires and were then screened for alexithymia through the use of the TAS-20 
(Bagby et al., 2013; Bagby et al., 1993; Bagby et al., 1994), and for symptoms of 
depression through the use of the BDI-II (Beck et al., 1996). Those measures were then 
held constant in the statistical analyses following the study. Participants documented all 
daily instances of laughter for a 14-day period. Participants also rated their pain levels 
and affective states 3 times per day. Daily measures employed in this study include the 
adapted Daily Laughter Record (DLR; Martin & Kuiper, 1999), the Pain Intensity- 
Numeric Rating Scale (PI-NRS; Farrar, Young, LaMoreaux, Werth, & Poole, 2001), and 
the Positive and Negative Affect Schedule (PANAS; Watson, Clark, & Tellegen, 1988). 
All assessment tools will be discussed further in the third chapter.  
8 
 
Research Questions and Hypotheses 
Research Question 1 
Will laughter frequency influence the affect of FMS patients after controlling for 
depression and alexithymia? 
H01: Laughter frequency will not influence the affect of FMS patients after 
controlling for depression and alexithymia. 
Ha1: Laughter frequency will influence the affect of FMS patients after 
controlling for depression and alexithymia. 
Research Question 2 
Will laughter frequency influence the perceived chronic pain levels of FMS 
patients after controlling for depression and alexithymia? 
H02: Laughter frequency will not influence difference in perceived chronic pain 
levels of FMS patients after controlling for depression and alexithymia. 
Ha2: Laughter frequency will influence difference in perceived chronic pain levels 
of FMS patients after controlling for depression and alexithymia.  
Theoretical Base  
Two related theories of pain guided this research. The first theory is the gate 
control theory of pain. This was the first theory of pain in which other variables beyond 
stimulus-response were considered in the pain experience—most notably psychological 
influences. This theory was developed largely to understand the experience of chronic 
pain in the absence of painful sensory stimuli (Melzack, 1993, 1999b, 2008; Melzack & 
Wall, 1965). More recently, a neuromatrix theory of pain was proposed. This theory 
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evolved from the gate control theory and builds on its principles to address more 
comprehensively the pain experience (Melzack, 1999a, 2001). The central concept of the 
neuromatrix theory of pain is that there exists a complicated neuronal network that 
consists of communication between multiple brain centers, including “the thalamus and 
cortex as well as between the cortex and limbic system” (Melzack, 1999b, p. 881). 
Relevant to this study is the neuromatrix theory’s tenet that part of this network includes 
an affective experience (for instance, the limbic system plays a role in modulating the 
experience of pain). 
In this study, I have drawn from and tested the dynamic model of affect, in which 
Zautra et al. (2001) suggested that “the relationship between negative and positive 
emotions changes as a function of ongoing events” (p. 787). According to the principles 
of this model, it is predicted that if individuals experience episodes of positive affect 
while experiencing pain, the positive emotions will serve to moderate pain-related 
negative emotions. This theory, as well as the pain theories above, will be discussed in 
greater detail in Chapter 2.  
Definition of Terms 
Affect: Often used interchangeably with mood and emotion. For the purposes of 
this study, it means the subjective experience of a temporary, changeable emotional state. 
This is in contrast to a more stable, enduring mood state (American Psychiatric 
Association, 2000).  
Chronic pain: Pain that persists past the time when the injury or tissue damage 
should have healed, or when it persists despite minimal evidence of physiological 
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pathology (Loeser, Butler, Chapman, & Turk, 2001). To be considered chronic, the pain 
must have lasted at least 3 months (Merskey & Bogduk, 1994).     
Laughter: Frequently used interchangeably in the literature with mirthful laughter 
and humor—which should be distinguished from sense of humor. Humor is something 
that may evoke laughter. It acts as a stimulus. Laughter is the psychophysiological 
reaction to something perceived as humorous or in response to some other stimulus 
(Mahony, Burroughs, & Lippman, 2002).  
Negative affect: An aversive emotional state characterized by subjective distress 
(Watson et al., 1988). 
Pain: A subjectively aversive state related to physiological damage sustained. It 
has both sensory and affective components (Merskey & Bogduk, 1994).  
Positive affect: A subjectively pleasant emotional state (Watson et al., 1988).   
Sense of humor: A trait that varies among individuals. What one individual finds 
humorous may differ from others. Having a sense of humor may or may not lead to actual 
laughter (Svebak, 1974; Svebak, Kristoffersen, & Aasarød, 2006).    
Assumptions 
 In this study, it was assumed that participants were accurately diagnosed by their 
physicians as having FMS. In addition, it was assumed that participants were capable of 
understanding and completing all questionnaires and assessments and that their responses 
were truthful. Lastly, it was assumed that the participants complied with all study 
protocols.     
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Limitations and Delimitations 
Because this study did not take place in the laboratory with the ability to control 
for confounds, there is the potential for other extraneous variables to have influenced 
study outcomes. There are also several inherent considerations that may limit the 
generalizability of this study’s outcomes. Firstly, women tend to comprise 75% to 90% of 
those diagnosed with FMS (NFA, 2009). This sample, likewise, was disproportionately 
composed of women (95.12%), thereby limiting generalizability of results to men with 
FMS.  
In addition, the study participants were all volunteers recruited from social media, 
bulletin board postings, support group meetings, and through a therapist’s practice. There 
may be intrinsic differences between those FMS patients who do and do not volunteer to 
participate in studies, making it difficult to generalize to the larger group of FMS 
patients. It could be that those FMS patients who did not volunteer to participate may 
have had such symptom exacerbations that they felt unable to fully participate in a study 
such as this. It could be that they were in too much pain or that they were feeling too 
fatigued or depressed to put forth the extra effort needed to fulfill the requirements of the 
study. Some may have also perceived the requirements of the study to be too taxing or a 
hassle to fit into their days. Personality factors may also influence who chooses to 
volunteer for studies (Lönnqvist et al., 2007; Saliba & Ostojic, 2014). Lönnqvist et al. 
(2007) conducted two studies—one with officers in the military, and one with siblings 
from large families. In both studies, the researchers found that those volunteering to 
participate tended to have significantly lower ratings of neuroticism and significantly 
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higher ratings of conscientiousness compared to those who did not volunteer to 
participate (Lönnqvist et al., 2007). Additionally, in the sibling study, those who agreed 
to participate had significantly higher ratings of extraversion and agreeableness compared 
to those who did not volunteer (Lönnqvist et al., 2007). In addition, Saliba and Ostojic 
(2014) compared the Myers-Briggs Type Indicator (Myers, McCaulley, Quenk, & 
Hammer, 1998), ratings of their study participants to a representative population sample 
in the United States. They found that individuals who chose to participate in their study 
tended to be overrepresented by those with the trait of “Intuition” (N; “a grasp of 
possibilities”) and underrepresented by those with the trait “Sensing” (S; “a reliance on 
facts”; Saliba & Ostojic, 2014, p. 241). Saliba and Ostojic suggested further study is 
warranted in order to assess whether such differences in personality traits impact study 
outcomes and the ability to generalize from such outcomes. Lastly, since only FMS 
patients were included, results will not easily generalize to other chronic pain conditions 
or to other types of medical disorders.  
Significance of the Study 
This is likely the first study to address laughter as it specifically relates to affect 
and perceived pain levels in FMS patients. Though fibromyalgia is not typically 
associated with increased mortality risk (Wolfe, Hassett, Walitt, & Michaud, 2011), it is a 
medical disease that (to date) has no cure. It can and does result in disability and results 
in significant costs in terms of health care resources, lost productivity and time on the 
job, and personal relationships. Since the results found in this investigation demonstrate 
that increased laughter frequency is associated with reduced pain severity ratings and 
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improved positive affect ratings, this could have positive social change implications at 
the individual level, within the FMS patients’ larger social networks, as well as within the 
research and medical communities.  
Summary 
Fibromyalgia is a chronic, potentially disabling syndrome that is often 
incompletely treated. In the research literature, laughter has been shown to effectively 
improve affect and increase pain tolerance and pain thresholds in various settings and 
with varying populations who have other ailments, but research has not been conducted 
on naturally occurring spontaneous laughter and its relationships with affect and pain 
perception in FMS.  
Chapter 2 includes a comprehensive discussion of the available literature 
regarding FMS, affect and FMS, and laughter and its physiological and psychological 
effects. Also detailed in Chapter 2 are the theories of pain and affect that formed the 
foundation for this study.  
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Chapter 2: Literature Review 
 In this study, I investigated the relationships between laughter, pain perception, 
and affect in individuals with FMS. In this chapter, the relevant extant literature 
pertaining to each topic is reviewed. First, I discuss FMS in greater detail—including 
signs and symptoms, diagnostic criteria, potential etiologic factors, common treatments 
administered, the costs associated with it, its association with psychiatric diagnoses, and 
coping strategies commonly used. Following the FMS overview is a discussion of 
laughter’s influences on various markers of health and pain. I then discuss pain theories, 
as well as how they relate to the experience of chronic pain. A section on affect, emotion 
regulation, and alexithymia findings in the FMS population follows. Finally, I discuss the 
dynamic affect model proposed by Zautra et al. (2001) as it pertains to persons who have 
chronic pain conditions.    
 In order to examine the current research, a comprehensive search was performed 
using several electronic databases. Thoreau was the primary electronic database 
employed for the literature search because it searches multiple databases and retrieves the 
largest body of search results. Other databases used include Academic Search Premier, 
PsycINFO, and Medline. Search terms included fibromyalgia, pain, laughter, chronic 
pain, alexithymia, and affect, as well as combined search terms such as pain and affect, 
laughter and pain, laughter and health, emotion regulation and fibromyalgia, and 
fibromyalgia and affect. References were also gathered through reference lists from 
related journal articles as well as through searching prominent researchers’ names in the 
databases. There was also an extensive search for articles that cited other articles central 
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to the study. Peer-reviewed journal articles were the primary source of information for 
this review, but there were also germane source websites used for important demographic 
and statistical information, as well as for the general overviews of fibromyalgia.  
Overview of Fibromyalgia Syndrome 
Signs, Symptoms, and Associated Conditions 
As discussed briefly in the first chapter, FMS is a medical condition with the 
hallmark feature of persistent, widespread musculoskeletal pain and tenderness in all 
quadrants of the body (above and below the waist, and both left and right sides of the 
body; ACR, 2010). Individuals with FMS experience all over body pain and a generally 
reduced pain threshold, but they also have localized body regions that are particularly 
sensitive to pain stimuli—called tender points (Bennett, 2009).  
Tender points should be distinguished from trigger points. Though these terms are 
often used interchangeably by patients and physicians, they are actually associated with 
similar but distinct medical symptoms. Tender points are simply used for diagnosing 
FMS. They are points that, when mechanically pressed, become painful. They do not 
appear to be the direct source of the pain experienced in FMS. Trigger points, on the 
other hand, are associated with myofascial pain disorder (MPS) and tend to be tender and 
painful without being pressed. The pain in MPS directly originates at the trigger points. 
That pain can be localized or can radiate to other body regions. Though there are other 
subtle differences between tender points and trigger points, there are two important 
distinctions between them. First, differences in the muscle fibers and electrical activity 
associated with trigger points (taut bands or nodules in the muscles) can be observed with 
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electromagnetic imaging or ultrasonography, whereas there are still no reliable imaging 
techniques or diagnostic tests available for the identification of FMS pain. Perhaps most 
important, in terms of therapeutic outcomes, pain appears to be instantly relieved in 
patients with MPS when treatments are used to target the trigger points (e.g., dry needling 
or physiotherapy). This is not the case with FMS. There are no treatments currently 
available that instantly relieve FMS patients’ pain (Skorupska, Bednarek, & Samborski, 
2013).  
FMS is also characterized by dysfunctions in the sleep cycle. For instance, in 
Stage 4 of the sleep cycle, FMS patients tend to have periodic brain waves characteristic 
of an awake state instead of those characteristics of a deep sleep state (NFA, 2009). 
Patients with FMS may also experience fatigue, pain processing irregularities 
(individuals with FMS tend to experience hypersensitivity to pain stimuli), and 
psychological distress such as symptoms of depression and anxiety (ACR, 2010; Centers 
for Disease Control and Prevention [CDC], 2011; NFA, 2009). Other common symptoms 
include stiffness upon waking, tingling in the extremities, headaches (tension headaches 
or more severe migraines), cognitive dysfunction, dizziness, vision difficulties, dry eyes 
and mouth, and impaired memory. Other disorders and syndromes commonly associated 
with FMS include irritable bowel syndrome, lupus, restless legs syndrome, 
temporomandibular disorder, other comorbid rheumatic disorders, pelvic and bladder 
pain syndromes, arthritis, and gastric reflux disorder (ACR, 2010; CDC, 2011; NFA, 
2009; Wolfe et al., 1990).   
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Symptoms associated with FMS are variable over time, may increase or decrease 
in intensity, and are sensitive to psychological stress, weather (cold or humid), physical 
overexertion, reduced sleep quality, and fatigue. The symptoms can become so 
debilitating at times that the individual may be unable to participate in work or social 
activities or to complete even the most basic daily tasks of living (ACR, 2010; CDC, 
2011; NFA, 2009; Wolfe et al., 1990).   
Prevalence and Demographics 
 Estimates of FMS in the adult (age 18 and older) U. S. population range from 2% 
to 4% (ACR, 2010; Wolfe, Ross, Anderson, Russell, & Hebert, 1995). This translates to 
between 5 and 10 million people estimated to have FMS in the United States (Lawrence 
et al., 2008; NFA, 2009). Worldwide, estimates of FMS range from 3% to 6%. The 
preponderance of patients with FMS are female (the incidence is at least 7 times greater 
in women than in men), but it is found in men and children as well. FMS is most 
commonly diagnosed during middle age. Rates of diagnosis increase with advancing age 
(8% of individuals meet the criteria for FMS by the age of 80; ACR, 2010; CDC, 2011; 
NFA, 2009). FMS is also observed in all racial groups (NFA, 2009).  
FMS may also have a heritable component, as it has been observed among 
siblings and among mothers and their children (NFA, 2009). For example, Arnold et al. 
(2004) gathered information from first-degree family members (total N = 533; 146 were 
directly interviewed and provided the researchers with information on 455 other first-
degree relatives not available to be interviewed at the time of the study. Of patients with 
FMS (n = 78), a strong familial relationship was found with both the presence of FMS 
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(18.5% in the family members who were interviewed and 6.4% in the overall sample) and 
increased tenderness to pain. This relationship, however, appears to be restricted mainly 
to female family members. In this sample of first degree relatives, Arnold et al. only 
observed two male family members (brothers of one of the patients with FMS) who met 
the criteria for FMS. 
Mortality Risks 
There is no difference in overall mortality rates between people with FMS and the 
general population. However, individuals with FMS have been shown to have an 
increased rate of death from suicide (Dreyer, Kendall, Danneskiold-Samsøe, Bartels, & 
Bliddal, 2010; Wolfe, Hassett, et al., 2011). Wolfe, Hassett, et al. (2011) also found a 
higher rate of death from accidental injuries in those with FMS as compared to the 
general population. Wolfe, Hassett, et al. were not able to provide a concrete explanation 
of their results but suggested that many of the deaths from accidental injuries may have 
truly been completed suicides that appeared accidental. Dreyer et al. (2010) suggested 
that the increased rate of suicides might be related to mental health problems (e.g., 
depression, anxiety, etc.; to be discussed later in the chapter) frequently observed in FMS 
patients. Suicide rates increased both at the initial diagnosis of FMS and at the time of 
follow-up 5 years later. Therefore, Dreyer et al. recommended that FMS patients be 
screened for suicide risk by their health care professionals.  
Etiology and Pathogenesis 
Researchers have not uncovered a single, specific, identifiable cause for FMS. 
Instead, it is generally thought that a predisposing genetic vulnerability may become 
19 
 
activated by some sort of trigger (ACR, 2010). For example, certain medical conditions 
(e.g., HIV, Hepatitis C, Lyme disease) or infections may act as potential triggers for the 
development of FMS (Buskila, Atzeni, & Sarzi-Puttini, 2008; Martinez-Lavin, 2012; 
Mease et al., 2009). Triggers could also include physical traumas (such as injuries or the 
development of arthritis), physical assault or abuse, or sexual assault or abuse (ACR, 
2010; Haviland, Morton, Oda, & Fraser, 2010). Histories of childhood sexual and 
physical abuse have frequently been reported by FMS patients (Thieme, Turk & Flor, 
2004). In Thieme et al.’s (2004) study, 40.9% of the FMS sample reported a history of 
sexual abuse, while 20.9% reported a history of physical abuse. Additionally, those in the 
study who had been sexually abused as children tended to report having more severe 
physical symptoms than other study participants (Thieme et al., 2004). Häuser, Kosseva, 
Üceyler, Klose, and Sommer (2011) conducted a meta-analysis of research related to 
emotional, physical, and sexual abuse in FMS patients. In their research, they observed 
that both physical and sexual abuse (either from experiences as a child or as an adult) 
were positively related to the development of FMS (Häuser et al., 2011). However, the 
results of their meta-analysis did not show emotional abuse to be related to the 
development of FMS (Häuser et al., 2011). In another study, Haviland et al. (2010) 
analyzed data obtained from self-report questionnaires (regarding religion and health) 
completed by older adults (N = 10,424). As with Häuser et al., they, too, found that 
having a history of physical and sexual abuse or assault was related to respondents 
reporting an FMS diagnosis (Haviland et al., 2010). In their study, emotional abuse and 
major life stress were not factors implicated in its development (Haviland et al., 2010). 
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Haviland et al. suggested that it appears that it might be the actual traumatic physical 
contact that plays a larger role in the development of FMS and not necessarily emotional 
stress.  
This assertion seems to run counter to the outcomes found by Jones, Power, and 
Macfarlane (2009) in their large prospective study (N = 7,571). Jones et al. followed 
participants for 38 years (from ages 7 to 45). Data were gathered from their parents at age 
7 regarding the incidence of various physical and psychosocial adverse events. Then at 
age 45, those individuals were interviewed regarding whether they experienced chronic 
pain. Several adverse events in childhood were found to significantly correlate with the 
later development of chronic widespread pain. These included being hospitalized 
specifically as a result of a motor vehicle crash (but not for hospitalization for surgery 
without a prior traumatic incident and not for other types of accidents or injuries), being 
separated from their mothers for more than 6 months, spending time in institutional care, 
experiencing their mother’s death, and experiencing financial hardships. Contrary to 
Haviland et al.’s (2010) outcomes, it appears that in Jones et al.’s study, significant 
emotional stress and major life stressors were related to the later development of chronic 
widespread pain.  
In another study, 73% of 2,569 FMS patients surveyed online identified particular 
triggers they believed to be associated with the development of their FMS (Bennett, 
Jones, Turk, Russell, & Matallana, 2007). These triggers are consistent with those 
discussed above and included chronic stress (the most frequently cited trigger, 41.9%), 
emotional trauma, acute illness, physical injury, surgery, vehicular accidents, emotional, 
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sexual, or physical abuse (both as children and as adults), thyroid dysfunction, 
menopause, and giving birth (Bennett et al., 2007).   
Wolfe et al. (2014) argued that the extant research about potential triggers is 
largely based on case studies and small, less scientifically rigorous studies, and that we 
are limited by participant self-report regarding what is believed to have triggered FMS. 
Wolfe et al. suggested we are far from discovering a clear causal model of FMS 
development. However, it is commonly thought that a traumatic triggering event, such as 
those discussed above (e.g. the presence of chronic stress, emotional trauma, vehicular 
accidents, etc.), might potentially create changes in certain chemicals in the body that 
alter the central nervous system’s (CNS) processing of pain signals (ACR, 2010; Bellato 
et al., 2012). Some of the chemicals that have been associated with some FMS symptoms 
include serotonin, norepinephrine, dopamine, and endorphins (Bellato et al., 2012). The 
resultant outcome is an increased sensitivity to pain stimuli (ACR, 2010) called central 
sensitization (Bellato et al., 2012). As the body of research has grown, there has been 
increasing evidence that the sets of symptoms observed with FMS may be caused by 
dysregulation in the CNS (Mease et al., 2009). This dysregulation is then influenced by 
other factors such as genetic expression, immune system functioning, and the presence of 
hormones, making this a complex and difficult syndrome to understand and treat 
effectively (Bellato et al., 2012).  
Diagnosis  
 Because FMS is not readily revealed through characteristic findings on objective 
laboratory tests and cannot be observed physically (it does not result in distinctive tissue 
22 
 
inflammation or joint damage), it has historically been challenging to diagnose (ACR, 
2010; Bellato et al., 2012; NFA, 2009; Wolfe et al., 2010); and the lack of objective 
markers for FMS has made the diagnosis “subject to numerous criticisms and 
controversies” (Wang et al., 2015, p. 677). Diagnosis is typically delayed for five years 
on average while patients are referred from physician to physician and undergo extensive 
testing in an effort to rule out other medical conditions (NFA, 2009). This period of time 
is difficult for the patients as they wait and wonder about potential diagnoses (Buskila, 
Neumann, Sibirski, & Shvartzman, 1997; NFA, 2009). Therefore, those in the medical 
community realized that it is important to have a standard set of criteria that physicians 
could use to enhance the accuracy and expediency of diagnosis (Wolfe et al., 1990).  
 1990 diagnostic criteria.  The diagnostic criteria for FMS were first developed in 
1990 by researchers at the American College of Rheumatology (ACR). The criteria were 
revised in 2010, and then modified again in 2011 (Garg & Deodhar, 2012; Wolfe et al., 
2011; Wolfe et al., 2010). In their development of the original criteria, the ACR 
researchers found that 97.6% of the FMS patients (compared to 69.1% of control 
participants with disorders similar in presentation to FMS) experienced widespread pain 
(pain found in both upper and lower parts of the body, as well as in both the left and right 
sides). This became the first criterion for diagnosing FMS. The second criterion 
necessitated the patient endorsing tenderness in at least 11 of 18 potential tender points as 
determined by physician palpation (Wolfe et al., 1990). Both criteria had to be present in 
combination in order to receive a diagnosis of FMS. The tender point examination made 
the biggest impact in differentiating between FMS patients and controls with other types 
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of rheumatic disorders (sensitivity = 81.1%). The final criterion necessary for diagnosis 
of FMS, as determined by the ACR, was that the widespread pain must have been present 
for at least 3 months (Wolfe et al., 1990).   
These criteria did not allow for differentiation between primary and secondary 
FMS (symptoms of FMS caused by the presence of another rheumatic disorder). FMS 
could still be diagnosed, even if another disorder was present. Though a large percentage 
(73% – 85%) of patients in the study conducted by Wolfe et al. (1990) also endorsed 
symptoms of fatigue, difficulties with sleep quality, or feeling stiff upon awakening, 
these symptoms were not deemed necessary for diagnosis. This is due to the variability in 
the experience of those symptoms. For instance, only 56% of the FMS patients endorsed 
experiencing all three symptoms, while 81% endorsed two of them. There were also other 
types of commonly reported signs and modulating factors (e.g., anxiety, irritable bowel 
syndrome, temperature fluctuations, etc.), but none were consistent enough within the 
sample to become a diagnostic criterion.  
2010 revision of diagnostic criteria.  Following the initial diagnostic criteria 
development, FMS began receiving greater attention and recognition. As the criteria were 
put into practice, some concerns and criticisms were raised (Wolfe et al., 2010). For 
instance, it was found that there was still confusion among family physicians regarding 
the specific FMS criteria. For example, Buskila et al. (1997) found that only 55% of their 
sample of family physicians were aware that widespread pain was a defining criterion of 
FMS, while only 25% of this same sample knew how many tender points were required 
for diagnosis. Physicians appeared to be more familiar with the associated signs and 
24 
 
symptoms of FMS (fatigue, headaches, disordered sleeping) than with the specific 
diagnostic criteria of widespread pain and tender points (Buskila et al., 1997). The focus 
on pain alone in the original criteria disregarded other hallmark signs and symptoms 
commonly associated with FMS. Crofford and Clauw (2002) argued that ignoring the 
constellation of other symptoms failed “to capture the essence of” FMS (p. 1136). 
Therefore, it was proposed that FMS should be evaluated based not just on the presence 
of pain and tenderness, but also on the presence of other types of symptom domains (e.g. 
cognitive dysfunction, disordered sleep, problems with mood, and impaired functioning; 
Mease et al., 2009).  
It also appeared that, despite having a set of standardized diagnostic criteria, there 
was a problem with physicians making inaccurate diagnoses. For example, Fitzcharles 
and Boulos (2003) found that only 34% of patients (N = 76) were correctly diagnosed 
with FMS following a rheumatology consultation. In this sample, FMS appeared to be 
most often over diagnosed, but was also misdiagnosed. It had been over diagnosed in 37 
of the patients who had been referred. These patients, instead, were diagnosed with 
conditions such as inflammatory arthritis, soft tissue rheumatism, and degenerative 
arthritis. On the other hand, 13 of the referred patients carried diagnoses other than FMS, 
such as arthralgia, OA, or back pain. Eleven of those patients were later diagnosed, 
instead, as having FMS (Fitzcharles & Boulos, 2003).  
In addition, the original criteria did not allow for a continuum of severity. Though 
patients with FMS present with a range of symptoms, with more or less severity, there 
was no way to capture the qualitative differences with the present criteria (Wolfe et al., 
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2010). Finally, there was also a concern regarding the standardization of physician 
palpation for the tender point examinations. It was found that physicians were quite 
variable in the pressure they exerted when assessing for the presence of tender points 
even after receiving formal training (Häuser & Wolfe, 2012; Wolfe et al., 1990). In 
addition, Staud, Price, Robinson, and Vierck (2004) found that tender point examination 
only accounted for 4% of the variance in pain intensity measures for FMS patients versus 
16% of the variance in pain intensity accounted for by the patients shading in all painful 
body regions on a diagram of the human body. Therefore, Staud et al. (2004) suggested 
that tender point examinations may not be as useful to diagnosis or as a predictor of pain 
severity as the use of a pain diagram, and that areas that may be sensitive to the 
palpations may not necessarily be where the patient is currently feeling pain.    
Keeping these various concerns in mind, Wolfe et al. (2010) devised an 
alternative set of diagnostic criteria. The new set of criteria includes a widespread pain 
index (WPI) scale and a symptom severity (SS) scale. The WPI assesses in how many 
areas of the body the patient has been experiencing pain over the past week (scores range 
from 0 to 19 body regions). The SS scale assesses the severity of symptoms patients are 
experiencing in four areas: 1) fatigue, 2) waking unrefreshed, 3) cognitive symptoms, and 
4) somatic symptoms (e.g., frequent or painful urination, dizziness, nausea, diarrhea, 
etc.). In this way, a patient who may not have 11 or more tender points (as the number set 
by the original criteria) but who has sufficient symptom severity may still meet 
diagnostic criteria for FMS. As with the original classification criteria, the patient must 
also have been having symptoms for at least 3 months and alternative diagnoses must be 
26 
 
ruled out, but there is no longer a physical examination or tender point count palpation 
required for diagnosis. Instead, points are added on the WPI and SS.  If scale scores fall 
into parameters established (WPI ≥ 7 and SS ≥ 5 or WPI between 3 and 6 and SS ≥ 9), 
the patients meet criteria necessary for FMS diagnosis. The importance of having the new 
scales means that symptom severity (as measured in levels of fatigue, cognitive 
symptoms, and a variety of somatic symptoms), ignored with the original diagnostic 
criteria, is now included as part of the diagnosis. These new criteria were found to 
accurately diagnose FMS 88.1% of the time without having the physician palpate for 
tender points or conduct a physical exam (Wolfe et al., 2010).   
Wolfe et al. (2010) suggested that this new set of criteria would be especially 
helpful in those patients who were previously diagnosed with the original classification 
criteria (this was the case for 25% of the sample in the Wolfe et al.’s study), but no longer 
meet those criteria. Rather than eliminating the original classification criteria, the new set 
of criteria could be used to follow existing FMS patients on a long-term basis, as a way of 
monitoring their symptoms over time, according to its creators. Interestingly, in this 
iteration of the diagnostic criteria, a mood variable was going to be added to the SS scale 
(it was originally one of the six most important variables considered for the SS), but was 
ultimately discarded. Though indications of mood were found to be strongly correlated 
with the SS (r = 0.73), the researchers determined it was not a “primary feature of the 
illness” (Wolfe et al., 2010, p. 608); instead it may be a result of living with FMS (Wolfe 
et al., 2010).  
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Oncu, Iliser, and Kuran (2013) determined that the 2010 criteria were 
significantly more sensitive at diagnosing FMS than the original 1990 criteria, both upon 
receiving the initial diagnosis of FMS as well as when following up with patients a year 
later. The researchers recruited participants (N = 100) who had experienced chronic, 
diffuse pain for over 3 months (but who had not previously been diagnosed with FMS). 
After ruling out other medical disorders and excluding those with symptoms of major 
depression, participants were evaluated using both sets of criteria three times; at baseline 
(before receiving treatment), following the third month of receiving treatment, and after 
one year. At the time of initial diagnosis, the two sets of criteria were in concordance in 
only 49 of the cases. This number then fell to 25 at the one-year follow-up. Oncu et al. 
(2013) further determined that the discordance in diagnostic agreement was largely 
derived from tender point counts and scores on the symptom severity (SS) scale.  The 
researchers argued that FMS is “more than just body pain and tender point count” (p. 
441) and that if the 1990 criteria continue to be used for diagnosis, this could result in 
patients being under-diagnosed and therefore untreated.  
2011 modification of criteria for research purposes. These criteria were 
modified once more in order to make assessment more useful for survey research or for 
epidemiological studies. The new criteria do not require a physician or interviewer as the 
scales are administered to the patient in questionnaire form (The Fibromyalgia Survey 
Questionnaire [FSQ]; Häuser & Wolfe, 2012; Wolfe et al., 2011). This assessment tool 
continues to measure a WPI, in which patients report how many areas of their bodies 
were painful over the previous 7 days (range of scores is 0 to 19) but the SS score has 
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been changed somewhat. Severity scores for fatigue, cognitive symptoms, and waking 
unrefreshed are tallied for the prior 7 days, and added to that score is the total of how 
many times in the past 6 months patients have experienced headaches, abdominal 
discomfort, and depressive symptoms. It is important to note that this is the first of the 
criteria sets to include depression in the diagnostic criteria. Scores necessary for 
diagnosis are WPI ≥ 7 and SS ≥ 5 or WPI falling between 3 and 6 and SS ≥ 9 (Wolfe et 
al., 2011).  However, Wolfe et al. (2011) cautioned that this new set of criteria should not 
be used for patients to diagnose themselves and that it is still necessary to receive a 
formal diagnosis through their physicians. Diagnosis can be made using any one of the 
sets of criteria discussed. One is not meant to be a substitute for another. Rather, the set 
of criteria should be used that is most relevant to the specific circumstances. As discussed 
above, this 2011 modification of the criteria may be most helpful in research studies, so 
that a physician examination is not necessary (Wolfe et al., 2011). For initial diagnoses, it 
may be most helpful to use either the original 1990 criteria or the 2010 criteria. However, 
for the purpose of monitoring FMS patients over time, the 2010 criteria may be more 
useful (Wolfe et al., 2010). 
Treatment 
 To date there is no cure for FMS, and there is no one treatment that effectively 
alleviates all symptoms. Additionally, because FMS is manifested in varying ways, with 
varying symptom sets and varying severity of symptoms from individual to individual, 
the optimal treatment strategy is likely to be one that is tailored to each individual. This 
tailored, multi-modal treatment plan would ideally treat the pain as well as other 
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problematic symptoms in order to produce the most beneficial patient outcomes. Though 
medication is one important tool frequently used to manage some symptoms of FMS, 
adding other types of treatments and making lifestyle modifications can more completely 
address the entire spectrum of symptoms (ACR, 2010; Bellato et al., 2012; Evans, 
Parthan, & Le, 2006; Mease, 2005; Mease et al., 2009; NFA, 2009; Tse et al., 2010; Turk 
et al., 2008). 
 Pharmacological strategies.  Pharmacotherapy for the treatment of FMS has 
typically been used to manage pain levels, aid patients in obtaining restful sleep, and help 
to control symptoms of anxiety and depression. As such, FMS patients are frequently 
prescribed multiple medications, such as analgesics, antidepressants, and sleep-aids 
(White et al., 2009). During the course of treatment, medications may be changed 
frequently and used in varying combinations in order to gain the most therapeutic effects.  
 With the exception of tramadol (a mild opioid), opioids are generally 
contraindicated for the treatment of pain associated with FMS. It is thought that these 
types of pain relievers may result in paradoxically making the pain even more severe and 
making the patient increasingly sensitive to painful stimuli (ACR, 2010). Patients using 
opioid analgesics may also run the risk of abuse or dependence (Evans et al., 2006; White 
et al., 2009). Therefore, opioids should only be prescribed after all other pain remedies 
have been explored and found lacking (Evans et al., 2006). Despite this guidance, White 
et al. (2009) found that the prescription of opioids as analgesics was prevalent in FMS 
patients. They observed that 39.5% were prescribed opioids in the time period leading up 
to diagnosis, 43.3% following FMS diagnosis, and 43.9% in established FMS patients. 
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Similarly, Palacio et al. (2010) found that opioids were the most frequently prescribed 
pain medications for FMS patients both before and after receiving the FMS diagnosis.   
 Some medications prescribed for FMS act on the neurotransmitters serotonin and 
norepinephrine (neurotransmitters associated with the pain response). These include such 
medications as duloxetine, milnacipran, amitryptiline, cyclobenzaprine, venlafaxine, 
fluoxetine, paroxetine, or sertraline (ACR, 2010). Other commonly prescribed 
medications for FMS act to block the nerve cells’ heightened response to pain signals. 
These include pregabalin and gabapentin. Unfortunately, all of the various prescribed 
medications for FMS pain have potentially deleterious side effects. Patients may also be 
advised to take over-the-counter pain relievers such as acetaminophen or non-steroidal 
anti-inflammatory drugs (NSAIDS), or may even have some areas of localized pain 
treated with injections of lidocaine (ACR, 2010; NFA, 2009). Currently, however, there 
are only three medications approved by the U.S.  Food and Drug Administration (FDA) 
specifically for use with FMS: duloxetine (Cymbalta), milnacipran (Savella), and 
pregabalin (Lyrica; Bellato et al., 2012).    
Psychological interventions.  As psychological factors may contribute to the 
exacerbation of symptoms, increased emotional distress, and increased disability 
associated with chronic pain, psychological treatment strategies have frequently been 
used as part of interdisciplinary treatment regimens for these patients (Kerns, Sellinger, & 
Goodin, 2011). Though psychological treatments do not completely ameliorate the pain, 
they may help individuals adapt to chronic pain and other related symptoms (Turk et al., 
2008). They have also been shown to be helpful in reducing pain (both in the short-term 
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and in the long-term), improving life functioning, reducing symptoms of depression, 
improving sleep patterns, and in reducing catastrophizing thoughts (Glombiewski et al., 
2010). 
Overall, psychological intervention outcomes for FMS have been shown to be as 
effective as other medical interventions for pain (Glombiewski et al., 2010). These 
complementary treatments may include strategies such as biofeedback, cognitive 
behavioral therapy (CBT), hypnosis, guided imagery, or mindfulness meditation (Kerns 
et al., 2011; Turk et al., 2008). The most promising psychological treatments are CBT 
(Turk et al., 2008) and biofeedback (Glombiewski et al., 2010). For example, patients 
with FMS receiving CBT compared to controls (FMS patients receiving treatment as 
usual) reported increased pain reductions and increased overall functioning; these 
outcomes were sustained until a follow-up 9 months later (Woolfolk, Allen, & Apter, 
2012). Glombiewski et al. (2010) conducted a meta-analysis (N = 23 studies) of 
psychological interventions for FMS. They found that CBT had the highest effect sizes of 
the studies reviewed, and that it outperformed other psychological interventions with 
regards to reducing pain in the short-term. They also found that biofeedback treatments 
were helpful in reducing problems with sleep quality in FMS patients. Glombiewski et al. 
concluded that it might be most helpful to combine CBT with biofeedback to address 
both pain and sleep quality.    
Biofeedback may also be potentially helpful in reducing other FMS symptoms. 
Babu, Mathew, Danda, and Prakash (2007) administered biofeedback to 15 FMS patients. 
Compared to a group of control participants (15 FMS patients receiving sham 
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biofeedback), those receiving biofeedback reported significantly lower pain levels and 
significantly fewer numbers of tender points. Guided imagery may be another useful tool 
for managing some symptoms of FMS, but study outcomes have been mixed (Verkaik et 
al., 2014). For instance, Menzies, Taylor, and Bourguignon (2006) conducted a 6-week 
long guided imagery intervention with FMS patients. Participants (N = 48) were 
randomized to either a treatment as usual group or a guided imagery group. Though pain 
levels did not differ significantly between groups at the conclusion of the study, those 
participating in guided imagery reported significantly improved functioning and 
significantly higher ratings of self-efficacy in their ability to manage their pain (p = 
<0.01) compared to those in the treatment-as-usual group (Menzies et al., 2006).   
On the other hand, Verkaik et al. (2014) did not observe any significant positive 
effects of guided imagery treatment in individuals with FMS. As in the Menzies et al. 
(2006) study discussed above, pain intensity did not differ significantly between 
fibromyalgia patients participating in guided imagery sessions compared to control group 
participants not participating. There was also no significant change over time within 
subjects over the course of the study (26 days). In addition, and in contrast to Menzies et 
al.’s outcomes, no significant differences were observed between the groups relating to 
functional status or pain-related self-efficacy. Verkaik et al. (2014) suggested that the 
lack of significant findings might have been related to factors such as the timing of pain 
ratings (participants rated their pain only once per day, at night). They proposed that 
findings might have been different if the ratings had been taken closely in time to when 
the guided imagery sessions took place.  
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Additionally, in Verkaik et al.’s (2014) study, the guided imagery sessions used a 
combination of positive imagery and direct focus on the pain perceived by participants. 
The researchers suggested that if they had simply focused on positive imagery and did 
not refer to pain intensity in the sessions, it might have made a quantifiable difference in 
the outcomes. Finally, Verkaik et al. speculated that their study might not have been long 
enough (4 weeks) to observe significant improvements. Though the participants doing 
guided imagery did not appear to have any objectively measured improvements 
compared to the control participants, 85% of them reported that they would recommend it 
to others and 96% of them reported that they found it useful for daily living (Verkaik et 
al., 2014). In their meta-analysis of the use of hypnosis and guided imagery for FMS, 
Bernardy, Füber, Klose, and Häuser (2011) found that overall outcomes tentatively 
supported a reduction in pain severity. However, they concluded that there were too 
many methodological concerns in the studies reviewed to draw any firm conclusions.  
Mindfulness meditation has also been tested as a potential treatment for FMS 
symptoms. The three studies reviewed for this investigation yielded mixed outcomes. 
Sephton et al. (2007) investigated the influence of mindfulness meditation on symptoms 
of depression in FMS patients. They randomly assigned FMS patients to either an 8-week 
mindfulness-based stress reduction (MBSR) group (n = 51) or to a control group assigned 
to a waiting list for treatment (n = 40). Participants were assessed for depressive 
symptoms at baseline, post-treatment, and again two months later. At the conclusion of 
the study, those in the MBSR group reported significantly improved depression ratings 
compared to those in the control group, and those improvements were sustained at the 
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two month follow-up (Sephton et al., 2007). Similarly, positive outcomes from the use of 
mindfulness meditation with this population were also found by Cash et al. (2015). Cash 
et al. assessed participants on several measures: stress, pain, fatigue, quality of sleep, 
physical functioning, symptom severity, and salivary cortisol. As with Sephton et al.’s 
(2007) study discussed above, participants in Cash et al.’s study were randomized to 
either an MBSR group (n = 51) or a control group waiting for treatment (n = 40), and 
they were assessed at baseline, at the end of the study (8 weeks), and again two months 
later. Though no significant differences were observed between the groups in terms of 
pain, cortisol levels, fatigue, or in physical functioning, the MBSR group did evidence 
significant improvements compared to the control group in terms of perceived stress, 
sleep quality, and severity of symptoms, and these improvements continued through to 
the 2-month follow-up (Cash et al., 2015)   
On the other hand, Schmidt, Grossman, Schwarzer, Jena, and Naumann (2011) 
did not find support for the use of mindfulness meditation with FMS patients. In their 
study, 177 FMS patients were randomized to either an MBSR group, an alternative 
control intervention (primarily relaxation exercises and stretching movements), or to a 
waitlisted control group and they were assessed for overall health related quality of life 
(HRQoL). All three groups evidenced significant improvement in HRQoL at the 
conclusion of the study, but there were no significant differences between the groups, 
indicating there was no advantage to the MBSR training for these patients (Schmidt et al., 
2011). Schmidt et al. also conducted some secondary analyses with these patients, 
investigating 16 other variables such as pain, sleep quality, anxiety, depression, etc. Of 
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the secondary analyses, the researchers found only two significant outcomes—and of 
those, the only significant finding relating to the MBSR group alone was that those in the 
MBSR group reported themselves higher in mindfulness than the other two groups. The 
other significant outcome was that anxiety was significantly reduced in both active 
treatment groups compared to the control, waitlisted group.     
Other complementary and alternative therapies. Some symptoms of FMS 
might be eased with the use of alternative treatments such as acupuncture, massage, or 
yoga (ACR, 2010). Langhorst, Klose, Musial, Irnich, and Häuser (2010) conducted a 
review of randomized, controlled studies (N = 7) testing the effectiveness of acupuncture 
for FMS. They found a significant reduction in pain across all studies (p = .04), but 
follow-up studies did not show this effect to hold up over time (n = 2). Additionally, 
acupuncture did not appear to have positive effects on any other FMS symptoms besides 
pain. No serious adverse events were reported, but aversive side effects (such as nausea, 
feeling sore from the needle, or experiencing an exacerbation of FMS symptoms) were 
reported in three of the studies reviewed (Langhorst et al, 2010). Langhorst et al. 
systematically rated the studies reviewed for potential sources of methodological bias and 
found that the most significant pain reductions were observed in those studies with the 
highest bias potential. The most methodologically rigorous study they reviewed did not 
demonstrate a significant reduction in pain. Though the overall reduction in pain finding 
appeared promising, Langhorst et al. concluded that there were too many methodological 
concerns and potential sources of bias in the studies reviewed to allow them to 
recommend acupuncture with confidence as a sole treatment for FMS.  
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 Massage therapy has evidenced some potentially positive outcomes with FMS. In 
a review of the available research, Tsao (2007) found that massage was more beneficial 
than other types of treatments (e.g., transcutaneous electrical nerve stimulation [TENS], 
sham TENS, and progressive muscle relaxation) in three of the four studies they 
reviewed. These benefits included reduced symptoms of anxiety and depression, reduced 
pain severity and stiffness, less fatigue, and better sleep. However, in one of the studies 
reviewed by Tsao (Alnigenis, Bradley, Wallick, & Emsley, 2001), initial outcomes 
appeared promising, but at the conclusion of the study, no significant differences were 
observed between study groups. Alnigenis et al. (2001) investigated the use of Swedish 
massage versus standard medical care (randomly assigned) with 37 individuals with 
FMS. At 4 weeks, those receiving Swedish massage treatments showed improvement in 
self-efficacy and mobility compared to those receiving standard care, but at the 
conclusion of the study those differences were no longer observed and there were no 
other significant differences in treatment outcomes between the groups. Alnigenis et al. 
(2001) suggested this might have been due to the very small sample of participants (total 
N = 16; there were only four patients receiving the massage therapy, six receiving 
treatment as usual, and six receiving treatment as usual plus a call from a nurse). 
Additionally, in one of the studies Tsao (2007) reviewed (Brattberg, 1999), it was 
revealed that the benefits of massage therapy (in this case, it was connective tissue 
massage, administered over a 10 week period) do not appear to be long lasting. In 
Brattberg’s (1999) study, participant outcomes included a 37% reduction in pain levels, 
improvements in depressive symptoms, reduced use of pain relievers, and improvements 
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in quality of life scores. However, within 3 months following the treatment, only 70% of 
the pain reduction remained, and within 6 months, only 10% of the reductions in pain 
were maintained, suggesting a potential need for maintenance massage treatments to 
sustain therapeutic gains (Brattberg, 1999). 
In a more recent randomized, controlled study, Castro-Sánchez et al. (2011) also 
demonstrated some helpful benefits of massage therapy in FMS patients. Over the course 
of 20 weeks (one 90-minute treatment per week), they used myofascial release therapy on 
the participants, focusing on the eighteen tender point sites. Similar to improvements 
found in the review discussed above, Castro-Sánchez et al. found massage helped to 
significantly reduce pain and anxiety in FMS patients (n = 30) compared to FMS patients 
receiving sham treatment (n = 29). Massage therapy also led to significantly increased 
sleep quality as well as significant improvements in life quality. However, at the 6-month 
follow-up only improvements in sleep remained (Castro-Sánchez et al., 2011).  
 The practice of yoga also appears to provide some therapeutic benefits for FMS 
patients. It has been shown to significantly reduce pain severity ratings (Curtis, 
Osadchuk, & Katz, 2011; Da Silva, Lorenzi-Filho, & Lage, 2007), and to significantly 
improve overall scores using the Fibromyalgia Impact Questionnaire (FIQ; Da Silva et 
al., 2007). This scale, the FIQ, an assessment tool developed by Burckhardt, Clark, & 
Bennett (1991) assesses the impact of FMS symptoms across several areas of 
functioning, to include physical symptoms such as pain, fatigue, and stiffness as well as 
measures of subjective well-being, anxiety, and dysphoria.    
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 Additionally, in a meta-analysis of 16 studies testing varying methods of 
alternative and complementary movement interventions (e.g., tai chi, yoga, qigong, 
Pilates) with FMS patients, Mist, Firestone, and Jones (2013) found a significant positive 
outcome overall (14 of the 16 studies reported significantly positive outcomes) in terms 
of improvements in pain ratings and overall functioning. Throughout all the studies 
reviewed, Mist et al. only found two reports of increased pain in participants (one 
reported planter fasciitis exacerbation and one reported increased shoulder pain severity).  
Other than those two specific examples, there were no reports of aversive side effects or 
“serious adverse events” (across all of the studies) related to the exercise interventions 
(Mist et al., 2013, p. 258). In contrast to these positive findings, though, FMS patients 
interviewed by Arnold et al. (2008) for a phenomenological study frequently noted that 
physical activity seemed to make their pain more severe. It appears, then, that some 
caution may be necessary before these patients embark on a treatment involving physical 
activity.  
 Most of the studies of nonmedical treatments for patients with FMS have been 
small pilot studies or have lacked control groups and randomization. To fully understand 
their effectiveness, larger, more rigorous trials are called for (Terhorst, Schneider, Kim, 
Goozdich, & Stilley, 2011). Although many studies have shown some potentially 
therapeutic benefits, it is not likely that any one alternative treatment in particular could 
feasibly replace more traditional therapies. If alternative treatments are used in 
conjunction with traditional treatment regimens, though, additional relief from some FMS 
symptoms might be obtained (Sueiro, Estévez, Ayán, Cancela, & Martin, 2008).     
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 Patient self-management strategies.  FMS patients may also benefit from 
adopting some self-management strategies. Self-management “refers to the individual’s 
ability to manage the symptoms, treatment, physical, and psychosocial consequences and 
life style changes inherent in living with a chronic condition” (Barlow, Wright, Sheasby, 
Turner, & Hainsworth, 2002, p. 178). The implementation of self-management strategies 
is helpful in encouraging patients to become actively involved in managing their 
conditions (Iversen, Hammond, & Betteridge, 2010). Using these strategies may also 
assist with addressing symptoms that may not be completely targeted with other 
treatments and may help increase patients’ physical functioning (Jones, Kindler, & 
Liptan, 2011). For example, patients may engage in activities geared toward reducing 
stress such as engaging in consistent physical exercise or stretching, meditative practice, 
or deep breathing techniques (ACR, 2010). Kelley, Kelley, and Jones (2011) conducted a 
meta-analysis of exercise studies with FMS patients. Overall (across both aerobic and 
strength training interventions) exercise significantly reduced tender point scores. The 
researchers suggested that engaging in regular exercise might help reduce pain and 
tenderness in this population (Kelley et al., 2011). In another meta-analysis, Häuser et al. 
(2010) reviewed aerobic exercise studies with FMS patients. They found that the most 
optimal outcomes for FMS patients were observed when they exercised 2 to 3 times a 
week (at a “slight to moderate intensity”) for at least 4 to 6 weeks, and improvements 
were more likely to persist if the patients continued participating in aerobic exercise 
activities (p. R87). Significant improvements were observed in pain level, fatigue, and 
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fitness level. Additionally, depressive symptoms were significantly reduced and health 
related quality of life measures were significantly improved (Häuser et al, 2010) 
Another potentially useful self-management tool for FMS patients includes 
practicing good sleep hygiene (e.g., going to bed at the same time every night, wearing 
earplugs, soaking in a warm bath before bed, etc.). Quality sleep is important in 
facilitating emotional and physical symptom repair and sleep disturbances are common in 
FMS (ACR, 2010; Jones et al., 2011). For instance, Theadom, Cropley, and Humphrey 
(2007) found that 99% of the FMS participants in their study (N = 101) reported poor 
sleep quality, including such problems as waking up frequently throughout the night and 
waking up feeling unrefreshed. Poor sleep quality in their study was significantly 
associated with increased pain and fatigue and significantly associated with poorer social 
functioning. Similarly, Wagner, DiBonaventura, Chandran, and Cappelleri (2012) found 
that FMS patients (n = 2196) reported significantly more trouble with sleep quality than 
matched control participants without FMS (n = 2194). In Wagner et al.’s (2012) study, 
63.05% of their FMS participants reported two or more different types of problems with 
sleep quality.   
It may also be empowering and helpful for patients to educate themselves about 
FMS. In this way, they can become more proactive in their treatment and are able to more 
easily explain their condition to others (ACR, 2010). In addition, FMS patients may 
benefit from attending individual counseling sessions or interacting with others in FMS 
support groups (NFA, 2009). Support groups tend to be seen as helpful in general by 
those attending. Of the active participants attending support groups for FMS and chronic 
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fatigue syndrome (CFS), 80.4% reported that attending meetings was helpful to them 
(Friedberg, Leung, & Quick, 2005). In addition, Barker (2008) found that postings on a 
popular fibromyalgia electronic support group were useful in validating for participants 
that FMS was a true medical condition. This validation was also reported by FMS 
members attending an in-person support group (Friedberg et al., 2005). Barker (2008) 
also found that the exchanges in the group helped empower participants to be more 
assertive in their relationships with their physicians, finding solidarity against those in the 
medical community who disregarded FMS as a mental condition. Those attending a 
traditional support group also reported learning beneficial information about their 
disorder (there were typically guest speakers at each meeting) and feeling an increased 
sense of understanding from others (Friedberg et al., 2005).    
Costs Associated With FMS 
 Health care resources. The economic burden associated with FMS is significant. 
In the U.S., overall yearly costs are estimated to be between $12 and $14 billion (NFA, 
2009). In a cross-sectional, retrospective study, Sicras-Mainar et al. (2009) reviewed 
claims for primary care in an insurance database, and found that those patients with FMS 
(1,081 out of a total of 63,526 patients) “used significantly more health care resources 
than the reference population and had more sick leave, and the percentage of subjects 
with premature retirement was also significantly higher (p < 0.001 in all cases)” [Sicras-
Mainar et al., 2009, p. 1].  In another retrospective study, Berger, Dukes, Martin, 
Edelsberg, and Oster (2007) compared 33,176 FMS patients to an age and sex-matched 
group of non-FMS patients over a year (data were acquired from an insurance plan 
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database), and found that FMS patients’ health care costs were about 3 times higher. 
Berger et al. (2007) also found that they visited the doctor 4 times as often, were 4 times 
more likely to need emergency room services, and were significantly more likely to have 
other comorbidities (e.g., mood disorders, sleep disorders, or irritable bowel syndrome.  
In a retrospective observational study assessing the healthcare utilization costs of 
patients newly diagnosed with FMS (N = 2613), Sanchez et al. (2011) found that 
patients’ health care costs increased during the 12 months prior to diagnosis, and then 
more steeply increased in the first six months following diagnosis (averaging $3481 for 
the six-month period). The researchers then followed the patients for three years 
following the diagnosis. During that time, costs stabilized, and then increased again—to 
an average of $3588 over the final six months they followed the patients. Interestingly, 
only 8% to 10% of these costs were from medications prescribed specifically for pain. 
This suggests a good proportion of health care costs may come from the various 
comorbidities associated with FMS, and not from costs directly related to FMS (Sanchez 
et al., 2011). 
 Berger et al. (2010) found that in the year leading up to a FMS diagnosis, patients 
(N =1803) averaged 20 visits to physicians for various medical complaints. Health care 
costs were also shown to rise by an average of $1725 over a 2-year period (the year 
leading up to the diagnosis and the year following diagnosis). Similarly, White et al. 
(2009) also saw health care costs rise significantly from the year prior to diagnosis 
($5180) to the year following diagnosis ($6921). In contrast, those with established FMS 
diagnoses incurred medical expenses averaging $6673. This suggests that overall health 
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care expenses may level off after the diagnosis of FMS is established. However, White et 
al. (2009) found that prescription costs continued to increase across all groups, therefore 
driving health care costs even higher. In addition, following diagnosis of FMS, patients 
significantly increased visits to various health care providers (including primary care 
physicians, chiropractors, rheumatologists, and mental health professionals).   
 Similarly, Palacio et al. (2010) compared insurance data of FMS patients with that 
of matched controls (each group had 9,988 patients). They found similar outcomes to the 
studies discussed above. Those with FMS had significantly higher health care costs, 
particularly during the 12 months before receiving the diagnosis and in the first six 
months following diagnosis; mostly due to increased numbers of office appointments, 
increased numbers of laboratory tests, and increased prescriptions to control pain 
symptoms (Palacio et al., 2010). Even more support for the economic burden of FMS was 
found by Lachaine et al. (2010) in their retrospective cohort study using Canadian health 
care plan data. They found that FMS patients accumulated 30% more in yearly health 
care costs than matched controls (N =16,010 for both groups) without FMS (C$4065 
versus C$2766). This translated into C$1299 more in yearly costs per FMS patient. To 
illustrate the substantial costs involved, the researchers calculated that in the cohort they 
studied, that added up to C$20,796,990. Lachaine et al. suggested that applying this 
finding to a U.S. population would drive the cost even higher because of the increased 
cost of health care provision in the U.S.  These significant costs in health care utilization 
by FMS patients emphasize the necessity for more scientific inquiry regarding FMS in 
order to lead to increasingly efficacious treatments (Spaeth, 2009). When symptoms 
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become better targeted and FMS becomes better managed, health care costs should be 
reduced (Palacio et al., 2010).  
 Occupational. Having FMS can significantly impact occupational activities and 
productivity while on the job, leading to monetary losses for both employers and 
employees. A common theme reported by FMS patients in a focus group study (N = 48) 
was difficulties with occupational status. While nearly half of the sample reported leaving 
the job force completely, others reported needing to work fewer hours because of their 
symptoms or that they frequently switched jobs (Arnold et al., 2008). Additionally, Choy 
et al. (2010) interviewed 800 FMS patients, and found that 48% of those who were 
employed missed at least 10 days of work in the prior year due to their symptoms. Sicras-
Mainar et al. (2009) found that 81% of economic losses related to an FMS diagnosis were 
due to losses in earnings (e.g., missing work or retiring early). Losses in productivity and 
days on the job as well as increases in health care costs were also observed by Kleinman 
et al. (2009). Compared to employees without FMS and those with OA, employees with 
FMS had the highest costs related to prescription medications, the most absentee days 
due to illness, and the highest costs due to workers’ compensation claims (Kleinman et 
al., 2009).  
In another study, Howard et al. (2010) investigated a group of patients with 
chronic disabling occupational musculoskeletal disorders (CDOMD) receiving 
rehabilitative treatment. Following a year-long treatment program, the patients in the 
group who met criteria for FMS (23.2%) were “5.6 times less likely to return to work and 
2.7 times less likely to retain work” than those who did not have FMS (p. 1190). Those 
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numbers were even higher for the women with FMS in the group. They were “9.6 times 
less likely to return to work and 4.3 times less likely to retain work” (p. 1190).  Those 
with FMS were also more likely to evidence psychological distress, report symptoms of 
depression, lower quality of life, increased perceptions of disability (Howard et al., 
2010).  
Interpersonal. FMS may negatively impact an individual’s relationships. For 
instance, people with FMS may feel as if others do not understand or as if they discount 
the validity of their diagnosis because it has no outward signs (Juuso, Skär, Olsson, & 
Söderberg, 2011). FMS patients also report having reduced social interactions with 
friends and family due to the limitations placed on them by their condition (Arnold et al., 
2008; Lempp, Hatch, Carville, & Choy, 2009). Caregiver responsibilities are also 
frequently compromised in these patients, with many of the tasks of providing care for 
children, as well as other daily household chores, falling on other family members 
(Arnold et al., 2008).  
FMS has also been associated with sexual dysfunction in intimate relationships 
(Bazzichi et al., 2012; Prins, Woertman, Kool, & Geenen, 2006; Rico-Villademoros et 
al., 2012). For example, compared to healthy male and female control participants (n = 
86), Rico-Villademoros et al. (2012) found that fibromyalgia patients (both male and 
female; n = 293) reported significantly higher rates of sexual dysfunction (86.9% versus 
23.6%). Bazzichi et al. (2012) conducted a review of the extant literature (35 journal 
articles) regarding this topic, and found that FMS patients frequently had difficulty with 
their sexual relationships. Though some of the articles they reviewed had conflicting 
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outcomes on some measures, one consistent finding was that FMS patients reported low 
measures of sexual satisfaction. A decrease in sexual desire was also a frequently 
reported problem in this population. Some potential factors discussed that may contribute 
to reduced desire in these patients include the presence of depressive symptoms, localized 
pain syndromes (such as vulvodynia or interstitial cystitis), or the side effects of 
medications used to treat FMS symptoms (Bazzichi et al., 2012).  
Interestingly, in their review of the literature Bazzichi et al. (2012) found the 
chronic pain experienced by these patients to have only a moderate association with 
sexual dysfunction. In other studies, they observed that the pain either played no role in 
sexual dysfunction or only had a weak relationship. In one of the studies they reviewed, 
Prins et al. (2006) found that psychological distress (and not pain) significantly predicted 
sexual dysfunction. Prins et al. concluded that the problems these patients tend to have 
with desire and satisfaction appear to be more strongly related to psychological 
disturbance than to actual physiology.    
Psychological Functioning 
 Though FMS is not a psychological disorder, psychological variables may act to 
trigger symptom flare-ups, exacerbate existing FMS symptoms, and may also be 
associated with increased disability (Bennett, 2009; DeLeo, 2006; Verbunt, Pernot, & 
Smeets, 2008). For example, 83% of FMS patients who took part in an Internet survey (N 
= 2,596) reported that experiencing emotional distress worsened their symptoms. Other 
psychological factors noted by FMS patients that exacerbated symptoms included mental 
stress and worrying (Bennett et al., 2007). Verbunt et al. (2008) found that mental health 
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was the most significant predictor (p < .02) of perceived disability in FMS patients and 
was a stronger predictor than physical functioning (p < .05). These patients also reported 
significantly greater psychological distress compared to other chronic pain patients 
(patients with chronic lower back pain or chronic regional pain syndrome, p < .01) 
[Verbunt et al., 2008].  Bennett (2009) asserted that in some cases patients might not be 
able to attain relief from the mental distress and pain until the psychological factors are 
addressed.   
FMS patients are likely to have comorbid psychiatric diagnoses (González, 
Elorza, & Failde, 2010; Hassett et al., 2008; van Middendorp, Lumley, Jacobs, Bijlsma, 
& Geenen, 2010). Uguz et al. (2010) found the prevalence of any Axis I disorder 
(American Psychiatric Association, 2013) in their sample of 103 FMS patients was 
47.6% compared to 15.7% in 83 socio-demographically matched control participants. 
The most common Axis I diagnosis observed in Uguz et al.’s study was major depressive 
disorder—14.6% compared to 4.8% in controls and to an estimated 7% in the general 
population (American Psychiatric Association, 2013). Uguz et al. also found increased 
rates of Axis II (American Psychiatric Association, 2013) disorders in their sample of 
FMS patients compared to the controls—31.1% versus 13.3%. The most commonly 
observed personality disorder in the FMS patients in Uguz et al.’s study was obsessive-
compulsive personality disorder—23.3% versus 3.6% of controls. This was a much larger 
percentage than that found in the general population estimate of between 2.1% and 7.9% 
(American Psychiatric Association, 2013).  
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Symptoms of depression that may not meet full criteria for diagnosis are also 
frequently observed in FMS patients. For example, in a study of 60 FMS participants, 
fully half of the sample reported symptoms of depression, and 33% of those reported 
moderate to severe symptoms (dos Santos et al., 2012). Similarly, Aguglia et al. (2011) 
found that 83.3% of their sample of FMS patients (N = 30) evidenced depressive 
symptoms, while 46% of them evidenced depressive symptom severity consistent with 
the diagnosis of major depressive disorder. Those participants reporting depressive 
symptoms also reported reductions in quality of life, increased pain severity ratings, and 
increased incidence of stressful life events compared to those without depressive 
symptoms.    
This is important, because even though FMS patients with depressive 
symptomology may not meet the full criteria for diagnosable depressive disorders, having 
those symptoms would still have the ability to negatively impact their functioning. In 
addition, depressive symptoms are associated with greater disability (Phillips & 
Stuifbergen, 2010), reductions in pain thresholds and quality of life measures (Aguglia et 
al., 2011), and more severe pain ratings (Baker et al., 2008) in these patients.   
FMS patients have also been found to have higher rates of depression than other 
chronic pain patients. Wolfe and Michaud (2009) found that 33.4% of FMS patients had 
depression compared to 15.1% of RA patients. Similarly, Hassett, et al. (2000) found 
significantly higher rates of depression in FMS patients compared to RA patients (nearly 
44% versus 19.9%). In another investigation, Ozcetin et al. (2007) compared FMS 
patients with RA and knee OA patients. They found 41% of the FMS patients exhibited 
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depression compared to 26.50% of RA patients and 26.30% of knee OA patients. FMS 
patients in their study also evidenced lower quality of life scores in the domains of 
“physical role, emotional role, pain, general health, vitality, and social functioning” 
compared to RA and knee OA patients (Ozcetin et al., 2007, p. 128). 
In Aguglia et al.’s study (2011), they concluded, “depressive symptoms are more 
the rule than the exception in patients with fibromyalgia” (p. 265). The first explanation 
for this they discussed was that depression might be a response to having a disorder such 
as FMS, which is chronic and impairs functioning. However, that would not explain why 
FMS patients have increased rates of depression compared to other patients with severe 
and chronic diseases. The second potential explanation they discussed was that perhaps 
depression was already present and produced the FMS symptoms. Aguglia et al. rejected 
that explanation as well, stating that it does not explain why some FMS patients never 
develop depressive symptomology. The more likely explanation for these authors is that 
depression and FMS likely “share overlapping pathophysiological processes” (Aguglia et 
al., 2011, p.264; Maletic & Raison, 2009). Maletic and Raison (2009) suggested that 
individuals may have similar genetic predispositions that are activated by risk factors. In 
their words, 
Chief among environmental risk factors are psychosocial stress and illness, both 
of which promote, in vulnerable individuals, relative resistance to glucocorticoids, 
increased sympathetic/decreased parasympathetic activity and increased 
production and release of proinflammatory mediators. Dysregulation of 
stress/inflammatory pathways promotes alterations in brain circuitry that 
50 
 
modulates mood, pain and the stress response. Over time, these functional 
changes likely promote disruptions in neurotrophic support and disturbances of 
glia-neuronal communication. These changes, in turn, have been associated with 
the related processes of central sensitization in pain disorders and “kindling” in 
depression, both of which may account for the progressive and self-perpetuating 
nature of these disorders, especially when inadequately treated. (p. 4292) 
 Raphael, Janal, Nayak, Schwartz, and Gallagher (2004) found some potential 
evidence for this genetic underpinning. They had four groups of participants: 1) those 
who had both FMS and major depressive disorder (MDD), 2) those with FMS only, 3) 
those with MDD only, and 4) those who did not have either FMS or MDD. They then 
interviewed first-degree relatives of the participants and found that “rates of MDD in the 
relatives of probands with FM but without personal histories of MDD were virtually 
identical to rates of MDD in the relatives of probands with MDD themselves.”(Raphael et 
al., 2004, p. 449).  Labeling FMS a depression spectrum disorder, Raphael et al. 
concluded that FMS and depression are part of the same affective spectrum, and that 
FMS may present as a manifestation of the genetic risk for depression.  
Symptoms of anxiety are also commonly observed in FMS patients. In Dos 
Santos et al.’s study (2012), 88% of their sample of FMS patients (N = 60) reported 
experiencing anxiety symptoms. Severe symptoms of anxiety were reported in 43% of 
the participants. Posttraumatic stress disorder (PTSD) also appears to be a frequent 
comorbid diagnosis with FMS (Peres, Gonçalves, & Peres, 2009). For example, in a 
sample of male patients (N = 124) who had experienced combat-related trauma, 49% of 
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those meeting the criteria for PTSD (n = 55) also met criteria for FMS (Amital et al., 
2006). This was in contrast to only 5% of those diagnosed with major depressive disorder 
(n = 20) and with 0% in control participants (n = 49). In addition, symptoms of PTSD 
were significantly more severe in those with comorbid FMS. Symptoms of PTSD (though 
not meeting the full criteria) were also observed in 40.9% of dos Santo et al.’s (2012) 
participants.  
Amital et al. (2006) attributed the development of FMS in these patients to the 
already present PTSD symptoms. They suggested that the distress that results from a 
traumatic life event and the subsequent development of PTSD might contribute to the 
later development of “ill-defined pain syndromes” (p. 667). They went on to propose that 
PTSD and FMS “might be driven from a common origin reflecting different aspects of 
adaptive behavior and somatization to an initiating traumatic event” (Amital et al., 2006, 
p. 667). 
Coping With FMS 
 Considering that fibromyalgia patients tend to receive only moderate benefit from 
medical interventions for their multiple symptoms, it is important to consider how they 
manage to “cope with a life encumbered with chronic pain and fatigue” (Traska, 
Rutledge, Mouttapa, Weiss, & Aquino, 2011, p. 632). In their qualitative study, Traska et 
al. conducted a group interview with eight female fibromyalgia patients regarding the 
strategies they used to cope with their multiple symptoms. An important theme discussed 
was the need for pacing themselves and planning activities in advance. The participants 
wanted to avoid overdoing it or taking on more than they could handle for fear of 
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exacerbating symptoms or triggering a flare. This included such things as prioritizing 
tasks to be sure to complete the most important ones, seeking help with some of the more 
arduous tasks, and limiting their social activity participation. This also included making 
modifications as necessary to make tasks easier to complete, such as using a shower chair 
instead of standing in the shower to conserve energy, and avoiding known symptom 
triggers such as cold water and being out in chilly weather. These participants also noted 
that it was important to keep physically moving. They reported feeling physically 
restless, and that it helped to remain in motion (though not through exercise). Social 
support was also reported as being important for coping in Traska et al.’s participants. 
Some of the participants reported that they attended support groups and that it helped to 
share experiences with others who truly understood. Another theme that arose in their 
interviews was the use of mind and body methods to aid in coping. This included 
relaxation strategies such as meditation or listening to soothing music, distraction 
activities such as writing in a journal, singing, etc., and using biofeedback and breathing 
techniques to gain some control over physiological processes. Traska et al. (2011) 
suggested that these techniques may have been helpful because they either redirect the 
focus from the pain and other symptoms to the new activity, or because they redirect the 
focus to another physiological activity (such as with the use of biofeedback).   
 Sim and Madden (2008) conducted a meta-synthesis of qualititative studies (N = 
23 studies reviewed) related to the subjective experiences of fibromyalgia patients. Some 
of the strategies that emerged in their meta-synthesis were similar to those discussed 
above in Traska et al.’s (2011) study. These included pacing activities, planning in 
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advance, limiting social activities, and seeking assistance from support groups. Other 
types of strategies discussed include working on thinking in a more positive manner, 
redefining one’s self-identity, developing a more complete understanding of FMS, and 
reevaluating one’s life and roles. However, in their meta-synthesis, Sim and Madden also 
found that emotion based (e.g., challenging aversive thoughts or feelings) and problem 
based (e.g., actively addressing challenges presented by FMS) coping methods had 
variable success, and were sometimes unhelpful. The individuals’ responses to such 
coping strategies were idiosyncratic and it remained “unclear why some use such 
strategies effectively, whilst others struggle to cope” (Sim & Madden, 2008, p. 64). 
It is important to identify strategies that offer the most optimal outcomes with 
FMS patients in order to improve treatment regimens in this population (Rodero et al., 
2011). Rodero et al. investigated behavioral coping strategies and measures of pain 
acceptance in 167 FMS patients. They found that the acceptance of pain (e.g., continuing 
to function and carry out tasks in spite of symptoms) was significantly associated with 
more favorable outcomes in terms of reduction of symptoms, distress, life impact, and 
improvement in functioning. Interestingly, the coping strategies of resting and 
guarding—geared toward reducing FMS impact and symptoms and avoiding distressing 
thoughts and feelings, were shown to be associated with “poorer general functioning” (p. 
146). Rodero et al. concluded that acceptance-based strategies might assist patients with 
adapting to FMS. 
 Similar themes were expressed by FMS patients in two narrative review studies 
relating to FMS patients’ experiences with FMS (Juuso et al., 2011; McMahon, Murray, 
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Sanderson, & Daiches, 2012). Juuso et al. (2011) interviewed 15 FMS patients. When 
discussing their experiences with FMS and how they managed their lives with it, they 
reported that they learned to adapt to their symptoms and continued with the tasks of 
daily life despite the pain. Though they did not specifically state that they had accepted 
the pain, they did express that they had become able to live with the pain, and had come 
to a place of acceptance that this was the way life was going to be for them. They 
continued as many of the activities in their lives as was physically possible. They also 
reported that it was important for them to remain optimistic and to think positively (Juuso 
et al., 2011). Similarly, some of the participants with FMS (n = 10) in McMahon et al.’s 
narrative review study tended to report pushing past the symptoms and attempting to 
continue performing their daily tasks in order to fulfill role obligations. Others reported 
scaling back activities so as to not over exert themselves and increase their symptoms. 
Participants in McMahon et al.’s study also spoke of the importance of positive thinking 
and accepting their limitations.    
 Theadom et al. (2007) investigated the influence of coping strategies on health-
related quality of life in fibromyalgia patients (N = 101). Participants reported which 
types of coping strategies they used most often (problem-focused vs. emotion-focused 
strategies). Only one aspect of health-related quality of life—physical functioning, was 
predicted by the use of a particular coping method. They found that the use of restraint 
coping (a problem-focused strategy that involves “delaying coping or not managing a 
stressful situation in some way”) was significantly associated with reduced physical 
functioning (p. 149). Though the researchers did not offer an explanation for why this 
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may be so, they suggested that in individuals with FMS, putting off coping with a certain 
situation until a better time may be “detrimental to physical functioning” (Theadom et al., 
2007, p. 149).  
Ablin, Cohen, Neumann, Kaplan, and Buskila (2008) compared the coping styles 
of 77 patients with FMS to 48 healthy volunteer control participants. They found that the 
FMS patients were significantly more likely than the controls to engage in the coping 
strategies of suppression (avoiding the stressor), help-seeking (asking others to assist), 
replacement (finding alternative ways of fulfilling duties), substitution (engaging in 
activities geared toward reducing stress), and reversal (behaving in a way contrary to how 
one is actually feeling). These strategies were not compared to any health outcomes, so it 
is unclear how and to what extent they impacted the patients with FMS. However, Ablin 
et al. explained that more passive, avoidant strategies of coping such as suppression, 
replacement, and substitution (three of the strategies FMS patients engaged in 
significantly more than controls) tend to be related to maladaptive outcomes. They 
suggested that it might be useful to use cognitive treatment strategies to address and 
modify the coping strategies used by these patients.  
Theories of Pain 
Gate Control Theory  
 In order to understand how laughter may be related to affect and pain perception, 
it is important to first have foundational knowledge regarding the available theories about 
pain. Developed in 1965, the gate control theory of pain was the first to consider 
psychological factors and the central nervous system’s relationships with the pain 
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experience (DeLeo, 2006; Melzack, 1999b; Melzack & Wall, 1965). Until that time, and 
dating back to Descartes in the 1600s, pain was thought to be more of a reflex response 
with a direct relationship between the noxious stimulus and the pain or injury. It was 
assumed that there was a particular pathway from the site of the stimulus (pain receptor) 
to a centralized pain center located in the brain and that the pain would be ameliorated if 
the pathway was cut. However, managing pain in this way may not lead to relief at all. 
Instead, cutting the nerves of the pathway sometimes enhanced the pain even further, 
leading to a chronic pain state (DeLeo, 2006). Because a direct stimulus-pain relationship 
was assumed, those presenting with chronic pain with no observable physiological signs 
of disease or injury were commonly referred for psychiatric care (Melzack, 1999b).  
 With the gate control theory, emphasis was placed on the roles of the spinal dorsal 
horns (where incoming stimuli were managed) and the brain (now considered an active 
and dynamic modulator of the pain experience) in the objective and subjective 
components of pain (Melzack, 1999b). It was proposed that there were neural gates that 
could be opened or closed by both information coming from sensory experiences as well 
as from signal transmissions from the brain (Melzack, 2008). In this way, psychological 
components such as “attention, emotion, and memories of prior experiences” could 
influence and modify the sensory input received (Melzack & Wall, 1965, p. 976).  
Though some pain can come on suddenly and be overwhelming and out of an 
individual’s control (like the pain that comes with a heart attack), other types of pain may 
be subject to some individual influence. Melzack and Wall suggested that in those cases 
any intervention that reduces the sensory input might reduce pain. This could include 
57 
 
distracting oneself by thinking of other things or using other strategies to control pain 
levels. As an example, they cited the case of a man who reduced his pain through tapping 
“his fingers on a hard surface” (Trent, 1956, as cited in Melzack & Wall, 1965, p. 978). 
Psychological variables became more important to the pain process and led to new ways 
of thinking about how to manage pain. The focus switched from “cutting nerves and 
pathways” to relieve the pain to finding other treatments designed to modify the sensory 
input (Melzack, 1999b, p.880) and to alter the individual’s perceptions of pain (Kerns et 
al., 2011).  
Neuromatrix Theory    
 Despite the advances in our understanding of pain with the development of the 
gate control theory, phenomena like phantom pain experienced by individuals with 
amputations or paralysis and chronic pain in the absence of observable stimuli or injury 
(or with the pain response being disproportionate to the stimuli) remained perplexing for 
pain researchers (Melzack, 1999a; Melzack, 2005). In chronic pain syndromes, the pain 
itself is the disease, rather than a warning to the individual that injury is or will be 
occurring. It is an indication that something has malfunctioned within the neural 
mechanisms responsible for the pain warnings (Melzack, 2001).  
To Melzack, this was evidence that the “brain itself can generate every quality of 
experience, including pain, which is normally triggered by sensory input” (Melzack, 
1999b, p. 881). From these observations and further research, Melzack went on to expand 
on the concepts in the gate control theory and developed a new conceptualization of pain 
he titled the neuromatrix theory (Melzack, 2001). Regarding this new conceptualization, 
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Melzack (2001) stated, “good theories are instrumental in producing facts that eventually 
require a new theory to incorporate them. And this is what has happened (p. 1378). He 
went on to state that the neuromatrix theory “does not negate the gate theory”, but 
explained that the gate control theory did not explain well the experiences of phantom 
limb pain patients, and a new theory was necessary to more completely address these 
types of experiences (Melzack, 2001, p. 1378). Melzack proposed that pain is produced 
from a “neural network in the brain”, which is susceptible to multiple types of influences 
and stimuli (Melzack, 1999b, p. 880; Melzack, 2005). Melzack suggested that the 
neuromatrix’s structure is mostly brought about through the influence of genes, but that 
the expression of it will be modified by our experiences and various inputs (Melzack, 
1999b; Melzack, 2005).  
An important tenet of the neuromatrix theory is that the sensory input from a 
noxious stimulus (that causes pain and injury) is only one of the potential sources of input 
that can lead to the experience of pain (the output from the neuromatrix; Melzack, 
1999b). According to this model, there are many dimensions in the perceptual 
experience. It is assumed that each dimension is managed by a certain subset of nerve cell 
networks within the neuromatrix (Melzack, 2005). Among these are the sensory 
dimension as well as the cognitive and affective dimensions (Melzack, 2005). The 
sensory dimension includes the stimuli from musculoskeletal and body tissue inputs; the 
cognitive dimension involves such inputs as the meaning attributed to pain, pain-related 
anxiety, or previous associations of pain experience; and the affective dimension is 
related to the emotional experience of pain along with the body’s attempt to maintain 
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homeostasis through the regulation of the stress response system (Melzack, 2005). 
Important to the affective dimension of the neuromatrix is the limbic system of the brain, 
which “evokes the essential motivational-affective dimension of pain” (Melzack, 1999b, 
p. 882).  
Neuromatrix and Chronic Pain 
 Melzack (1999b) suggested that it is not a single particular sensory input that 
creates the chronic pain response. Rather, it is the “output of the neuromatrix” that leads 
to the perception of pain (p. 882). “Stimuli may trigger the patterns but do not produce 
them” (Melzack, 2005, p. 86). Melzack stated that “the neuromatrix, which is 
spontaneously active in the absence of sensory input, and which integrates multiple 
inputs from body and brain, provides a plausible explanation for the majority of chronic 
pain syndromes” (p. 882). “The brain does more than direct and analyze inputs; it 
generates perceptual experience even when no external inputs occur” (Melzack, 1999b, p. 
883).   
Melzack (2005) suggested that perhaps the neuromatrix is alerted when something 
stressful happens (e.g., a virus, an injury or accident, or a psychological stressor) but 
malfunctions and continues to remain alerted after the stress has passed. The constant 
state of arousal in the neuromatrix may lead to fatigue symptoms as well as to increased 
muscle tension (which may then be responsible for the characteristic tender points found 
in FMS). In essence, it is as if the neural gates are continuously open to be on guard 
against threats, causing a constant level of physiological stress. As the body attempts to 
regain a homeostatic state, cortisol is released in large quantities. If the pain state 
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continues, the cortisol continues to be pumped out, and eventually leads to it being 
depleted. This depletion is associated with symptoms such as muscle weakness and 
fatigue. It may also lead to bone decalcification and neural degeneration (Melzack, 2001). 
Because the chronic pain process appears to be related to a failed effort at regaining 
homeostasis instead of actual sensory inputs triggering the pain, it could help explain why 
traditional pain therapies geared toward managing stimulus driven pain do not work 
effectively with chronic pain syndromes (Melzack, 2001).   
McAllister (2015) suggested that treatments for chronic pain, then, should focus 
on changing the neuromatrix in order to reduce pain in these patients. In order to change 
the neuromatrix, treatment should involve an interdisciplinary approach in order to target 
several dimensions of the pain experience. For example, in addition to conventional 
medical therapies and physical therapy, these patients should also receive interventions 
and education from health psychologists and cognitive behavioral therapists. In this way, 
the patient is also reducing the impact of cognitive and affective inputs on the pain 
experience (McAllister, 2015). 
Laughter  
 Though laughter has been demonstrated to have positive influences on many 
varying physiological markers and conditions, it has yet to be used as a formal treatment 
in medical settings (Dolgoff-Kaspar, Baldwin, Johnson, Edling, & Sethi, 2012). For 
example, laughter is associated with an increase in the production of beta-endorphins and 
human growth hormone (HGH), not only during the actual laughter, but also in the 
anticipation of laughter. These beneficial changes in neuropeptides and neuroendocrine 
61 
 
functioning brought about by laughter may help reduce stress levels and may be 
accompanied by improvements in affect (Berk & Tan, 2006).   
In terms of medical conditions, laughter is frequently used to enhance coping in 
cancer patients (Christie & Moore, 2005). Johnson (2002) interviewed nine breast cancer 
survivors and found that a common theme among them was that laughter helped them to 
cope with their diagnosis. They also reported that it became easier over time to find 
humor in their situation, and that laughter helped them to relax and persevere through 
their treatment and recovery. Also, in a cross-sectional, survey study of breast cancer 
patients, Lengacher et al. (2002) found that 21% of their sample (N = 105) reported using 
humor or laughter therapy to help them reduce stress. In a more formal use of laughter 
with breast cancer patients, Kim, Kim, Kim, Lee, and Yu (2009) found that laughter 
therapy (four sixty-minute group sessions over two weeks) significantly decreased 
measures of stress, depression and anxiety in those receiving laughter therapy (n = 31) 
versus those in the control group (n = 29).  
Laughter has also been found to reduce levels of blood prorenin (a receptor gene 
implicated in the progression of kidney disease) and to decrease plasma renin (high levels 
are associated with injury to small blood vessels) in diabetic patients, potentially 
providing some protection against microvascular problems and the progression of 
diabetic nephropathy (Hayashi, Urayama et al., 2007; Nasir et al., 2005). Laughter has 
also been shown to modulate the physiological stress markers in patients with advanced 
kidney disease receiving hemodialysis treatment (Bertini et al., 2010) as well as in a 
healthy sample of adult males (Toda, Kusakabe, Nagasawa, Kitamura, & Morimoto, 
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2007); and it has been found to have several potentially beneficial effects on immune 
system functioning (Bennett, Zeller, Rosenberg, & McCann, 2003; Berk, Felten, Tan, 
Bittman, & Westengard, 2001; Hayashi, Tsujii et al., 2007; Matsuzaki, Nakajima, 
Ishigami, Tanno, & Yoshino, 2006).  
More recently, Kong et al. (2014) tested laughter therapy on patients with breast 
cancer undergoing radiation therapy. Those in the experimental group receiving laughter 
therapy (n = 15) reported less severe pain and had a lower incidence of more severe 
radiation dermatitis than those in the control group (n = 19), but the results were not 
significant. However, the researchers found that the participants in the experimental 
group tended to have larger breasts and had increased incidence of diabetes compared to 
the participants in the control group, and those factors are related with increased risk of 
experiencing more severe radiation burns. Despite their increased risk of radiation 
dermatitis, they still reported less pain and observed lower incidence of more severe 
burns. Kong et al. suggested that this provided additional strength to their findings 
despite the results not reaching the level of statistical significance. Because this was 
simply a small pilot study, the researchers proposed a larger, randomized study to test this 
further.  
Laughter appears to have many beneficial effects on health. However, in one 
study, Lebowitz, Suh, Diaz, and Emery (2011) found that the physical act of laughter was 
actually shown to worsen patients’ physical status. It was found to lead to lung 
hyperinflation in patients with chronic obstructive pulmonary disease (COPD). However, 
Lebowitz et al. also found that having a positive emotional state had protective effects in 
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terms of life quality and psychological factors. The researchers concluded, “…less overt 
expressions of humor may be more favorable than overt laughter in patients with COPD.” 
(p. 318). In contrast, Brutsche et al. (2008) found that only those COPD patients laughing 
the most intensely suffered any deleterious effects (increased hyperinflation of the lungs). 
Those who laughed less intensely demonstrated a beneficial reduction in lung volume and 
reported higher ratings of cheerfulness.  
Similarly, Kimata (2004) found that laughter did not negatively influence patients 
with bronchial asthma. Kimata conducted two investigations with two sets of 
participants. In the first study, they tested 20 individuals with asthma triggered by dust 
mites (compared to 20 healthy participants without asthma), and in the second they tested 
15 participants with asthma triggered by epigallocatechin gallate (EGCg; a component 
found in green tea leaves) compared to 15 healthy participants without asthma. Each 
group had baseline measures of allergen responsiveness taken and then were randomly 
assigned to watch a humorous or non-humorous film. Immediately following the film, 
participants were exposed to the allergen and bronchial responsiveness was measured. 
Two weeks later, participants watched the other video, and the same procedure was 
followed at the conclusion of the film. All participants were noted to be laughing during 
the humorous film, while none of the participants were observed laughing during the non-
humorous film. Kimata found that laughter not only did not appear to aggravate asthma, 
but it acted to significantly decrease responsiveness to asthma triggers.  
Laughter has also evidenced beneficial effects on patients with atopic eczema 
(Kimata, 2007a, 2007b, 2009). It has been shown to decrease the production of 
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immunoglobulin E (IgE) by seminal cells (providing potential protective effects against 
allergy responses affecting reproductive functioning), to increase the production of 
melatonin in nursing mothers with infants affected with atopic eczema (it also resulted in 
reductions in the infants’ allergic responses), and has been found to increase the 
production of dermicidin-derived peptides in the sweat of patients with atopic eczema 
(enhancing antimicrobial protection; Kimata, 2007a, 2007b, 2009).  
Simulated laughter (as part of a laughter yoga intervention) has also been shown 
to improve heart rate variability and mood in both healthy participants (Sakuragi et al, 
2002) as well as in patients waiting for organ transplants (Dolgoff-Kaspar et al., 2012); 
and it has been shown to have positive effects on vascular function (Sugawara, Tarumi, & 
Tanaka, 2010). Additionally, among older adults, laughter therapy has produced 
improvements in levels of anxiety and depression, cognition, sleep, feelings of subjective 
wellbeing, and quality of life (Ganz & Jacobs, 2014; Ko & Youn, 2011). It may also 
provide some therapeutic benefits to those with Alzheimer’s disease or dementia (Takeda 
et al., 2010; Walter et al., 2007).  
Laughter’s Influence on Pain 
 Laughter and induced acute pain. The effects of laughter on pain have typically 
been investigated using healthy study participants and have tended to be conducted in the 
laboratory where both the laughter and the pain (acute) were induced (Dunbar et al., 
2011; Mahony et al., 2001; Stuber et al., 2009; Zweyer et al., 2004). Though the 
circumstances were artificially created, the outcomes were fairly consistent in providing 
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evidence that laughter is beneficial in reducing some of the deleterious effects of acute 
pain.  
In an older study of induced laughter and acute pain (through the use of a blood 
pressure cuff), Mahony et al. (2001) investigated the influence of expectations on 
discomfort thresholds following the viewing of either a relaxing (a film about Hawaii) or 
funny (an episode of Seinfeld) video. Study participants (nonclinical volunteers from the 
community) were either led to believe that viewing the videos would reduce or increase 
their pain thresholds. A control group watched the videos without any instructions on 
what to expect. Following the viewing of the videos, participants rated them. The funny 
video was rated as significantly funnier (and nearly every participant in the funny video 
condition rated the video as funny) than the relaxation video, and the relaxation video 
was rated as significantly more relaxing than the funny video. In addition, each 
participant in the funny video condition was observed laughing on at least one occasion 
during the viewing (Mahony et al, 2001).  
 Overall, both the relaxing and funny videos increased participants’ discomfort 
thresholds (they could tolerate the blood pressure cuff squeezing their arms for longer 
periods of time) from baseline. When looking at the influence of expectations, Mahony et 
al. (2001) found that those who expected their pain threshold to decrease did exhibit 
lower discomfort thresholds than those in the control group, whereas those who expected 
their pain threshold to increase did not evidence a significant difference from the control 
group. Mahony et al. suggested that might be due to culturally implicit expectations that 
laughter and relaxation will increase pain thresholds. Those in the control conditions may 
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have already expected their discomfort thresholds to increase following laughter or 
relaxation without being instructed.  
 An important finding of Mahony et al.’s (2001) study for the purposes of this 
current research is that scores on sense of humor measures were not associated with 
discomfort thresholds. Whether or not participants were high on the humor trait scale, 
there was significant concordance from them on how funny the Seinfeld episode was. 
This indicates that the benefits of laughter are available to anyone, not just those who 
measure higher on the humor trait scale. Though Mahoney et al. found that relaxation and 
laughter had similar effects on discomfort thresholds in this study, they suggested that 
laughter may have a qualitative benefit over relaxation, in that, “It is fairly safe to assume 
that most people in pain would prefer a laughter intervention, particularly one of their 
own choosing, over relaxation exercises, hypnotism, or reading a brochure arguing the 
benefits of a particular program” (p. 225). The researchers went on to speculate that 
laughter’s unique qualitative benefits may be due to such factors such as resulting 
“…enhanced mood, physiological and emotional arousal, altered perspective, and 
increased sense of control” (Mahony et al., 2001, p. 225)—all factors that have yet to be 
investigated by researchers.     
In another example, Dunbar et al. (2011) conducted a series of six experiments 
studying laughter’s effects on induced acute pain tolerance. Five of the studies took place 
in a laboratory environment, while the sixth one took place in a public setting. In these 
studies, laughter was induced through either the use of a comedy video or through a live 
comedy show with actors, and pain was induced through a frozen wine-sleeve, a blood 
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pressure cuff, or a “ski exercise” (participants having their backs against a wall while 
bending their knees until they formed 90° angles). A baseline measure of pain tolerance 
was taken for each participant before each experiment and then once more following the 
experiment to assess for within-person differences. Dunbar et al. proposed that if 
increases in pain tolerance were observed following laughter, that would be an indication 
of increased endorphin levels brought about from the act of laughing. To test the 
possibility that changes in pain tolerance could be brought about through laughter-related 
affect changes rather than through the physical act of laughter alone, the researchers also 
measured affect in two of the studies. Laughter incidence was measured through one of 
the following methods: researcher observation and recording, recordings taken by tape 
recorders worn by the participants, or through participant self-report. Results showed that 
rates of laughter were significantly higher in the comedy video conditions than in control 
conditions. Pain tolerance was also found to be significantly higher in the comedy versus 
control video conditions. There was no direct effect of affect alone on pain threshold, 
which the researchers felt was increasing evidence for endorphins released during 
laughter being responsible for the changes in pain tolerance. They concluded that 
laughter itself and not affect was responsible for the increase in pain threshold. The 
researchers also found that those in comedy conditions that took place in groups 
evidenced even higher levels of pain tolerance than those in the funny video condition 
where they watched on their own.  The researchers suggested, “Experiencing comedy in a 
group ramps up the laughter response, and this is reflected in a proportional change in 
pain threshold” (Dunbar et al., 2011, p. 3). 
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An increase in pain tolerance following the viewing of humorous video segments 
was also observed in a sample of 18 healthy children, ages 7 to 16 (Stuber et al., 2009).  
Before beginning the study, the researchers conducted a pilot phase in which they 
recruited 37 children (ages 7 to 13) to watch a series of five-minute-long video clips. 
During the clips, the researchers counted the frequency of laughs and following the 
viewing had the children rate how funny the videos were. They then decided which 
videos to use for the main study based on those that had consistently received the most 
laughs and highest funny ratings.   
Stuber et al. (2009) then recruited 18 more children (they increased the age range 
to 16 due to the difficulty some of the children had with completing the rating scales 
during the first phase) to conduct the actual study. They used a cold pressor test to assess 
both subjective ratings of pain and tolerance (how long they could hold their hands in the 
cold water before taking them out). They were also asked to rate how funny they thought 
the videos were. In the first trial, baseline levels of pain intensity and pain tolerance were 
measured by having the children undergo a cold pressor test before viewing the videos. In 
the second trial, they watched funny video segments for 15 minutes, and then had the 
cold pressor test. In the final trial in Stuber et al.’s study, the children had the cold pressor 
test while they were engaged in watching the video (consisting of clips from the video 
they already watched once).   
Pain severity ratings did not differ across conditions, but during and after the 
viewing of the humorous video segment the children were able to keep their hands in the 
cold water for significantly longer periods of time (increased pain tolerance). 
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Interestingly, frequency of laughter (raters coded all laughter episodes during the videos) 
did not appear to influence either pain severity or tolerance. Stuber et al. (2009) 
suggested that this might mean that watching something humorous can lead to an 
increased ability to cope with pain, but the increase in pain tolerance did not appear to be 
due to the physiological effects of laughter. This is in contrast to Dunbar et al.’s (2011) 
conclusions, discussed above, that laughter itself appears to be responsible for the 
increase in pain tolerance. However, in Stuber et al.’s (2009) study, the total length of 
time spent watching the funny video segment was only 15 minutes the first time (pain 
tolerance was measured directly following) and no longer than three minutes for the last 
trial, during which the children held their hands in the cold water during the viewing 
(three minutes was the maximum time the children could safely hold their hands in the 
cold water). Perhaps if there had been a longer segment, the outcomes would have been 
different. Laughter frequency was significantly associated with ratings of how funny the 
video was, but concordance rates for how funny the video was rated overall were not 
provided. The videos were chosen based on the ratings of children up to age 13, while the 
actual study was conducted with children up to age 16. It may be that some of the 
children in the study did not find the video segments as funny as those in the preliminary 
group. Perhaps the outcomes would have varied if the test sample had remained in the 
range of ages 7 to 13. However, the finding that pain tolerance was increased during the 
funny video intervention suggests that a humorous video (whether there is laughter or 
not) can provide a distraction for children who are enduring painful medical procedures 
(Stuber et al., 2009).  
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In yet another cold-pressor pain induced humorous video study, Zweyer et al. 
(2004) placed 56 healthy adult female participants into one of three conditions. The first 
group’s instructions were to watch the video without smiling or laughing, but to “get into 
a cheerful mood” (p. 85); the second group was instructed to exaggerate their laughing 
and smiling reactions to the video; and the third group was instructed to produce a 
humorous commentary related to the video as it was shown. All groups reported 
significantly higher pain thresholds and tolerance immediately following the film (with 
no significant differences between them) and these ratings remained above baseline 
assessments when measured again 20 minutes later. On the other hand, though all three 
groups in Zweyer et al.’s study reported elevations in affect immediately following the 
film, those measures had already returned to baseline when measured again 20 minutes 
later. It would appear that pain effects might last longer than mood effects from watching 
a funny video.  
Zweyer et al. (2004) conducted further within-group analyses and found that 
“facial enjoyment” (genuine smiles) was an important moderator of the pain effects. 
Those who engaged in more displays of facial enjoyment had significantly higher 
increases in pain tolerance and pain thresholds. This same effect was not observed with 
laughter, especially if the laughter was forced. The researchers suggested that the actual 
physiological act of laughter might not be as important as it is to find something 
genuinely funny. Zweyer et al. concluded that genuine enjoyment might be the key (with 
big smiles and lower intensity laughter) to maximizing the beneficial effects on pain 
threshold and pain tolerance. However, Zweyer et al.’s (2004) study did not also include 
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a control group that just watched the video and behaved normally. Each of their groups 
was instructed in how to behave during the viewing. It would have been interesting to 
note the differences between natural behavior during the video and the outcomes from the 
experimental groups.  
 Laughter and chronic pain. There have been few studies of the effects of 
laughter on chronic pain, and no studies were found that were focused specifically on 
FMS patients. However, Herschenhorn (1994) tested the use of focused laughter therapy 
with patients with the chronic pain of RA. Herschenhorn proposed that focused laughter 
therapy could help with pain by acting as a natural painkiller (releasing substances that 
act as opiates and binding to pain receptors), exercising the body’s internal systems, 
releasing tension, and facilitating the release of anti-inflammatory hormones. In this 
therapy, participants were directed to focus on their pain (thereby causing a state of 
tension) and then laugh, which was expected to release the tension caused by focusing on 
the pain. Once the tension was relieved by laughter, it was expected that the body would 
then return to a state of homeostasis. Focusing on the pain became the trigger for 
laughter.   
Herschenhorn (1994) placed eight female RA patients into two groups of four. 
The first group consisted of patients who had had RA for less than or equal to 5 years; 
and the second group consisted of patients who had had RA for at least 10 years. In each 
group, each participant was randomly assigned to one of four conditions: (a) control (no 
laughter therapy), (b) 30 minutes of laughter therapy, (c) 45 minutes of laughter therapy, 
and (d) 60 minutes of laughter therapy. For a week prior to the intervention, participants 
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recorded ratings of pain and how much the pain bothered them four times daily. The 
treatment intervention took place on the eighth day, with pre- and post-measures of 
severity and how much the pain bothered them. The participants then continued to rate 
their pain for the next 6 days. Herschenhorn also collected data pertaining to how many 
times each participant laughed (frequency) during the sessions, the intensity of the 
laughter, and how long each laugh lasted (duration).   
Though the sample size in Herschenhorn’s (1994) study was too small to be 
meaningfully analyzed quantitatively, her study did yield some promising information 
that could be used in testing larger populations of chronic pain patients. Though the 
findings were complex and it was difficult to make generalizations from them (each 
treatment condition only had one participant, and the results did not readily display 
obvious patterns), in general, it was found that half of the participants evidenced 
reductions in pain levels directly following the treatment. The rest of the participants also 
showed decreases in pain intensity within the following one to two days. Interestingly, 
two of the participants’ pain levels continued to fall even further below their baselines 
past two days after treatment. Additionally, four of the six participants in the treatment 
conditions reported reductions in how much the pain bothered them directly following the 
therapy. The other two participants showed an increase in distress due to the presence of 
pain at first, but their scores began to decrease following the intervention and continued 
to do so over the next 48 hours. There was no effect from the treatment duration, and no 
differences were observed based on length of time since patients were diagnosed with 
RA. However, laugh intensity did show an effect with all treatment condition 
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participants. The results were idiosyncratic, however, with three participants showing 
reductions in pain intensity while the other three evidenced increases in pain intensity. In 
addition, four of the participants in Herschenhorn’s study reported reductions in distress 
due to pain, while two reported an increase in pain-related distress as a function of 
laughter intensity.  
Herschenhorn (1994) found partial support for the effects of the duration of 
laughter and the effects on pain levels. All eight participants experienced a change in pain 
levels after treatment (or no treatment, as was the case with the two control participants—
which was attributed to the placebo effect), but not all of the changes reflected a decrease 
in pain. There was no clear trend in participant outcomes, but the participant in the first 
group (those with RA 5 years or less) with the longest duration of laughter reported the 
most improvement in pain after the treatment. However, over the next several days, pain 
levels climbed up again (though not to baseline levels). On the other hand, the participant 
with the longest duration of laughter in the second group (those with RA for at least 10 
years) experienced an initial increase in pain following the treatment, but then her pain 
levels steadily declined over the next five days.  
Based on these study outcomes, Herschenhorn (1994) was able to conclude that 
focused laughter therapy “does have an effect on RA pain and pain bothersomeness” and 
that “there is an additive effect of the frequency, intensity, and duration of laughter on 
pain intensity and pain bothersomeness over time” (p. 205). These findings, though 
preliminary, warrant a larger, more rigorous evaluation in order to be able to draw any 
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formal conclusions regarding the use of focused laughter therapy with chronic pain 
patients.   
Though they did not study the specific effects of laughter alone, Tse et al. (2010) 
investigated the use of humor therapy with older persons with chronic pain who were 
residents of a nursing home. Compared to a control group of nursing home residents not 
participating in humor therapy (n = 34), those in the humor group (n = 36) evidenced 
significant decreases in pain intensity, significant reductions in feelings of loneliness, and 
experienced significant improvement in measures of happiness and life satisfaction. 
During the 8-week long study (1 hour per week), participants engaged in games and 
exercises designed to elicit laughter and also worked on projects geared toward 
increasing cheerfulness and humor. This included such things as telling jokes, sharing 
humorous life experiences, and creating collections of media participants found amusing. 
Based on study outcomes, it was concluded that humor therapy might be an “effective 
cognitive, non-pharmacological intervention in chronic pain management” (Tse et al., 
2010, p. 5).  
Laughter and Affect 
 There is a dearth of scientific literature about the influence of laughter on affect. 
One of the few studies found and reviewed for this study was conducted decades ago. 
Young (1937) collected data about the frequency of laughter in general and the types of 
stimuli that led to laughter in undergraduate students (N = 240). He found that laughter 
frequency was positively correlated with cheerfulness (r = 0.28). Young found that those 
who laughed more were more cheerful, and their laughter seemed to be related to social 
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stimuli (e.g., hearing someone tell a joke or laughing at the clumsiness of a friend). It has 
also been demonstrated that eliciting laughter may exert temporary effects on affect. 
Sakuragi et al. (2002) found that a sample of female undergraduate students reported 
significant, temporary mood improvements after watching funny videos that evoked 
laughter.  
Mora-Ripoll (2011) posited that it may be possible to reap affective benefits of 
laughter even if the laughter is simulated or forced, in the absence of any type (social or 
otherwise) of humorous stimulus. An example of this was observed by Foley et al. (2002) 
when they conducted a forced laughter study with a group of college students. 
Participants were instructed to “laugh hilariously for one minute” (p. 184), and their 
moods were assessed before and after the minute of laughter. Foley et al. found there was 
a significant increase in positive affect from pre- to post laughter episode (p < .01). Mora-
Ripoll (2011) suggested that, though an individual may cognitively be aware that he or 
she is engaging in simulated laughter, the effect may be the same. In addition, that 
simulated laughter may also lead to spontaneous and contagious laughter, which could 
then enhance any already existing laughter-related psychophysiological changes. On the 
basis of Foley et al.’s (2002) study outcomes, they concluded, “One may wonder if we 
may not be overlooking a powerful, readily available, and cost-free way to regularly 
boost the mood and psychological wellbeing of many adults” (p. 184).  
 In a follow-up study, Neuhoff and Schaefer (2002) compared the influences of 
forced laughing with howling (a vigorous vocalization to serve as an alternative to 
laughter in order to assess whether laughter is unique in its mood boosting effects) and 
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smiling on the affect of 22 adults recruited from a graduate school and the community. 
The forced laughter in both studies (Foley et al., 2002; Neuhoff & Schaefer, 2002) was 
engaged in alone, rather than in a group setting. The researchers were interested in 
controlling for any possible influences caused by the social setting of the laughter. Each 
participant engaged in all three activities for one minute each. Though howling was not 
found to have any significant effect on affective states, there were significant 
improvements in affect after smiling and laughing (p < .01 for both). However, there was 
a significantly higher increase in affect when the participants laughed than when they 
smiled (Neuhoff & Schaefer, 2002). This suggests that laughter may be used as an 
additive intervention at any time, without the need of a humorous set of circumstances or 
the need for a social setting.   
 One of the studies that served as inspiration for this study is older, but continues 
to be relevant. Kuiper and Martin (1998) instructed study participants from the 
community (a nonclinical sample) to record all instances of laughter for three days. They 
also rated their affect and reported their stressful life events during that time. The 
researchers found that although overall laughter frequency did not appear to directly 
influence affect (in contrast to Young, 1937), laughter was an important moderating 
effect of negative affect experienced from increasing numbers of stressful life events. 
Those who laughed more did not show as high an increase in negative affect as stressors 
increased compared to those who did not laugh frequently (Kuiper & Martin, 1998). 
In a more recent study, laughter therapy was shown to significantly improve 
mood state among cancer patients going through radiation treatment. Kim et al. (2015) 
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randomly assigned cancer patients to an experimental laughter therapy condition (n = 33) 
or to a waiting list control group condition (n = 29). Those in the experimental condition 
participated in three 1-hour laughter therapy sessions daily for 3 days. Mood states were 
assessed before the beginning of the intervention and then again following the last 
laughter therapy treatment session. At the completion of the study, those in the laughter 
therapy intervention reported significant decreases in anger, tension, and depression and a 
significant increase in vigor compared to the control group. Kim et al.’s study was limited 
in that it did not assess for potential long-term effects of laughter therapy, but the positive 
outcomes on mood states suggests that laughter therapy may be a beneficial additive 
treatment for cancer patients while undergoing more conventional treatment.      
Affect, Emotion Regulation, and Alexithymia  
Affect  
Though consistent relationships have been established in the literature between 
negative emotions and various medical conditions, there are fewer studies available 
detailing the influences of positive affect on physical health (Hassett et al., 2008; Zautra, 
Johnson, & Davis, 2005). Some researchers have demonstrated that in patients with 
chronic pain, positive affect may be an important tool in aiding the recovery from times 
of increased pain (Zautra et al., 2001; Zautra, Johnson, et al., 2005). However, when 
compared to others with different types of chronic pain conditions, individuals with FMS 
appear to have increased difficulty drawing from episodes of positive affect in order to 
mediate the aversive affective states related to their pain (Furlong, Zautra, Puente, Lόpez-
Lόpez, & Valero, 2010).  
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For instance, Davis, Zautra, and Reich (2001) compared women with FMS (n = 
20) to women with OA (n = 21). Participants in their study were either instructed to 
“relax quietly for several minutes” (p. 222) to induct a neutral emotional state, or were 
primed into a negative emotional state by the presentation of a sadness evoking scenario 
and being asked to imagine themselves experiencing it. Participants then discussed an 
upsetting interpersonal conflict for 30 minutes (creating a stress experience). Those FMS 
patients in the negative emotion priming condition demonstrated larger increases in pain 
severity compared to those with OA in the same condition, and their pain levels also 
remained elevated, while the other patients’ pain levels returned to baseline. The 
researchers proposed that FMS patients may be especially vulnerable to pain 
exacerbations related to negative emotional states (Davis et al., 2001). 
McAllister et al. (2013) surveyed 858 individuals with FMS. They found that both 
positive and negative affect were significantly associated with symptomology in their 
participants. Those with higher positive affect reported lower symptom burdens of FMS, 
while those reporting higher levels of negative affect reported increased symptomology. 
McAllister et al. proposed that finding ways to improve these patients’ affect might have 
a beneficial impact on their symptoms.  
Davis, Thummala, and Zautra (2014) compared depressed versus nondepressed 
chronic pain patients with OA (n = 38) or FMS (n = 72) on their ratings of pain and affect 
following a stress inducing task and a subsequent mood induction task (viewing either a 
neutral or a comedy video clip). All participants (both depressed and nondepressed) 
evidenced significantly higher levels of despondency affect following the stress inducing 
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task (recounting a stressful conflict with someone in their lives), and all evidenced 
significant declines in despondency following the mood induction condition (back to 
baseline levels). In addition, the positive affect state, joviality, declined significantly 
among all conditions during the stressful conflict task. However, there was a significant 
difference between depressed and nondepressed chronic pain patients on the recovery of 
joviality during the mood induction conditions. Nondepressed participants showed 
significant increases in joviality in both the neutral and positive mood induction 
conditions, but depressed participants only evidenced significant increases in joviality 
following the positive mood induction condition. Similarly, nondepressed participants’ 
pain levels significantly decreased during both neutral and positive mood induction 
conditions, but depressed participants only saw decreases in pain levels during the 
positive mood induction condition. Unfortunately, there were not enough participants in 
the OA group for the researchers to compare findings across groups (FMS versus OA 
patients), so it is difficult to make generalizations to FMS patients alone based on these 
findings. However, Davis et al. (2014) suggested that nondepressed chronic pain patients 
in general might be able to naturally bounce back from stressful situations, whereas those 
with depression may need a strong positive affect stimulus to see such recovery.    
Furlong et al. (2010) described positive emotions in FMS patients as assets they 
can harness to help mediate negative symptoms associated with their condition. In their 
study of fibromyalgia patients, they found that the presence of assets such as positive 
affect, self-efficacy with regards to coping with their condition, and the presence of an 
internal locus-of-control increased FMS patients’ tolerance to thermal pain. Furlong et al. 
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argued that although prior research tended to focus on the influence of vulnerabilities 
(such as negative affect or stress) on FMS symptoms, their research demonstrated that 
assets also play a role in predicting how well those with FMS tolerate their symptoms and 
continue to function in their daily lives.   
Additionally, in two separate studies, pain-related negative affect accounted for a 
significant proportion of the variance (25% and 19% respectively) for the pain intensity 
levels reported by FMS patients (Staud et al., 2004; Staud et al., 2006). Staud et al. 
(2004) assessed FMS patients (N = 280) for pain levels and pain-related negative affect 
(PRNA). PRNA in these patients was measured by having participants complete the 
Medical College of Virginia (MCV; Riley, Robinson, & Price, 2000) questionnaire. The 
PRNA component of this questionnaire asks patients to rate the severity of chronic pain 
related negative emotions on a scale of 0 to 100. Staud et al. (2004) also asked 
participants to use a diagram of the human body to shade in all of the body regions in 
which they were experiencing pain. Then they used a trained researcher to perform tender 
point examinations. PRNA was found to be a significant predictor of pain intensity. It 
accounted for 25% of the variance in levels of pain intensity. The participants’ reported 
areas of local pain (shaded in on the diagram) accounted for 16% of the variance. On the 
other hand, the tender point examination only accounted for 4% of the variance. Staud et 
al. concluded that PRNA contributes significantly to FMS patients’ perceptions of pain.  
In a similar follow-up study, Staud et al. (2006) again found PRNA to be a 
significant predictor of pain intensity in FMS patients. In Staud et al.’s (2006) study, 
maximal and or average local pain levels (peripheral pain) accounted for 27% of the 
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variance in pain intensity; the number of body areas said to be painful (the participants 
again shaded all of the regions on their bodies where they experienced pain) accounted 
for 9% of the variance; and PRNA accounted for 19% of the variance. Because PRNA 
accounted for a significant proportion of pain intensity variance, treatments that aim to 
reduce accompanying negative affect may assist in enhancing pain relief.  
Emotion Regulation  
 Emotion regulation refers to the influence individuals have over their own 
emotional lives. This includes not only what emotions they feel, but also at what times 
and in what manner they experience and express their emotions (Gross, 1998). Because 
emotions are paired with and influence the pain experience, emotional regulation may 
provide an important role in modulating the pain experience (Ruiz-Aranda, Salguero, & 
Fernández-Berrocal, 2010). Potential evidence of this relationship was observed in a 
prospective study of older adult patients (N = 30) in a rehabilitation hospital. Paquet, 
Kergoat, and Dubé (2005) assessed patients for measures of global and day-to-day 
emotional regulation and pain intensity. Those patients who more successfully managed 
their emotional states reported significantly lower pain intensity levels. Paquet et al. 
suggested that effective emotion regulation might enhance treatment outcomes for pain 
patients.  
 In another study, Ruiz-Aranda et al. (2010) investigated emotion regulation with 
a sample of female undergraduate students (N = 177). They assessed participants for 
emotional regulation and then subjected them to a cold pressor test to induce acute pain. 
In particular, participants were measured for their ability to “use positive thinking to 
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repair negative moods” (p. 565). Overall, those with high repair scores reported 
significantly lower levels of pain and lower levels of negative affect throughout the test 
than those with low repair scores. Additionally, those with high mood repair scores 
reported more positive affects before beginning the cold pressor test, and again following 
the test. This suggests that those with more ability to repair their moods evidenced less 
negative affect when being faced with a stressful pain-inducing task, and that they were 
“better able to reduce its emotional impact” (Ruiz-Aranda et al., 2010, p. 568). Another 
interesting finding in this study is that those who reported more positive affect before the 
test did not report significantly lower ratings of pain during the test, but they did report 
more positive affect during the test. It is possible that although they were feeling similar 
ratings of pain, they were not as bothered by it affectively than those with lower affect 
scores. Ruiz-Aranda et al. concluded that the ability to regulate emotions might delay the 
impact of negative emotions related to the pain experience.       
 Emotion regulation may therefore be an important factor in FMS patients’ pain-
related suffering. For instance, compared to medical controls (patients with resolved 
conditions or other chronic pain disorders), Hassett et al. (2008) found that FMS patients 
not only had increased incidence of negative affect, but they also had reduced incidence 
of positive affect, and more dysfunction in their styles of affective balance (“negative 
affect minus positive affect = affect balance”; p. 834). FMS patients were more likely to 
have reactive (high negative and high positive affect) or depressive (low in positive affect 
while high in negative affect) styles, and these dysfunctional styles were associated with 
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decreased ability to function and with the presence of comorbid mental disorders (Hassett 
et al., 2008).    
Some of the most compelling evidence of affect dysregulation in FMS comes 
from a series of studies conducted by Zautra and colleagues (Finan et al., 2009; Zautra et 
al., 2001; Zautra, Fasman, et al., 2005; Zautra, Fasman, Parish, & Davis, 2007; Zautra, 
Johnson, et al., 2005). This present investigation is largely based on and modeled after 
these studies. In one of the initial studies, Zautra et al. (2001) investigated pain and affect 
in 89 individuals with FMS. For 30 days participants rated their affect and pain severity 
three times per day at random intervals. The researchers found that the presence of 
positive emotional states tended to significantly reduce the strength of the relationship 
between pain and negative emotional states. Interestingly, though, those participants who 
had higher on average positive affect scores did not fare better than those with lower on 
average positive affect scores. It appears that what was important in reducing the strength 
of the pain and negative affect relationship was having the positive affect episode take 
place within the day in which the pain was increased. Therefore, it’s possible that even 
those individuals who tended to have lower affect ratings overall might still benefit from 
episodes of positive affect during times of increased pain.  
Sustained positive affect may have protective effects against negative affect 
arising from increased pain or interpersonal stress. In another study conducted by Zautra, 
Johnson, et al. (2005), FMS and OA patients were assessed weekly for ratings of pain, 
affect, and the presence of interpersonal stressors. Though both OA and FMS participants 
reported significantly high ratings of pain and negative affect, FMS patients reported 
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significantly higher ratings of pain (p = .05) and stress (p = .027) than the OA patients. 
They also reported significantly lower ratings of positive affect than the OA patients (p = 
.001). Zautra, Johnson, et al. also found that “negative affect was highest during weeks 
when pain was high, interpersonal stress was high, and positive affect was low” (p. 215). 
In addition, when participants experienced weeks with elevated pain levels and increased 
stress, the strongest relationship was observed with negative affect. The researchers 
concluded, “A rise in positive affect not only lowers negative affect directly, but also 
blunts the effects of high pain and high interpersonal stress on negative affect.” (p. 215). 
Interestingly, those participants with higher average positive affect ratings over the 
course of Zautra, Johnson et al.’s (2005) study tended to experience less of a rise in 
negative affect during weeks when they were experiencing increased pain or stress. This 
indicates that positive affect may be a possible resource to draw from when challenged 
with stress and increasing pain. Because there may be a possible deficit in FMS patients’ 
ability to sustain positive affect, they may benefit from interventions targeted at 
increasing their overall affect. Zautra, Johnson, et al. pointed out that it was not that the 
patients had too much negative affect; instead they did not have enough positive affect 
stores available to buffer against increasing pain and stress.    
In yet another study, Zautra, Fasman et al. (2005) again compared FMS patients 
to OA patients. Over the course of 12 weekly assessments, they found that those with 
FMS reported more severe ratings of pain and fatigue. Also, although there were no 
significant differences between the groups in levels of negative affect, the FMS 
participants reported significantly “lower levels of positive affect” (p. 147). This 
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difference was enhanced even further when participants reported increased interpersonal 
stress, indicating that FMS patients had more trouble holding on to positive emotions as 
stress increased. Based on these findings, Zautra, Fasman et al. proposed that a core 
symptom of FMS might be a decreased ability to regulate positive affect. They further 
suggested that this feature might uniquely differentiate FMS patients from other chronic 
pain conditions. The researchers concluded,  
If indeed the lack of positive affect contributes to the maintenance or worsening 
of this chronic health condition, then treatments that assist patients with FMS in 
broadening their emotional repertoire and increasing their capacity for positive 
emotion, especially during stressful times, may be particularly effective as a 
means of improving their condition. (Zautra, Fasman et al., p. 154)  
 Dysfunction in FMS patients’ positive affect regulation was observed also in a 
study conducted by Finan et al. (2009). In this study, patients with FMS were compared 
to patients with OA, and also to patients who had comorbid FMS and OA. Participants 
were assessed once per day for ratings of affect and pain. FMS patients had reduced 
average positive affect ratings compared to the OA patients (trending toward 
significance, p = .055). They also experienced significantly more pain than the OA 
patients (but the pain ratings of the group of patients with FMS and OA were 
significantly higher than both the OA and FMS groups). In addition, the FMS and FMS 
and OA groups were more likely to report a loss of positive affect when negative affect 
was also present in the same day. The OA patients’ positive affective states appeared less 
susceptible to being diminished by the presence of negative affective states. Finan et al. 
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explained this by suggesting that individuals with FMS have an impaired ability to 
“differentiate between the two affects” (p. 479). Additionally, compared to OA patients, 
the FMS patients in Finan et al.’s (2009) study showed increased negative affect and 
decreased positive affect in response to elevations in pain severity. This provides 
additional evidence for an impaired ability in these patients to sustain a positive affective 
state when also experiencing negative affect. The apparent deficit of positive affect in 
FMS patients was again observed in a study investigating fatigue in chronic pain patients 
(Zautra et al., 2007). Compared to patients with OA and RA, those with FMS showed a 
stronger relationship between low ratings of positive affect and daily fatigue. FMS 
patients seem to be particularly vulnerable to having difficulty with affective regulation 
compared to other chronic pain patients. Because FMS is difficult to diagnose (it is not 
readily revealed upon physical exams or laboratory tests like RA or OA) and treat, Davis, 
Zautra, and Smith (2004) suggested that the increased affective dysfunction observed in 
this population might be related to the increased uncertainty regarding their condition and 
the inability to predict symptomology. 
Van Middendorp et al. (2008) also found evidence of significantly increased 
negative affect and reduced positive affect in FMS patients compared to control 
participants (women without FMS). In addition, negative affective states were associated 
with increased symptomology, while the opposite was true for positive affective states. In 
this same study, FMS patients also reported feeling their emotions more intensely than 
did the controls, and engaged in significantly more emotion-avoidance strategies, 
particularly endorsing items consistent with evidence of alexithymia (difficulty with 
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identifying one’s affective state). Interestingly, though, “affect intensity was related to 
more severe pain only in combination with the inability to process or verbalize emotions, 
suggesting that the intense experiencing of emotions is not necessarily maladaptive as 
long as these emotions are adequately processed” (van Middendorp et al., 2008, p. 165). 
In contrast to the studies discussed above (Finan et al., 2009; Zautra et al., 2001; Zautra et 
al., 2007; Zautra, Fasman, et al., 2005; Zautra, Johnson, et al., 2005), van Middendorp et 
al. did not find positive affective states to be a mediator of the relationship between pain 
and negative emotional states in individuals with FMS.  
Alexithymia 
 Alexithymia is a concept developed by Sifneos (1973) through his observations of 
patients with psychosomatic illnesses, and it generally refers to having a lack of 
emotional awareness, constricted emotional expression, and, in particular, having 
difficulties with identifying and describing emotions. Sifneos suggested that this inability 
to verbally describe their emotions was likely both psychological and neurophysiological 
in nature. Evidence for this suggestion may have been found by Kano, Hamaguchi, Itoh, 
Yanai, and Fukudo (2007). They conducted a study with 45 healthy participants. First, 
they assessed the participants for alexithymia using the TAS-20 (Bagby et al., 2013) and 
then during colonoscopy procedures subjected them to colonic distension (with varying 
amounts of pressure) to induce discomfort. Those who were alexithymic in Kano et al.’s 
study showed greater activation in several brain regions, produced more adrenaline, and 
expressed greater anxiety during the procedure than those who were not alexithymic. The 
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physiological hypersensitivity noted in these participants may partially explain how 
alexithymia can impact physical disease.   
Though a prevalence study of alexithymia in the general population of the United 
States was not found in the literature search, a randomly selected and stratified 
representative sample of the Finnish population (N = 1285) showed an overall rate of 
13%, with men significantly higher than women in alexithymia ratings—17% versus 10% 
(Salminen, Saarijärvi, Äärelä, Toikka, & Kauhanen, J., 1998). Alexithymia has been 
frequently observed in patients with chronic pain (Huber, Suman, Biasi, & Carli, 2009). 
For instance, Evren et al. (2006) found 39.2% of a sample of FMS participants were 
alexithymic, and Steinweg et al. (2011) found that 44% of the fibromyalgia patients in 
their study were alexithymic –compared to 8% in a group of general medicine patients 
and 21% in a group of RA patients.  
Tooyserkani et al. (2011) assessed 100 patients with chronic musculoskeletal pain 
for alexithymia, affect, and pain intensity (participants reported their affect and pain 
levels over the week prior to the study). Some clear relationships were observed in the 
outcomes. Alexithymia was positively correlated with pain intensity (r = 0.51, p = 0 .001) 
and negative affect (r = 0.51, p = 0.001) and negatively correlated with positive affect (r 
= -0.38, p = 0.001). Tooyserkani et al. also observed that as positive affect increased, pain 
intensity decreased (r = -0.67, p = 0.001), and that experiencing positive affect acted to 
moderate perceptions of pain intensity. In addition, alexithymia and negative affect were 
significant predictors of pain intensity. However, this relationship between alexithymia 
and pain intensity was not found in a later study of chronic pain patients conducted by 
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Makino et al. (2013), but alexithymia was shown to be positively associated with 
negative affect in study participants. Though it was not found to predict pain intensity, 
alexithymia was significantly correlated with pain interference (how much the pain 
impacted the patients’ daily lives) and pain catastrophizing (how frequently patients 
experienced ruminative pain-related thoughts, magnification of pain, and feelings of 
helplessness, as measured by the Pain Catastrophizing Scale; Sullivan, Bishop, & Pivik, 
1995). 
Martínez et al. (2014) compared 97 women with FMS to 100 
sociodemographically matched, healthy women. They found those with FMS were 
significantly more likely to report having difficulties with both identifying and describing 
their emotions. The researchers went on to analyze the relationship between alexithymia 
and other clinical measures in the FMS participants. Two particular aspects of 
alexithymia—problems with identifying emotional states and problems with describing 
those states, were associated with reductions in sleep quality, increases in symptoms of 
anxiety and depression, fear related to the pain experience, and pain catastrophization. 
Difficulty in describing emotional states was also associated with increases in sensory 
pain, and increases in pain vigilance. Those who tended to catastrophize about their pain 
also tended to have increased anxiety. The researchers summarized their findings in this 
way:  
Our findings suggest that FM patients have difficulties identifying their affective 
states, differentiating them from other emotions or physical complaints, and 
expressing and communicating their feelings. These facets of alexithymia in 
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interaction with negative pain appraisal (catastrophizing about pain and fear of 
pain) may contribute to the development of emotional distress (anxiety), which in 
turn is associated with more severe symptoms (increased pain experience and 
poorer sleep quality). Therefore, interventions that guide patients to acquire an 
adequate knowledge of their emotional experiences may improve their clinical 
condition. (Martinez et al., 2014, p. 20)    
In another study with FMS patients (N = 51), Huber et al. (2009) found 
alexithymia to be associated with reduced pain tolerance, increased affective distress, and 
increased psychological distress in their initial correlational analyses. However, when 
Huber et al. conducted further multiple regression analyses, they found that when 
psychological dysfunction ratings were controlled, alexithymia no longer significantly 
predicted pain-related affective distress. This indicates that psychological dysfunction 
may be an important mediating variable in the effects of alexithymia. Evren et al. (2006) 
also found a relationship between alexithymia in FMS patients and measures of anxiety, 
depression, and other psychiatric symptoms. However, alexithymia was not related to 
pain severity in their sample. Evren et al. concluded that alexithymia appeared to be more 
closely related to psychopathology in FMS patients than it was to pain intensity.  
 Compared to patients with RA and to patients with other medical conditions than 
RA and FMS, Steinweg et al. (2011) found that patients with FMS had significantly 
higher rates of alexithymia (44% of the sample versus 8% for those in general medicine 
and 21% for those with RA). A strong relationship was observed between alexithymia 
and depression in the FMS participants. However, when the Steinweg et al. controlled for 
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depressive symptoms, the differences between the groups were no longer significant. 
FMS patients “may have problems expressing their feelings, particularly compared with 
patients with other medical conditions, and the comorbid state of depression is likely 
responsible” (Steinweg et al, 2011, p. 260).  
Affect Induction and Pain Response 
 Researchers have effectively induced emotional states in the laboratory setting in 
order to observe their effects on pain responses and tolerance (Tang et al., 2008; 
Weisenberg, Raz, & Hener, 1998; Willoughby, Hailey, Mulkana, & Rowe, 2002). 
Weisenberg et al. (1998) used movies (humorous ones versus an account about the 
Holocaust) to elicit positive and negative emotional states. Serving as controls were a 
group who did not see any movie and a group who saw a neutral movie. The movies were 
varied in length (15 minutes, 30 minutes, and 45 minutes). Participants (volunteers from 
the community) were also subjected to a cold pressor test. The cold pressor tests took 
place before the film condition, right after viewing the movie, and again 30 minutes later. 
Results showed that those in the positive mood induction conditions showed significantly 
higher pain tolerance (left their hands in the cold water longer) and significantly lower 
ratings of pain—but, interestingly, these differences were only observed after the 30 
minute delay, and the effects were only seen in the longer movies. The first two cold 
pressor tests showed no significant differences in pain ratings between the positive and 
negative mood induction conditions. Additionally, following the 30-minute delay, those 
participants who did not view a movie at all evidenced higher ratings of pain and reduced 
pain tolerance compared to the other groups (Weisenberg et al., 1998).  
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In another mood induction and cold pressor study, Willoughby et al. (2002) 
randomly assigned healthy undergraduate students to either a neutral mood state group, a 
depressed mood state group, or an elation mood state group. Mood induction was 
performed by having participants read a set of cards while being instructed to try to feel 
the emotion elicited by the cards. Immediately following the mood induction task, 
affective measures were quickly obtained. The induction task successfully elicited a 
depressed mood state, but was unsuccessful in eliciting an elated mood state, so 
Willoughby et al. compared the neutral and depressed mood state groups (n = 50). The 
participants were then subjected to a cold pressor test. Analyses following the test 
revealed that those in the depressed mood state group evidenced significantly lower pain 
tolerance (p = .05) as well as higher rates of catastrophizing about pain. In other words, 
the participants in the depressed mood state were unable to keep their hands in the ice 
water as long as those in the neutral mood state, and they also experienced more negative 
cognitions about the pain following the test (Willoughby et al., 2002).      
A similar type of study was also conducted with a group of chronic lower back 
pain patients (N = 55). Tang et al. (2008) randomly assigned participants to one of three 
inducted affective state groups (depressed, neutral, or happy) and then measured pain 
levels and pain tolerance following a task designed to elicit pain. In this study, the 
researchers used music to induce mood, and the task to elicit pain was holding a 
“moderately-heavy shopping bag” (p. 394) for as long as they could. First, Tang et al. 
assessed participants for baseline measures of affect and pain. The participants then 
completed the task of holding the bag, and were then assessed again for pain. The mood 
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induction then took place, followed by a measure of affect and another rating of pain 
severity. They then held the bag for a second time, and were finally assessed once more 
for pain. Study outcomes were as the researchers predicted, “The induction of depressed 
mood resulted in significantly higher pain ratings at rest and lower pain tolerance, whilst 
happy mood resulted in significantly lower pain ratings at rest and greater pain tolerance” 
(Tang et al., 2008, p. 398).  
In another emotion induction study, van Middendorp et al. (2010) compared 62 
female FMS patients with 59 females from the general population without FMS (although 
they could have had other types of medical conditions). The researchers induced neutral 
states, as well as affective states of anger and sadness (through having participants recall 
episodes in their lives that continued to elicit such emotions). Following the emotion 
induction, pain was elicited through the use of electrical current, while assessing 
threshold and tolerance levels. Both the normal controls and the FMS patients evidenced 
significantly reduced pain thresholds and tolerance levels following both conditions as 
compared to a neutral state. This suggests that people in general (whether they have FMS 
or not) may experience a pain amplification response while in an aversive emotional 
state. Van Middendorp et al. noted, however, “Nonetheless, it is a clinically relevant 
finding that pain in the women with fibromyalgia was increased above an already high 
baseline level when anger and sadness were induced.” (van Middendorp et al., 2010, p. 
1374). This indicates that, for individuals who may already be in pain, aversive emotional 
states can serve to exacerbate pain levels to an even less tolerable level. Therefore, it 
seems to be important to address the incidence of aversive emotional states in FMS 
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patients as part of their treatment in order to minimize the amplification of pain. 
Importantly, the researchers did not induce any positive emotional states. Comparisons 
were only made between two negative emotional states and a neutral state. Outcomes 
may have been different if a positive emotional state induction had been added for 
comparison.  
Emotion Intervention 
No studies were found directly related to increasing positive emotion states in 
FMS patients. However, Hsu et al. (2010) conducted a psychosocial intervention with 
female FMS patients (N = 45) geared toward helping to increase their awareness of their 
emotional states. Each participant had one individual session and then met each week in 
groups for 3 weeks. Besides the group sessions, the participants also had daily exercises 
to complete. The treatment plan consisted of four components. The first was 
psychoeducational in nature, and assisted participants with understanding chronic pain 
and its biopsychosocial influences; the second component was 30 minutes per day of 
free-writing about stress and emotions experienced; the third component was designed to 
help participants become more aware of their moment to moment emotional states and to 
accept them without judgment (using a CD with guided exercises); and the fourth 
component was encouraging participants to reengage with activities they had stopped due 
to the impact of FMS pain. Participants were assessed prior to the study, again after 6 
weeks, and once more at 6 months following the intervention. Compared to participants 
in the control group (participants were randomly assigned to intervention and control 
waitlist groups), those in the intervention group reported significantly lower pain levels 
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of pain severity both at the six-week and six-month assessments. More specifically, while 
none of the control group participants reported reductions in pain severity, 45.8% of the 
intervention group participants reported 30% or more improvements in pain ratings, and 
20.8% of them reported improvements above 50%. Those in the intervention group also 
reported significantly increased levels of physical functioning, and higher pain thresholds 
at both post-study assessments. Importantly, Hsu et al. (2010) demonstrated that the 
effects from exercises geared toward increasing affective awareness and exploring the 
relationship between psychological and physiological processes could produce sustained 
improvements in pain and functioning in individuals with FMS.    
Dynamic Model of Affect Theory 
 Zautra et al. (2001) developed the dynamic model of affect. The researchers 
proposed that during times of increased stress (such as when pain becomes more severe) 
or uncertainty, affective processing may become more simplified, resulting in reduced 
ability to differentiate between positive and negative affective states (Davis et al., 2004). 
The dynamic model of affect serves to explain how being able to experience and sustain 
positive emotions may be able to reduce the impact of negative pain-related emotion 
states (Zautra et al., 2001; Zautra, Johnson, et al., 2005), and increase patients’ resilience 
to heightened pain and stress (Davis et al., 2004).  
If these individuals also tend to have reduced positive affect in general, they 
become increasingly vulnerable to the deleterious impact of negative affective states 
during times of increased stress (Zautra et al., 2001). Zautra, Johnson, et al. (2005) 
suggested that the tendency for FMS patients to have lower positive affect overall may 
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help drive the “cycle of increased pain and negative affect so frequently observed in 
chronic pain conditions” (p. 216). They found that increased pain leads to increased 
negative affect and this was especially true for those with low average positive affect. 
Further, in the dynamic model of affect theory, the timing of the positive emotions 
experienced may be important, as positive emotions present during the actual time of 
increased pain may produce the most benefit to FMS patients in helping to modulate 
pain-related negative affective states (Zautra, Johnson, et al., 2005).  
Considering the principles behind the dynamic model of affect, specific 
treatments could be used or developed that assist these individuals in increasing their 
ability to differentiate between positive and negative emotions, and in improving their 
ability to hold on to positive emotions even when their pain has worsened or if they are 
experiencing other stressors that could result in dominant negative affective states (Davis 
et al., 2004). It is my intention with this study to examine the principles in the dynamic 
model of affect theory as they relate to people with FMS. If increased laughter frequency 
is associated with higher levels of positive affective states and decreased pain levels, it is 
possible that positive affect (laughter) can mediate the relationship between pain and 
negative affect. In turn, that may potentially open the door to future research using 
laughter as a formal intervention with this population.  
Discussion and Chapter Summary 
 In this chapter, the signs and symptoms of FMS and related syndromes were 
discussed, as well as the diagnosis of FMS, its treatment, and its related costs. A literature 
review pertaining to the topics of pain theories, laughter, and affect was conducted. This 
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concluded with a discussion of the dynamic model of affect—the theory that will be 
tested in the course of this study. Laughter has been shown repeatedly to have beneficial 
effects on acute pain (Dunbar et al., 2011; Mahony et al., 2001; Stuber et al., 2009; 
Zweyer et al., 2004), but there is less information available regarding its effects on 
chronic pain, and there are no studies found regarding laughter and the chronic pain that 
comes from FMS. In addition, the research available regarding laughter and affect also 
suggests it has a positive influence on emotional state (Foley et al., 2002; Neuhoff & 
Schaefer, 2002; Sakuragi et al., 2002; Young, 1937). Again, though, it has not been tested 
on affective states in individuals with FMS.  
 Individuals with FMS have difficulties with affect and emotion regulation (Finan 
et al., 2009; Zautra et al., 2001; Zautra et al., 2007; Zautra, Fasman, et al., 2005; Zautra, 
Johnson, et al., 2005), and experience alexithymic rates higher than that of the general 
population (Evren et al., 2006; Steinweg et al., 2011). On the other hand, positive mood 
induction studies have produced decreases in pain levels and increases in pain tolerance 
(Tang et al., 2008; Weisenberg et al., 1998; Willoughby et al., 2002). This leads to an 
important question: If we can induce mood to bring about changes in pain levels and 
tolerance, will that give patients more perceived control over their symptoms? If mood 
can be induced in a lab, perhaps the patients can learn ways of inducing positive 
emotional states (like laughing) themselves in order to help reduce pain symptoms. The 
next chapter will discuss the design of the study, the recruitment process for participants, 
assessment tools that were used, the procedures for the study, and a discussion of 
statistical methods that were used to analyze the data.   
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Chapter 3: Research Method 
 In this study, I investigated the influence of laughter frequency on affect and 
perceived chronic pain levels of individuals who have FMS, while controlling for the 
potential influence of depressive symptoms and alexithymia. The purpose of the study 
was to analyze whether increased laughter frequency is predictive of increases in positive 
affect or decreases in negative affect as well as reductions in perceived chronic pain 
levels using multiple linear regression analysis. In this chapter, in addition to discussing 
and justifying the research design and analyses used, I detail characteristics of the 
sample, including who was chosen, how participants were chosen, and inclusionary and 
exclusionary variables. I also discuss the procedures followed as well as the specifics 
pertaining to the various measures employed. Following is a discussion of the potential 
threats to validity, how the data were collected and analyzed, and how participants were 
protected from harm during the course of the study. I conclude the chapter with a 
summary and an introduction to Chapter 4.     
Research Design and Approach 
A quantitative, correlational design was used in this investigation. The decision to 
conduct a quantitative study arose from the nature of the problem to be investigated, the 
questions asked, and the literature reviewed (see Creswell, 2012). After reviewing the 
extant quantitative research discussing the benefits of laughter for dealing with acute pain 
(Dunbar et al., 2011; Mahony et al., 2001; Stuber et al., 2009; Zweyer et al., 2004), I 
wondered if laughter could have similar effects with chronic pain. The types of research 
questions asked in this study lent themselves to a quantitative, statistical analysis. 
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Similarly, this study’s research questions were rooted in a review of the literature. There 
were three variables of concern in this study. The independent variable was laughter 
frequency. Affect and perceived pain levels were the dependent variables in this study. 
Relationships were explored between laughter frequency and affect as well as between 
laughter frequency and levels of perceived pain in patients with FMS. In addition, the 
instruments used in this study are objective assessment tools that produce numerical data 
to be analyzed statistically. 
Setting and Sample 
Population and Sampling Method 
 Participants consisted of persons aged 18 and over who have been diagnosed with 
FMS by their physicians. Study volunteers were recruited through a mixture of 
convenience and snowball sampling. Firstly, I delivered the flyer to an alternative 
therapist’s practice and support group for distribution. Participants were also recruited 
through posting the flyer to community bulletin boards at a local Starbucks as well as at a 
local recreation center. The study was then advertised via local newspapers, and the flyer 
was additionally posted to the PsiChi web site 
(http://www.psichi.org/?Research_Rules#.VvAUDXn2aUK) and to the Clinical Trials 
web site (http://www.clinicaltrials.gov). The flyer was also posted within the Walden 
Participant Pool, as well as to social media. Social media tended to yield the most 
interest, and the most fruitful social media source for participant recruitment was the 
NFA Facebook support group page (https://www.facebook.com/fmaware). The 
administrator of this group posted the flyer twice, and these postings were directly 
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responsible for recruiting the majority of the study sample. Finally, participants were also 
recruited via referrals from individuals who knew of other FMS patients who might have 
been willing to participate.  
The study sample depended upon those who saw the flyer, were available, and 
chose to participate. Since the sample depended on those volunteering to participate, it is 
more difficult to generalize study outcomes to the larger population than it would be if 
the sample was randomly selected (see Creswell, 2012). 
Expected Effect Size Calculation 
Studies related to this research yielded a mix of small, medium, and large effect 
sizes. In terms of improvements in mood and or reductions in levels of depression 
following humor or laughter interventions, effect sizes (all reported as Cohen’s d) were as 
follows: .60 (medium; Foley et al., 2002), 1.29 (large; Ganz & Jacobs, 2014), .45 (small; 
Ko & Youn, 2011), 1.40 and 1.41 (large; Walter et al., 2007), and 1.48 (large; Tse et al., 
2010). Tse et al. (2010) also found significant reductions in chronic pain levels (Cohen’s 
d = 1.25; large).  
In terms of laughter and its effects on discomfort thresholds and/or pain tolerance 
in the case of acute pain, effect sizes (again, all reported as Cohen’s d) were as follows: 
.57 (medium; Stuber et al., 2009) and .82 (large; Zweyer et al., 2004). Related to the 
influence of mood induction (elation) on pain tolerance in individuals with chronic back 
pain, Tang et al. (2008) found a large effect size (Cohen’s d = .98). Finally, the effect 
sizes (reported as Cohen’s d) for the influence of affect in individuals with FMS were as 
follows: .45 (small; Zautra et al., 2001), and .67 (medium; Zautra, Johnson, et al., 2005).  
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The average effect size from the studies discussed above is .95 (Cohen’s d; large). The 
sample size for this study, therefore, was based on an expected large effect size. 
Sample Size 
 A sample size power analysis was conducted in G*Power 3.1.9.2 (see Faul, 
Erdfelder, Buchner, & Lang, 2009). To examine the research questions, multiple 
hierarchical linear regressions were planned, with a total of six predictor variables 
(laughter frequency, depression, alexithymia, and potential demographic confounds: age, 
gender, and ethnicity). Using a large effect size (f2 = 0.35), an alpha level of .05, and a 
power of .80, the power analysis calculated the required sample size for a multiple linear 
regression with six predictors at 46.  Thus, information from at least 46 participants 
should have been gathered to assess the research questions. 
Eligibility and Exclusion Criteria 
 To be eligible for the study, participants had to have been adults (18 and older) 
with confirmed diagnoses of FMS. Participants were either expected to sign a release of 
information form (see Appendix A) to allow me to contact their physicians for 
confirmation or to provide documentation of diagnosis, such as a letter from their medical 
provider, a printout from an electronic medical data base, or a printout from a doctor 
appointment. In this way, diagnosis was confirmed for each participant in the study. 
Procedures 
 The study flyer contained my email address and phone number, and first contact 
with me was initiated by the participants. When potential participants made initial contact 
(typically by email or responding to a social media post), I would email them with a brief 
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overview of the study, including a discussion of exclusionary criteria (diagnosis 
confirmation required), attaching a copy of the study’s flyer and the informed consent 
form. Because the duration of participant recruitment stretched out longer than 1 year, it 
was necessary to return to the IRB to obtain an updated one (IRB No. 2017.07.07; 
16:00:45-05’00’).  
 In the same email, prospective participants were encouraged to follow up with 
any questions they had, and that if they felt they were ready at that time to commit to 
joining the study, to email back with the words, “I consent.” Once the commitment to 
participate was received, participants provided diagnosis confirmation or were emailed a 
release of information form to review and sign. Participants then completed two 
screening instruments (for symptoms of depression and for the trait of alexithymia) and a 
demographics form. These forms were either mailed via regular mail or emailed to 
participants, depending on their preferences and computer and or printer and scanner 
access.  
Participants completed the BDI-II (Beck et al., 1996) in order to screen for 
depression. Those reporting moderate to severe symptoms of depression (scores of 21 or 
higher) were encouraged to seek treatment if not currently receiving treatment for 
depression. Depression, a disorder of mood, is associated with negative affect. Anas and 
Akhouri (2013) assessed depressed patients and normal controls for measures of affect 
and found that those who were depressed were more likely to score significantly higher 
on levels of negative affect, whereas the normal participants had significantly higher 
scores on measures of positive affect. Depression is also associated with increased pain 
103 
 
intensity ratings in those with chronic pain. Baker et al. (2008) found that depression and 
locus of control variables accounted for 13% of the variance in chronic pain intensity 
ratings. Thus, participants’ laughter frequency as well as measures of affect and pain may 
have been influenced by active depressive symptoms. To avoid potentially misleading 
study outcomes, it was necessary to control for symptoms of depression in the analyses.  
To measure alexithymia, participants completed the TAS-20 (Bagby et al., 2013; 
Appendix B). As discussed in the second chapter, alexithymia is frequently observed in 
chronic pain and FMS patients (Evren et al., 2006; Huber et al., 2009; Steinweg et al., 
2011; Tooyserkani et al., 2011). Steinweg et al. (2011) found that moderate to severe 
depression was also increased in FMS patients, with the measures of depression closely 
correlated with measures of alexithymia. When they controlled for moderate to severe 
depression in their analyses, however, FMS patients no longer evidenced significantly 
higher alexithymia measures compared to general medicine patients and RA patients. To 
reduce the likelihood of either depression or alexithymia affecting this study’s results, all 
participants were screened for depression and assessed for alexithymia, and both of those 
measures were held constant in the analyses. Finally, participants completed a 
questionnaire in order to gather personal and demographic data (see Appendix C).  
Once the initial screening tools and demographics form were completed, I either 
mailed or emailed participants the forms needed to complete their daily assessments. For 
14 days, participants completed the PANAS (Watson et al., 1988; Appendix D) and rated 
their pain using the PI-NRS (Farrar et al., 2001; Appendix E) 3 times daily: shortly after 
waking up in the morning, at 3:00 p.m., and an hour before bedtime. Additionally, they 
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recorded all daily episodes of laughter on the adapted DLR (Martin & Kuiper, 1999; 
Appendix F). Participants recorded the time of each episode of laughter, and for analysis, 
the researcher then divided the frequency of laughter into two time frames: from wake-up 
to the 3:00 p.m. measures, and from 3:00 p.m. to the hour before bedtime measures.  
Typically, I sent participants automatic email reminders (via an automatic 
calendar scheduling program) to assess their affect and pain shortly before the 3:00 p.m. 
collection time, as well as later in the evening for the nightly assessments. However, 
some preferred to receive text messages, and others preferred to set their own alarms or 
reminders. In general, participants were expected to submit their data to the researcher 
each night (via email) when their final assessments of the evening were completed.  
 At the conclusion of their 2 weeks of participation, study volunteers received a 
$50.00 Visa® gift card as compensation (either via mail or electronic delivery, depending 
on the participants’ preference). However, for the international participants (n = 4), it was 
not possible to order the gift card. For those participants, I sent $50.00 via PayPal 
accounts, which was automatically converted into their individual currencies. Finally, I 
entered the data into a spreadsheet corresponding to each participant’s assigned numeric 
code that I analyzed following the conclusion of the study.  
Data Collection and Analyses 
Instrumentation and Materials 
 In this study, basic demographic information was collected and participants 
completed assessments for depression, alexithymia, affect, pain, and laughter frequency. 
The measures are discussed below.  
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 BDI-II. The BDI-II (Beck et al., 1996) is a widely used self-report instrument 
used to assess adolescents and adults for the presence and severity of depressive 
symptoms. It typically takes five to ten minutes to complete, and it consists of 21 items 
that correspond to varying symptom criteria of depression, as classified in the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV; American 
Psychiatric Association, 1994). Patients are asked to circle the choice under each item 
that reflects most closely their experience over the previous two weeks. The options on 
each item provide a score range from 0 to 3, with possible total score ranges from 0 to 63. 
The instrument is scored by adding all of the circled items together. Those with scores 
totaling from 0 to 13 are considered to have minimal depressive symptoms; those with 
scores from 14 to 19 are considered to have mild symptoms of depression; those with 
scores from 20 to 28 are considered to have moderate symptoms of depression; and those 
with scores from 29 to 63 are considered to have severe symptoms of depression (Beck et 
al., 1996).  
 The BDI-II was normed with 500 patients from four psychiatric outpatient clinics 
(two urban-based and two suburban-based), and with a group of undergraduate students 
to act as a comparison group (n = 120). It was found to have high coefficient alphas for 
reliability--.92 for the outpatient population, and .93 for the undergraduate normal 
comparison group. Test-retest stability was assessed by having 26 outpatients take the 
test twice, a week apart. The test-retest correlation was .93. To assess construct validity, 
191 outpatients were administered the BDI-II as well as the BDI-IA (the previous version 
of the BDI) in a counterbalanced order. The correlation between them was .93. With 
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regard to convergent validity, the BDI-II has been shown to be significantly positively 
associated with other similar measures, and an estimate of factorial validity (.95) was 
evidenced “by the intercorrelations among the 21 BDI-II items” (Beck et al., 1996, p. 28).  
TAS-20. The TAS-20 (Bagby et al., 1993; Parker, Taylor, & Bagby, 2003; 
Appendix B) is an instrument developed to assess the trait of alexithymia, and consists of 
three distinct, related factors. The first factor is difficulty in identifying feelings; the 
second factor is difficulty in describing feelings; and the third factor is a measure of 
externally oriented thinking (a lack of focus on inner experience). It is a self-report 
measure that consists of 20 questions. The items are rated on a five point Likert scale 
from strongly disagree (1) to strongly agree (5). When scoring the instrument, points are 
added up according to the number circled, except for five items which are reverse scored 
(assigned the opposite score of what is circled; e.g. if a 1 is circled, the score assigned is 
5). According to G. J. Taylor (personal communication, June 27, 2017), alexithymia is 
dimensional rather than categorical, so alexithymia scores fall on a continuum.  Scores ≤ 
51 indicate low or nonalexithymia, while scores ≥ 61 indicate a high range of 
alexithymia.   
 The internal consistency of the TAS-20 has been found to be good (Cronbach’s 
alpha = 0.81), and each of the factors also has adequate internal consistency. F1 
(difficulty identifying feelings) = 0.78; F2 (difficulty describing feelings) = 0.75, and F3 
(externally oriented thinking) = 0.66. Additionally, it has demonstrated good test-retest 
reliability (0.77; Bagby et al., 1993). Its internal reliability has also been found to be 
replicable in a large community population (N = 1933--all factors demonstrated 
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coefficient alphas greater than .70; Parker et al., 2003) and across undergraduate students 
in three varying cultures (Canada, Germany, and the United States), with an average 
Cronbach’s alpha of 0.79 (Parker, Bagby, Taylor, Endler, & Schmitz, 1993). It has also 
been used to assess the prevalence of alexithymia in the FMS patient population. Evren et 
al. (2006) and Steinweg et al. (2011) found that 39.2% and 44% of their samples of FMS 
patients had alexithymia as measured by the TAS-20.  
To assess the convergent and discriminant validity of the TAS-20, Bagby et al. 
(1994) had undergraduate students complete the TAS-20 as well as other measures 
expected to have either no relationship (conscientiousness and agreeableness on the NEO 
Personality Inventory (McCrae & John, 1992)—assessing discriminant validity) or a 
negative relationship (Psychological Mindedness Scale; Conte, Ratto, & Karasu, 1996) 
and The Need for Cognition Scale (Cacioppo & Petty, 1982) -assessing convergent 
validity) with alexithymia. As predicted, there was a strong, negative relationship 
between alexithymia and the psychological mindedness scale and the need for cognition 
scale, demonstrating good convergent validity; there also was a nonsignificant 
relationship between alexithymia and conscientiousness and agreeableness, providing 
evidence of discriminant validity. Concurrent validity was assessed with a sample of 
behavioral medicine outpatients. The patients completed the TAS-20 and were also 
clinically interviewed while two other interviewers observed behind one-way glass (for 
inter-rater reliability). There was a strong, positive correlation between TAS-20 ratings 
and clinician interviews, demonstrating good concurrent validity (Bagby et al., 1994).  
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In this study, participants completed the TAS-20 either via mail or via electronic 
communication. The online administration version has been demonstrated to have 
adequate validity and reliability compared to the paper version of the TAS-20. This was 
assessed through administering the different versions to undergraduate students (N = 
621)—randomly assigned to either the paper or internet versions. Measures of internal 
consistency between them were similar—Cronbach’s alpha for the paper administration 
was .75 and Cronbach’s alpha for the internet administration version was .80 (Bagby et 
al., 2013). The factors of the scale were also similar and significantly correlated, 
supporting consistent external validity between them. Bagby et al. concluded that the 
tests are “comparable and can be used interchangeably” (p. 5).  
PANAS. The PANAS (Watson et al., 1988; Appendix D) is a 20-item self-report 
assessment tool, and it consists of two scales: the positive affect (PA) scale and the 
negative affect (NA) scale. Each scale consists of ten items—words that characterize 
various positive or negative affect states. PA is described as “the extent to which a person 
feels enthusiastic, active and alert”, whereas NA is described as “a general dimension of 
subjective distress and unpleasurable engagement that subsumes a variety of aversive 
mood states” (Watson et al., 1988, p. 1063). PA items include “interested, excited, strong, 
enthusiastic, proud, alert, inspired, determined, attentive, and active”. NA items include 
“distressed, upset, guilty, scared, hostile, irritable, ashamed, nervous, jittery, and afraid” 
(Watson et al., 1988, p. 1070). Items are rated by participants on a 5-point Likert scale, 
ranging from one being “very slightly or not at all” to five being “extremely” (p. 1070). 
The item ratings are summed for each scale, and range from 10 to 50, with higher scores 
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indicating higher levels of that affect. The PANAS is brief, easy to complete, and flexible 
in that it can be used to rate affect in the current moment, over the course of a day, a few 
days, a week, or longer intervals (Watson et al., 1988). The standardized instructions for 
the PANAS include a space to insert the researcher’s time frame for ratings. It was used 
in this study to assess affect at the present moment, three times per day.  
Reliability data for the PANAS were gathered from mostly undergraduate 
students. Internal consistency ratings were “all acceptably high, ranging from .86 to .90 
for PA and from .84 to .87 for NA” (Watson et al., 1988, p. 1065). The researchers also 
found the reliability scores to be unaffected by ratings given for different time frames 
(e.g., over the past day versus the present moment). Test-retest reliability was also stable, 
and became more so as the length of time from which ratings were taken increased (e.g., 
ratings of how a person has felt over the past year).  
The researchers also collected reliability data from a smaller sample of adults who 
were not students (n= 164; coefficient alpha for PA = .86 and for NA = .87) as well as 
from a small group of psychiatric inpatients (n = 61; coefficient alpha for PA = .85 and 
for NA = .91). Though the researchers cautioned that the sample sizes were small, they 
suggested this indicated that the PANAS was likely reliable across patient and non-
patient samples (Watson et al., 1988). The PANAS was later normed with a large adult 
population in the United Kingdom (N = 1003). With this population, reliability for PA 
was Cronbach’s alpha = .89 and NA = .85 (Crawford & Henry, 2004).  
Scale validity was similarly robust, with convergent validity correlations ranging 
from .89 to .95 and discriminant validity correlations ranging from -.02 to -.18. Watson et 
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al. (1988) also determined there was strong item validity, with a factor analysis revealing 
that the two dimensions (PA and NA) accounted for “virtually all of the common 
variance”—from 87.4% (from ratings taken at the present moment) to 96.1% (from 
ratings of how affect is in general). 
PI-NRS. The PI-NRS is frequently used in studies assessing chronic pain (Farrar 
et al., 2001; Appendix E). It is a simple, 11-point scale, ranging from 0 (no pain at all) to 
10 (the worst pain one can imagine). Ratings of 1, 2, or 3 indicate mild pain; ratings of 4, 
5, or 6 indicate moderate pain, and 7, 8, 9, or 10 indicate severe pain. It is brief and quick 
to administer (less than 3 minutes), and the individual selects the number that best 
represents the pain he or she has been experiencing (Van Der Laan, 2013). Farrar et al. 
(2001) observed that, though the PI-NRS was used quite often in the literature, it was still 
not known what constituted a clinically important change in pain intensity ratings. From 
their analysis of 10 chronic pain studies (with varying chronic pain populations) that used 
similar methods, they determined that a 2-point difference reduction in pain ratings 
represented a clinically significant improvement.   
 Reliability and validity of the PI-NRS were tested with 200 chronic pain patients 
(Jensen & McFarland, 1993). Test-retest reliability was tested by comparing the ratings 
given on the first day of the first week of the study and the ratings given on the first day 
of the second week of the study (both taken at the second hour of the day). The 
correlation coefficient of these two ratings resulted in a correlation of 0.63, but as the 
researchers increased the numbers of ratings compared (two hours of ratings on two days 
during the two weeks and upward all the way to 28 ratings compared), test-retest 
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reliability also increased. The range was from 0.63 to 0.95. To reach an adequate stability 
coefficient (correlations greater than 0.90), they indicated that participants would need to 
assess their pain levels three times per day for four days; and excellent reliability was 
reached (0.95) when participants rated pain four times per day for all seven days of the 
week. Similarly, validity coefficients also rose as more measures were included in the 
analysis—ranging from 0.74 (with a single rating of pain), to 0.97 (three ratings per day 
for four days) to 1.00 (four ratings per day for seven days). Internal consistency of the PI-
NRS was also excellent, ranging from 0.94 to 0.96—with minimal difference between 
them whether ratings were taken from a single day or multiple days. Based on their 
findings, Jensen and McFarland concluded, “the reliability and validity of pain intensity 
measurement may be increased by increasing the number of assessments made, and by 
assessing pain over multiple days” (p. 202).  
DLR. Though the DLR is an unpublished instrument, I gained permission from 
Dr. Rod Martin (Appendix F; Martin & Kuiper, 1999) to adapt it for use in this study. 
This instrument is a tool participants used to log each instance of laughter per day, and to 
capture some descriptive information as well. This form has six columns. In the first 
column, the participant counted laughter frequency. He or she began with the number one 
and continued down the column until completing his or her final assessments of the 
evening, and then began a new DLR each day for 14 days. In the second column, 
participants noted the time the laughter took place. The third column was used for noting 
what types of things made the participants laugh. The options include mass media (M), a 
spontaneous situation (S), a joke (J), or an event (E). In the fourth column, participants 
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noted the strength of their laughter: 1) a silent chuckle or forceful exhale/snort, 2) a little 
bit of laughter, or 3) a lot of laughter. In the fifth column, participants noted who caused 
their laughter: self (S) or other (O). Finally, in the sixth column, participants noted 
whether others were present or not at the time of the laughter. Though this study 
primarily investigated laughter frequency alone, regardless of the circumstances 
surrounding each laugh, gathering additional information may yield some interesting 
qualitative data for follow-up studies.      
Data Analysis and Research Questions 
Data analysis. Data were entered into SPSS version 24.0 for Windows.  
Descriptive statistics were conducted to describe the sample demographics and the 
research variables used in the analysis. Frequencies and percentages were calculated for 
nominal data.  Means and standard deviations were calculated for continuous data. Data 
were collected via email once a day for baseline (shortly after wake up), afternoon (3:00 
p.m.), and night (an hour before bed) observations. Hierarchical regressions were 
conducted to assess the research questions.  
Research Question 1. Will laughter frequency influence the affect of FMS 
patients after controlling for depression and alexithymia? 
H01: Laughter frequency will not influence the affect of FMS patients after 
controlling for depression and alexithymia. 
Ha1: Laughter frequency will influence the affect of FMS patients after 
controlling for depression and alexithymia. 
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 To examine Research Question 1, a hierarchical multiple linear regression was 
conducted to assess if laughter frequency influences affect. A hierarchical multiple linear 
regression is the appropriate analysis to conduct when the goal is to assess the 
relationship between a set of continuous predictor variables and a continuous dependent 
variable. It may also be used when the researcher wants to control for the influence of 
another variable (see Pallant, 2010). In this case, laughter frequency, depressive 
symptoms, alexithymia, and affect are all continuous variables.   
 Prior to conducting the hierarchical regression the demographic variables were 
tested for as covariates. If any of the demographic variables, such as age, gender, or 
ethnicity, were related to the affect scores, then they would have been controlled for in 
the regression. Covariates were entered into the model first followed by any predictor 
variables. Additionally, bivariate correlations were conducted to examine the bivariate 
relationships between the potential predictor variables and the dependent variables. Any 
predictor variable not related to the dependent variable would have been removed from 
the regression. The multiple linear regression was assessed using the F test.  If the 
regression model was found to be significant, the individual predictors would also be 
assessed. An alpha level of .05 was used to assess significance. Prior to analysis, the 
assumptions of the regression were assessed. Normality was assessed with a P-P plot of 
the residuals. Homoscedasticity was assessed with a scatterplot of the residuals (Pallant, 
2010). Lastly, multicollinearity was assessed for by examining Variance Inflation Factors 
(VIFs). 
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Research Question 2. Will laughter frequency influence the perceived chronic 
pain levels of FMS patients after controlling for depression and alexithymia? 
H02: Laughter frequency will not influence difference in perceived chronic pain 
levels of FMS patients after controlling for depression and alexithymia. 
Ha2: Laughter frequency will influence difference in perceived chronic pain levels 
of FMS patients after controlling for depression and alexithymia. 
 To examine Research Question 2, another hierarchical linear regression was 
conducted to assess if laughter frequency influences difference in perceived chronic pain 
levels after controlling for depressive symptoms and alexithymia. In this case, laughter 
frequency, depressive symptoms, alexithymia, and perceived chronic pain levels are 
continuous variables. The hierarchical regression was then conducted in an identical 
manner to that of the procedure used above for the first research question.  
Threats to Validity 
 In this particular study there were several potential considerations. Perhaps the 
most important and most salient potential threat was the danger that a completely 
different variable other than laughter frequency could be responsible for changes in affect 
and pain in participants. Two of those potential cofounding variables (depressive 
symptoms and alexithymia scores) were controlled for through holding them constant in 
the statistical analyses. When analyzing outcomes these potential covarying factors 
needed to be considered. History was another potential confounding variable. This 
research was not conducted in a strictly regulated laboratory environment. Instead, data 
were gathered as participants went about their daily lives. During the course of this study, 
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the participants may have had events happen in their lives that influenced study 
outcomes. 
In addition, selection of participants may have been a confounding variable. 
Because I relied on volunteers to participate instead of using random selection, there may 
be differences between the study’s participants and the larger population of FMS 
patients—making it difficult to generalize this study’s results to other FMS patients, or to 
those with any other chronic pain conditions. Attrition of participants may also have been 
a problem for this study. The study was two weeks long and required participants to 
assess affect and pain three times per day while also logging each instance of laughter. 
This may have been perceived by some as too taxing, or it may have been difficult for 
them to keep up with all data submissions. Over the course of the study, there was a risk 
that participants may have dropped out, leaving potentially too few remaining to ensure 
the power of the study would be adequate. During the participant selection process, it was 
planned to gather more participants than strictly needed (46) for .80 power to guard 
against this happening. After averaging dropout rates from several related studies (Finan 
et al., 2009; Ganz & Jacobs, 2014; Ko & Youn, 2011; Tang et al., 2008; Tse et al., 2010; 
Walter et al., 2007; Zautra et al., 2001; Zautra, Fasman, et al., 2005; Zautra, Johnson, et 
al., 2005) it was estimated that at least 16 additional participants should have been 
recruited. This means that an initial total of at least 62 participants should have been 
recruited to take potential attrition into account.  
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Protection of Human Participants 
 To protect confidentiality, each participant’s data were de-identified through the 
assignment of a numerical code. They used this code instead of their names to submit all 
assessments and daily logs. All data and assessments are stored on a password-protected 
computer or in a locked filing cabinet (for those who preferred to compete the study via 
regular mail). The original list containing their names and matching code numbers is also 
stored in a password protected computer. The computer used to analyze data in SPSS is 
also password protected. All data and protocols will be retained in a locked filing cabinet 
and/or a password-protected computer in the researcher’s home for a minimum of six 
years (Institutional Review Board for Social & Behavioral Sciences, 2012), and will then 
be shredded and or disposed of via a commercial software-erasing program.  
 Additionally, though it is unlikely, it may be possible that the enhanced focus on 
pain and affect in this study could have exacerbated symptoms of psychological distress. 
Broderick and Vikingstad (2008) tested whether frequent reporting of symptoms (in their 
study, they looked at pain and fatigue) exacerbated symptoms of depression in 
rheumatology patients. Patients were assessed for levels of depression before and after a 
30-day period in which they rated symptoms 6 times per day. The researchers found that 
overall levels of depression actually improved significantly at the end of the study.  
Though it was observed that 10% of their participants experienced a worsening of 
symptoms, 20% of their participants reported fewer symptoms of depression from pre- to 
post-study. Compared to their six assessments per day, in this study participants only 
reported 3 times per day, and the study only lasted 2 weeks (compared to a month in 
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Broderick & Vikingstad’s study). Participants received a handout at the beginning of the 
study with crisis hotline numbers and helpful guidance on what to do should they 
experience significant worsening of mental health status during the course of the study 
(see Appendix G). In addition, if any participants had reported worsening physical status, 
they would have been encouraged to see their physicians for care. None did. 
Summary 
 In this study, I set out to examine the influence of laughter frequency on affect 
and perceived chronic pain levels in individuals who have FMS. After completing initial 
assessments and a demographics form, participants rated their pain and affect 3 times per 
day for 14 days, while at the same time documenting each time they laughed. Descriptive 
statistics were generated in order to describe the characteristics of the sample, and 
hierarchical multiple linear regressions were conducted in order to assess the research 
questions. In this chapter, I have also discussed the participant selection process and 
sample size as well as all procedures followed and instruments employed. I also 
presented the research questions and discussed the various potential threats to this study’s 
validity. The chapter concluded with a discussion of how it was planned to protect 
participants from a potential breach in confidentiality and procedures were put in place to 
follow in the event their symptoms were exacerbated during the course of the study. In 
the next chapter, study analyses and results will be discussed.   
118 
 
Chapter 4: Results  
The purpose of this study was to analyze whether increased laughter frequency is 
predictive of increases in positive affect or decreases in negative affect as well as 
reductions in perceived chronic pain levels using multiple linear regression analysis. I 
addressed the following research questions: (a) Will laughter frequency influence the 
affect of FMS patients after controlling for depression and alexithymia? and (b) Will 
laughter frequency influence the perceived chronic pain levels of FMS patients after 
controlling for depression and alexithymia? In this chapter, I present a discussion of the 
data collection procedures as well as descriptive statistics to describe the sample. Finally, 
I present the analyses used to answer each research question.  
Data Collection 
Participant recruitment took place over the course of 13 months from September 
2016 through October 2017. A total of 71 people formally consented to participate. Of 
those, 18 dropped out before completing any of the initial assessments. Ten participants 
completed the initial forms only but dropped out before beginning daily assessments, and 
two participants completed their initial forms and began daily assessments, but dropped 
out after completing very few measures. This left a total of 41 participants who 
completed the study. Though the original intended sample size was 46, recruitment had 
slowed after exhausting all recruitment methods. At that time, I decided to close the study 
to new participants and to move forward with data analysis.   
The original plan called for participants to begin their daily assessments the next 
day following the completion of their initial forms. Several participants experienced a 
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delay in beginning their daily assessments, depending on their individual circumstances. 
Generally, they began within a few days, but there were two participants who were 
delayed longer than 2 weeks. In those cases, they were asked to complete a current BDI-
II (Beck et al., 1996) due to the time sensitive nature of the instrument (participants are 
asked to rate their symptoms for the previous 2 weeks including the day of completion). 
Additionally, though the general expectation was that participants would submit 
their daily assessments each evening following their last assessments, there were times 
that extenuating circumstances prevented some from submitting them on time. When that 
happened, participants were encouraged to submit their data as soon as possible. For 
those completing the forms via regular mail, it was typical that all measures would not be 
submitted until the conclusion of their 2 weeks of participation. For those participants, I 
communicated with them periodically via email in case they had any questions and to 
ensure the assessments were being completed. 
Descriptive Statistics 
 The sample consisted of 41 participants, the great majority of whom were female 
(95.12%) and White (82.93%). Participants’ ages ranged from 19 to 75 years old, with an 
average of 41.88 (SD = 15.12) years old. The largest percentage was married or partnered 
(46.34%) and had a college graduate education (39.02%). The largest proportion of 
participants was employed full-time (39.02%). The largest percentages of participants 
made $15,000 to $29,000 (19.51%) and $30,000 to $44,000 (19.51%). See Table 1 for 
the frequencies and percentages of participant demographic characteristics. 
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The largest proportion of participants was diagnosed with FMS 1 year to 5 years 
ago (36.59%). The vast majority was taking medications (95.12%) and were engaged in 
alternative therapies (82.93%). The majority (92.68%) reported having comorbid medical 
conditions. The most commonly reported conditions include inflammatory bowel 
syndrome (n = 10), hypertension (n = 8), migraine syndrome (n = 7), high cholesterol (n 
= 6), allergies/rhinitis (n = 6), temporomandibular joint dysfunction ( n = 5), asthma (n = 
5), degenerative disc disease (n = 5), polycystic ovary syndrome (n = 5), vitamin D 
deficiency (n = 5), and sleep apnea/obstructive sleep apnea (n = 4). The majority of the 
sample (58.4%) had also engaged in behavioral health treatment (attending sessions with 
psychiatrists, psychologists, social workers, and/or other counselors). More than half of 
the participants reported moderate to severe symptoms of depression (53.6%). A majority 
of the sample reported low alexithymia (58.5%), although 24.4% reported high 
alexithymia. See Table 2 for the full frequencies and percentages of diagnosis and 
medical-related demographic variables.  
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Table 1 
 
Frequencies and Percentages of Demographic Variables 
 
Variable n % 
Sex   
    Female 39 95.12 
    Male 2 4.88 
Ethnicity   
    African American/Black 1 2.44 
    Asian/Pacific Islander 2 4.88 
    White 34 82.93 
    Hispanic/Latino 1 2.44 
    Other 1 2.44 
    Missing* 2 4.88 
Marital status   
    Married/Partnered 19 46.34 
    Single 11 26.83 
    Divorced 8 19.51 
    Widowed 2 4.88 
    Other 1 2.44 
Education   
    High school graduate 3 7.32 
    Some college 10 24.39 
    College graduate 16 39.02 
    Post graduate degree 12 29.27 
Employment status   
    Full-time 16 39.02 
    Part-time 6 14.63 
    Self-employed 2 4.88 
    Student 3 7.32 
    Retired/Medically retired 9 21.95 
    Unemployed 5 12.20 
Average family income   
    Less than $15,000 4 9.76 
    $15,000 to $29,000 8 19.51 
    $30,000 to $44,000 8 19.51 
    $45,000 to $59,000 5 12.20 
    $60,000 to $74,000 4 9.76 
    $75,000 to $89,000 3 7.32 
    $90,000 to $114,000 3 7.32 
    $115,000 to $129,000 1 2.44 
    $130,000 to $200,000 4 9.76 
    Missing 1 2.44 
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Table 2 
 
Frequencies and Percentages of Diagnosis and Medical-Related Demographic Variables 
Variable n % 
   
Years ago FMS diagnosed   
    1 year ago or less 8 19.51 
    1 year to 5 years ago 15 36.59 
   6 years to 10 years ago 14 34.15 
    Greater than 10 years ago 4 9.76 
Taking medications   
    No 2 4.88 
    Yes 39 95.12 
Engaged in alternative therapies   
    No 6 14.63 
    Yes 34 82.93 
    Missing 1 2.44 
Comorbid medical conditions   
    No 2 4.88 
    Yes 38 92.68 
    Missing 1 2.44 
Behavioral health treatment   
    No 17 41.46 
    Yes 24 58.54 
Depression   
Minimal 14 34.1 
Mild 5 12.2 
Moderate 11 26.8 
Severe 11 26.8 
Alexithymia   
Low alexithymia 24 58.5 
Mid-range alexithymia 7 17.1 
High alexithymia 10 24.4 
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Depression scores were considered minimal if the score on the BDI-II was 
between 0 to 13, mild if between 14 to 19, moderate if between 20 to 28, and severe if 29 
to 63. Study participants reported an average depression score of 21.80 (SD = 12.16), 
which corresponds to moderate symptoms of depression (Beck et al., 1996). Alexithymia 
scores were considered low if the score on the TAS-20 was less than or equal to 51, 
midrange if between 52 to 60, and high alexithymia if greater than or equal to 61 (Bagby 
et al., 1993; G. J. Taylor, personal communication, June 27, 2017; Parker et al., 2003). 
Participants reported an average alexithymia score of 49.61 (SD = 12.92), which 
corresponds with a low level of alexithymia. Although this sample reported a higher 
average alexithymia score than that of the norming population (45.57, SD = 11.35, N = 
1933; Parker et al., 2003), it was similarly in the low alexithymia range.  
 Participants had an average overall (i.e., all ratings for each day) positive affect 
score of 20.95 (SD = 6.13), with a lower evening positive affect score of 19.21 (SD = 
6.16). Participants had an average overall negative affect score of 14.14 (SD = 3.64), with 
a slightly higher evening negative affect score of 14.86 (SD = 5.26). Participants had an 
average overall pain level of 5.17 (SD = 1.62), which was higher in the evening (M = 
5.46, SD = 1.76). Participants had an average overall laughter frequency of 3.97 (SD = 
2.77). See Table 3 for the ranges, means, and standard deviations of these variables.  
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Table 3 
 
Means and Standard Deviations of Continuous Variables 
 
Variable Min Max. M SD 
     
Depression 4.00 52.00 21.80 12.16 
Alexithymia 24.00 75.00 49.61 12.92 
Factor 1 8.00 30.00 19.54 6.34 
Factor 2 5.00 24.00 12.90 5.21 
Factor 3 8.00 26.00 17.17 4.27 
Overall positive affect 10.44 34.38 20.95 6.13 
Midday 10.50 39.00 23.20 7.09 
Evening 10.42 37.14 19.21 6.16 
Overall negative affect 10.21 25.48 14.14 3.64 
Midday 10.21 40.36 14.60 5.21 
Evening 10.07 35.07 14.86 5.26 
Overall pain level 1.95 7.98 5.17 1.62 
Midday 1.64 8.14 5.05 1.64 
Evening 1.71 8.15 5.46 1.76 
Overall laughter frequency 0.89 11.96 3.97 2.77 
Morning 0.21 15.36 3.75 2.92 
Evening 0.36 12.00 4.19 2.93 
 
Covariates 
 I assessed the preliminary bivariate relationships between potential covariates and 
overall positive affect, overall negative affect, and overall pain level through a correlation 
matrix. I used a Pearson’s correlation for the correlation between continuous variables. 
However, some covariates were not continuous, which would make interpretation of 
Pearson’s correlations conducted on these variables faulty (see Field, 2013). I 
dichotomized (i.e., turned into a single variable with two categories) the multicategory 
categorical variables and assessed them with a point-biserial correlation instead. The 
point-biserial correlation is appropriate to use when assessing the relationship between a 
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continuous and a dichotomous variable (Field, 2013). Only depression and alexithymia 
had a significant relationship with the dependent variables of interest. As such, I did not 
include any other variable as a covariate while hypothesis testing. See Table 4 for the full 
correlation matrix.  
Table 4 
Correlation Matrix for Potential Covariates  
Variables Positive affect Negative affect Pain level 
    
Sex .10 .14 -.06 
Ethnicity  .21 -.14 -.04 
Age .13 -.20 -.10 
Marital -.24 .01 .04 
Education .24 -.15 -.16 
Employment .24 .05 -.22 
Income -.01 .00 -.10 
Taking medications -.12 .05 .21 
Engaged in alternative therapies -.12 .15 -.02 
Comorbid medical conditions .02 .08 .01 
Behavioral health treatment -.11 -.04 -002 
Depression -.40* .68* .46* 
Alexithymia -.19 .41* .13 
Note. *Significant at the .05 level. 
Regression Results 
I performed hierarchical multiple linear regressions in order to answer the 
research questions. This is the appropriate analysis to perform when assessing the 
relationship between two or more continuous or categorical independent variables and 
one continuous dependent variable in several steps (Field, 2013). For Step 1 of each 
regression, I entered the covariates of depression and alexithymia. For Step 2 of each 
regression, I added the main independent variable of interest, laughter frequency, to the 
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model. As the results of Step 2 were most important, I only provided a detailed narrative 
of the results of Step 2, although the full results are presented in each regression table. I 
conducted each main analysis with the overall scores of interest (i.e., an average of each 
measurement overall). If there was a significant result for the main analysis, I conducted 
two follow-up multiple linear regressions where the dependent variables were midday 
and evening scores, respectively. For these analyses, the independent variable of laughter 
frequency was split into morning and evening laughter frequency. Morning laughter 
frequency was defined as laughter frequency from the time of the first morning 
assessments to the 3pm assessments. Evening laughter frequency was defined as laughter 
frequency from the 3pm assessment to the bedtime assessment. Each main analysis was 
assessed at the p = .05 level. Prior to interpreting each regression, I assessed the 
assumptions of normality, homoscedasticity, and absence of multicollinearity.  
Research Question 1 
 Will laughter frequency influence the affect of FMS patients after controlling for 
depression and alexithymia? 
 H01: Laughter frequency will not influence the affect of FMS patients after 
controlling for depression and alexithymia. 
 Ha1: Laughter frequency will influence the affect of FMS patients after 
controlling for depression and alexithymia. 
 In order to answer this research question, I performed two hierarchical multiple 
linear regressions. For each regression, the independent variable of interest was overall 
laughter frequency and the covariates were depression and alexithymia. The dependent 
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variable for the first regression was positive affect, while the dependent variable for the 
second regression was negative affect.  
 Prior to conducting the analysis, I assessed the assumptions of normality, 
homoscedasticity, and absence of multicollinearity for both regressions. I assessed 
normality through a Normal P-P plot. As the data involving positive affect generally 
conformed to the diagonal normality line, the assumption was met (see Figure 1; Field, 
2013). I assessed homoscedasticity through a scatterplot of the residuals. As the data 
involving positive affect presented in a generally equally distributed, random pattern, the 
assumption was met (see Figure 1; Field, 2013). There was slight deviation of normality 
and homoscedasticity for the plots involving overall negative affect (see Figure 2), but 
according to Stevens (2009), violations of normality and homoscedasticity are a matter of 
degrees, and merely weaken the power of the analysis rather than invalidating the results. 
I assessed absence of multicollinearity through VIF values (see Tables 5 and 6). VIF 
values were below 10.00, indicating that the assumption was met (Stevens, 2009).  
 
Figure 1. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving overall positive affect.  
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Figure 2. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving overall negative affect. 
 
 The overall results of Step 2 of the analysis involving overall positive affect were 
significant, F(3, 37) = 6.05, p = .002, R2 = .275. This indicates that when assessed 
collectively, the covariates and overall laughter frequency significantly predicted 
approximately 27.5% of the variability in overall positive affect. Examination of the 
individual predictors indicated that depression (B = -0.18, p = .031) and overall laughter 
frequency (B = 0.92, p = .005) were individually significant predictors of overall positive 
affect. For every one-unit increase in depression, there was a 0.18 unit decrease in overall 
positive affect. For every one-unit increase in overall laughter frequency, there was a 0.92 
unit increase in overall positive affect. See Table 5 for the full results of this analysis.  
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Table 5 
 
Results of the Regression With Overall Laughter Frequency and Covariates Predicting 
Overall Positive Affect 
Step Variable B SE β t P VIF 
        
1 Depression -0.22 0.09 -0.43 -2.43 .020 1.43 
 Alexithymia 0.02 0.08 0.05 0.28 .778 1.43 
        
2 Depression -0.18 0.08 -0.36 -2.24 .031 1.46 
 Alexithymia 0.04 0.08 0.08 0.51 .614 1.44 
 Overall laughter frequency 0.92 0.31 0.42 3.02 .005 1.05 
 
 The overall results of Step 2 of the analysis involving overall negative affect were 
significant, F(3, 36) = 10.62, p < .001, R2 = .425. This indicates that when assessed 
collectively, the covariates and overall laughter frequency significantly predicted 
approximately 42.5% of the variability in overall negative affect. Examination of the 
individual predictors indicated that depression (B = .21, p < .001) was an individually 
significant predictor of overall negative affect. For every one-unit increase in depression, 
there was a 0.21 unit increase in overall negative affect. There was no significant 
relationship between overall laughter frequency and overall negative affect after 
controlling for the covariates (p = .55). In Table 6, I present the full results of this 
analysis. The null hypothesis may be partially rejected, as there was a significant 
relationship between overall laughter frequency and overall positive affect, but not 
overall negative affect (see Table 6).  
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Table 6 
 
Results of the Regression With Overall Laughter Frequency and Covariates Predicting 
Overall Negative Affect 
Step Variable B SE β T P VIF 
        
1 Depression 0.22 0.05 0.69 4.55 .000 1.57 
 Alexithymia 0.00 0.04 -0.01 -0.05 .962 1.57 
        
2 Depression 0.21 0.05 0.68 4.46 .000 1.57 
 Alexithymia -0.01 0.04 -0.02 -0.11 .914 1.58 
 Overall laughter frequency -0.10 0.16 -0.07 -0.60 .554 1.04 
 
Because there was a significant relationship between overall laughter frequency 
and overall positive affect, I conducted two additional hierarchical linear regressions with 
a main independent variable of morning and evening laughter frequency, and a dependent 
variable of midday and evening positive affect, respectively. Due to the inflated risk of 
Type I error (i.e., making a “false positive” conclusion) due to familywise error, I used 
the Bonferroni correction to reduce the alpha level to .016 (Field, 2013). The assumptions 
for these analyses were met (see Figures 3 and 4 and Tables 7 and 8).  
 
Figure 3. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving midday positive affect. 
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Figure 4. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving evening positive affect. 
 
For morning laughter and midday positive affect, the results of the overall 
regression for Step 2 were significant, F(3, 37) = 6.34, p = .001, R2 = .286 at the reduced 
alpha level, indicating that the covariates and morning laughter significantly predicted up 
to 28.6% of the variability in midday positive affect. Morning laughter frequency was the 
only individually significant predictor (B = 1.05, p = .003) at the reduced alpha level. For 
every one-unit increase in morning laughter frequency, there is a corresponding 1.05 unit 
increase in midday positive affect (see Table 7).  
Table 7 
 
Results of the Regression With Morning Laughter Frequency and Covariates Predicting 
Midday Positive Affect 
Step Variable B SE β T P VIF 
        
1 Depression -0.24 0.10 -0.42 -2.34 .024 1.43 
 Alexithymia 0.01 0.10 0.02 0.09 .926 1.43 
        
2 Depression -0.19 0.10 -0.32 -2.00 .053 1.48 
 Alexithymia 0.03 0.09 0.06 0.35 .730 1.44 
 Morning laughter frequency 1.05 0.34 0.43 3.12 .003 1.08 
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For evening laughter and evening positive affect, the results of the overall 
regression for Step 2 were not significant at the reduced alpha level, F(3, 37) = 3.83, p = 
.017, R2 = .175, indicating that the covariates and evening laughter overall did not 
significantly predict variability in evening positive affect. Evening laughter frequency 
was not an individually significant predictor (p = .031) at the reduced alpha level. See 
Table 8 for the full results of this analysis.  
Table 8 
 
Results of the Regression With Evening Laughter Frequency and Covariates Predicting 
Evening Positive Affect 
Step Variable B SE β t P VIF 
        
1 Depression -0.19 0.09 -0.37 -2.03 .050 1.43 
 Alexithymia 0.00 0.09 0.00 0.00 .998 1.43 
        
2 Depression -0.17 0.09 -0.34 -1.95 .059 1.44 
 Alexithymia 0.01 0.08 0.02 0.10 .921 1.43 
 Evening laughter frequency 0.68 0.30 0.32 2.24 .031 1.02 
 
Research Question 2 
Will laughter frequency influence the perceived chronic pain levels of FMS 
patients after controlling for depression and alexithymia? 
 H02: Laughter frequency will not influence difference in perceived chronic pain 
levels of FMS patients after controlling for depression and alexithymia. 
 Ha2: Laughter frequency will influence difference in perceived chronic pain levels 
of FMS patients after controlling for depression and alexithymia. 
To answer this research question, I performed a hierarchical multiple linear 
regression with a dependent variable of overall pain level, an independent variable of 
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overall laughter frequency, and covariates of depression and alexithymia. I concluded 
that the assumptions of the regression were met (see Figure 5 and Table 8).  
 
Figure 5. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving overall pain level.  
 
 The overall results of Step 2 of the analysis were significant, F(3, 37) = 5.44, p = 
.003, R2 = .25. This indicates that when assessed collectively, the covariates and overall 
laughter frequency significantly predicted approximately 25% of the variability in overall 
pain level. Examination of the individual predictors indicated that depression (B = -0.07, 
p = .004) and overall laughter frequency (B = -0.17, p = .05) were individually significant 
predictors of overall pain level. For every one-unit increase in depression, there was a 
0.07 unit increase in overall pain level. For every one-unit increase in overall laughter 
frequency, there was a 0.17 unit decrease in overall pain level. See Table 9 for the full 
results of this analysis. The null hypothesis was rejected.  
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Table 9 
 
Results of the Regression With Overall Laughter Frequency and Covariates Predicting 
Overall Pain Level 
Step Variable B SE β t P VIF 
        
1 Depression 0.07 0.02 0.55 3.23 .003 1.43 
 Alexithymia -0.02 0.02 -0.17 -0.99 .327 1.43 
        
2 Depression 0.07 0.02 0.51 3.05 .004 1.46 
 Alexithymia -0.02 0.02 -0.19 -1.16 .253 1.44 
 Overall laughter frequency -0.17 0.08 -0.28 -2.03 .050 1.05 
 
Because there was a significant relationship between overall laughter frequency 
and overall pain level, I conducted two additional hierarchical linear regressions with a 
main independent variable of morning and evening laughter frequency, and a dependent 
variable of midday and evening pain levels, respectively. Due to the inflated risk of Type 
I error (i.e., making a “false positive” conclusion) due to familywise error, I used the 
Bonferroni correction to reduce the alpha level to .016 (Field, 2013). The assumptions for 
these analyses were met (see Figures 6 and 7, Tables 10 and 11).  
 
Figure 6. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving midday pain levels.  
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Figure 7. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving evening pain levels.  
 
For morning laughter and midday pain levels, the results of the overall regression 
for Step 2 were significant, F(3, 37) = 7.48, p < .001, R2 = .327 at the reduced alpha level, 
indicating that the covariates and morning laughter significantly predicted up to 32.7% of 
the variability in midday pain levels. Depression was an individually significant predictor 
at the reduced alpha level (B = 0.07, p = .002); for every one-unit increase in depression, 
midday pain levels would increase by 0.07 units. Morning laughter frequency was also an 
individually significant predictor at the reduced alpha level (B = -0.19, p = .016). For 
every one-unit increase in morning laughter frequency, midday pain levels were predicted 
to decrease by 0.19 units. See Table 10 for the full results of this analysis.  
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Table 10 
 
Results of the Regression With Morning Laughter Frequency and Covariates Predicting 
Midday Pain Levels 
Step Variable B SE β t P VIF 
        
1 Depression 0.08 0.02 0.59 3.57 .001 1.43 
 Alexithymia -0.02 0.02 -0.17 -1.01 .317 1.43 
        
2 Depression 0.07 0.02 0.52 3.30 .002 1.48 
 Alexithymia -0.03 0.02 -0.20 -1.28 .209 1.44 
 Morning laughter frequency -0.19 0.08 -0.34 -2.53 .016 1.08 
 
For evening laughter and evening pain levels, the results of the overall regression 
for Step 2 were not significant at the reduced alpha level, F(3, 37) = 3.21 p = .034, R2 = 
.142, indicating that the covariates and evening laughter overall do not significantly 
predict variability in evening pain levels. The covariate of depression was the only 
individually significant predictor (B = 0.07, p = .011), indicating that for every one-unit 
increase in depression, there is a 0.07 unit increase in evening pain levels. However, the 
individual result should be treated with caution due to the nonsignificance of the overall 
regression. See Table 11 for the full results of this analysis.  
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Table 11 
 
Results of the Regression With Evening Laughter Frequency and Covariates Predicting 
Evening Pain Levels 
Step Variable B SE β t p VIF 
        
1 Depression 0.07 0.03 0.48 2.77 .009 1.43 
 Alexithymia -0.01 0.02 -0.10 -0.55 .588 1.43 
        
2 Depression 0.07 0.03 0.47 2.68 .011 1.44 
 Alexithymia -0.01 0.02 -0.10 -0.58 .565 1.43 
 Evening Laughter Frequency -0.07 0.09 -0.12 -0.83 .411 1.02 
 
Post-Hoc Analyses 
 In addition, I performed two post-hoc regressions. I used the first regression to 
examine the relationship between morning laughter and evening positive affect, and the 
second regression to examine the relationship between morning laughter and evening 
pain levels. The assumptions for these regressions were met (see Figures 8 and 9, Tables 
12 and 13). Additional Bonferroni corrections resulted in reduced alpha level of .013.  
 
Figure 8. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving morning laughter and evening positive affect.  
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Figure 9. Normal P-P plot (left) and scatterplot of residuals (right) for regression 
involving morning laughter and evening pain levels.  
 
The results of Step 2 of the regression with a dependent variable of evening 
positive affect were significant at a Bonferroni-controlled alpha level, F(3,37) = 6.54, p = 
.001, R2 = .293, indicating that overall, covariates and morning laughter together 
significantly predict variability in evening positive affect. Morning laughter frequency 
was the only individually significant predictor at a Bonferroni-controlled alpha level, B = 
1.01, p = .001. This indicates that for every one-unit increase in morning laughter 
frequency, there is a corresponding 1.01 unit increase in evening positive affect (see 
Table 12). 
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Table 12 
 
Results of the Regression With Morning Laughter Frequency and Covariates Predicting 
Evening Positive Affect 
Step Variable B SE β t P VIF 
        
1 Depression -0.19 0.09 -0.37 -2.03 .050 1.43 
 Alexithymia 0.00 0.09 0.00 -0.00 .998 1.13 
        
2 Depression -0.13 0.08 -0.27 -1.64 .109 1.48 
 Alexithymia 0.02 0.08 0.04 0.27 .790 1.44 
 Morning laughter frequency 1.01 0.29 0.48 3.47 .001 1.08 
 
 The results of Step 2 of the regression with a dependent variable of evening pain 
levels were significant at a stringent alpha level, F(3,37) = 12.67 p = .003, R2 = .249, 
indicating that overall, covariates and morning laughter significantly predict variability in 
evening pain levels. However, morning laughter frequency was not an individually 
significant predictor at a Bonferroni-controlled alpha level, B = -0.21, p = .019. See Table 
13 for the full results of this analysis.  
Table 13 
 
Results of the Regression With Morning Laughter Frequency and Covariates Predicting 
Evening Pain Levels 
 
Step Variable B SE β t P VIF 
        
1 Depression 0.07 0.03 0.48 2.77 .009 1.43 
 Alexithymia -0.01 0.02 -0.10 -0.55 .588 1.43 
        
2 Depression 0.06 0.02 0.041 2.46 .019 1.48 
 Alexithymia -0.02 0.02 -0.13 -0.77 .445 1.44 
 Morning laughter frequency -0.21 0.09 -0.35 -2.46 .019 1.07 
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Summary 
 The sample consisted mostly of White women whose ages ranged from 19 to 75 
years, were married, had a college education, and were employed full time. The majority 
of them were taking medications, engaged in alternative therapies, had comorbid 
conditions, and had engaged in behavioral health treatment. In the results for Research 
Question 1, it was indicated that the null hypothesis could be partially rejected; higher 
overall laughter frequency was associated with higher overall positive affect, but not 
overall negative affect. In follow-up testing, it was found that higher morning laughter 
frequency was associated with higher midday positive affect, but that higher evening 
laughter frequency was not associated with higher evening positive affect.  
 In the results for Research Question 2, it was indicated that the null hypothesis 
could be rejected; higher overall laughter frequency was associated with lower overall 
pain levels. In follow-up testing it was found that higher morning laughter frequency was 
associated with lower midday pain levels, but there was not a significant relationship 
between evening laughter frequency and evening pain levels. Post-hoc testing revealed 
that there was not a significant relationship between morning laughter frequency and 
evening pain levels. However, higher morning laughter frequency was associated with 
higher evening positive affect.  
 In Chapter 5, I will present a discussion of these results contextualized by the 
relevant literature. I will discuss the strengths and weaknesses of this study. Finally, I will 
provide recommendations for future research.  
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Chapter 5: Discussion, Conclusions, and Recommendations 
The purpose of this correlational study was to examine whether increased laughter 
frequency is predictive of increases in positive affect and or decreases in negative affect 
as well as reductions in perceived chronic pain levels in FMS patients using multiple 
linear regression analysis.  
FMS is typically incompletely treated via conventional medicine alone (ACR, 
2010; NFA, 2009). There is no cure, and it may result in significant disabilities (ACR, 
2010; NFA, 2009) and reductions in patients’ quality of life (Howard et al., 2010). Thus, 
additive alternative treatments or coping strategies may be helpful in assisting these 
patients with ameliorating residual symptoms (ACR, 2010; NFA, 2009).  
Laughter has been shown to be helpful in improving emotional states (Dolgoff-
Kaspar et al., 2012; Ganz & Jacobs, 2014; Ko & Youn, 2011; Sakuragi et al., 2002), in 
increasing pain thresholds and pain tolerance with laboratory-induced acute pain (Dunbar 
et al., 2011; Mahony et al., 2001; Stuber et al., 2009; Zweyer et al., 2004), and in 
reducing symptoms of various types of medical conditions (Bennett et al., 2003; Berk et 
al., 2001; Bertini et al., 2010; Christie & Moore, 2005; Hayashi, Urayama et al., 2007; 
Hayashi, Tsujii et al., 2007; Kim et al., 2009; Kimata, 2007a, 2007b, 2009; Kong et al., 
2014; Lengacher et al., 2002; Matsuzaki et al., 2006; Nasir et al., 2005; Sugawara et al., 
2010; Takeda et al., 2010; Walter et al., 2007). Laughter has also shown promise within a 
small sample of patients experiencing the chronic pain of RA (Herschenhorn, 1994). 
However, it has not yet been studied with regards to FMS patients. This present study 
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was conducted in order to investigate whether laughter has positive effects on pain and 
affective states of those with FMS.  
Summary of Findings 
After controlling for measures of alexithymia and depression, it was indicated in 
the results of the hierarchical analyses that higher overall laughter frequency among study 
participants was significantly associated with higher overall positive affect but not with 
overall negative affect. In follow-up and posthoc testing, it was indicated that higher 
morning laughter frequency was associated with significantly higher midday positive 
affect, as well as with significantly higher evening positive affect, but that higher evening 
laughter frequency was not associated with higher evening positive affect. 
 It was also indicated that higher overall laughter frequency was associated with 
significantly lower overall pain levels. In follow-up and posthoc testing, it was indicated 
that higher morning laughter frequency was significantly associated with lower midday 
pain levels, but there were no significant relationships observed between evening laughter 
frequency and evening pain levels or between morning laughter frequency and evening 
pain levels.  
Interpretation of the Findings 
General Analysis 
Descriptives. The great majority of this sample was female (95.12%) and White 
(82.93%), and their ages ranged from 19 to 75 years old, with an average age of 41.88 
(SD = 15.12) years old. These demographics are consistent with literature reviewed for 
this study. FMS tends to be seen predominantly in females in middle age (ACR, 2010; 
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CDC, 2011), and though it has been observed in all races (NFA, 2009), it appears it may 
more frequently occur in White populations. For instance, Bennett et al. (2007), in their 
extensive survey of 2,569 FMS patients, found that the preponderance of their sample 
was White (91.5%), similar to the higher percentage (82.93%) found in this study. 
Therefore, findings from this study may potentially be generalized to other samples of 
FMS patients, but may not so easily generalize to other, more diverse, medical or general 
populations.  
Depression. An overall average depression score of 21.80 (suggestive of 
moderate levels of depression) was observed in this study’s sample. Over half of the 
participants reported moderate to severe symptoms of depression (53.6%). This 
percentage is higher than figures reported in other research samples of FMS patients 
reviewed for this study, which ranged from 14.6% to 46% (Aguglia et al., 2011; dos 
Santos et al., 2012; Hassett et al., 2000; Ozcetin et al., 2007; Uguz et al., 2010; Wolfe & 
Michaud, 2009).  
As discussed in earlier chapters, depression has been shown to be associated with 
higher levels of negative affect (Anas & Akhouri, 2013) and with increased severity of 
pain ratings in those who have chronic pain (Aguglia et al., 2011; Baker et al., 2008). 
Because depression symptoms could potentially influence participants’ pain and affect 
ratings, these scores were controlled for in the hierarchical analyses. Indeed, when I 
tested for covariates, depression was found to be significantly associated with decreased 
positive affect, increased negative affect, and increased pain severity ratings. Although 
depression continued to be a significant predictor of the variability in positive affect, 
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negative affect, and overall pain levels even after being entered in the analyses as a 
covariate, laughter frequency was also shown to be a significant individual predictor of 
both reduced pain and improved positive affect. Because depression is so common 
among those with FMS, this is a hopeful result. It is suggestive that even those FMS 
patients who have depression can still benefit from laughter.  
  Alexithymia. The average alexithymia score for study participants was 49.61 
(SD = 12.92), corresponding to a low level of alexithymia. This is consistent with the 
TAS-20 general population norms in which the average alexithymia score is also in the 
low range (45.57, SD = 11.35). High levels of alexithymia are associated with 
physiological hypersensitivity (Kano et al., 2007) and could potentially influence the 
symptoms experienced by FMS patients. As such, measures of alexithymia were held 
constant in order to minimize any influence on this study’s results. However, a majority 
of the current study’s sample reported low alexithymia (58.5%) although 24.4% reported 
high alexithymia. This is in contrast to higher percentages observed in FMS patient 
samples by other researchers. For example, Evren et al. (2006) found that 39.2% of their 
FMS patient sample reported high alexithymia, and Steinweg et al. (2011) found that 
44% of their FMS patient sample reported high alexithymia.  
When breaking apart the individual alexithymia factors, the sample reported 
average alexithymia Factor 1 (difficulty in identifying feelings) scores of 19.54 (SD = 
6.34), average Factor 2 (difficulty in describing feelings) scores of 12.90 (SD = 5.21), and 
average Factor 3 (externally oriented thinking) scores of 17.17 (SD = 4.27). The highest 
score for this sample was Factor 1: difficulty in identifying feelings. The second highest 
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was Factor 2: externally based thinking, and the lowest measure was Factor 3: describing 
their emotions. To put this in context according to the literature, Martínez et al. (2014) 
found that when compared to a healthy control group, FMS patients evidenced 
significantly higher ratings on measures of both identifying and describing their 
emotional states. In their study, however, those in the control group scored higher than 
the FMS participants on the third factor: externally based thinking (Martínez et al., 2014).  
Alexithymia has been shown to be positively correlated with negative affect 
(Makino et al., 2013; Tooyserkani et al., 2011). This was also the case in this study. 
When performing the analysis of covariates, alexithymia was shown to have a significant 
positive correlation (r = .41) with negative affect. As alexithymia scores increased, so too 
did measures of negative affect. Tooyserkani et al. (2011) also observed a positive 
correlation between alexithymia and pain levels as well as a negative correlation between 
alexithymia and positive affect. These findings were not observed in this current study. 
However, the majority of the participants in this study reported low alexithymia scores—
which is in contrast to what has previously been found in other samples of FMS patients, 
so it could be that these correlations were not found because alexithymia did not seem to 
be problematic overall in this sample of FMS patients.  
Laughter frequency. Participants in this current study laughed, on average, 3.97 
times per day (SD = 2.77), with an overall range of 0.89 to 11.96. This is considerably 
lower than what was found by Martin and Kuiper (1999) in their study with 80 
community volunteers. Martin and Kuiper had participants log their overall laughter 
incidence for 3 days, and their study participants averaged 18 instances of laughter per 
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day, with a range of 0 to 89. The seeming deficit of reported laughter found in this 
sample may be worthwhile researching further with larger populations of FMS patients as 
well as with other chronic illness populations. Though it appears that laughter frequency 
has not yet been studied with medical outcomes of FMS patients (or with other chronic 
pain populations), it has been studied with regards to cardiovascular disease and as a 
predictor of disability in older adults (Hirosaki et al., 2011; Hayashi et al., 2016).  
 Hirosaki et al. (2011) conducted a 1-year prospective study with 162 older adults 
(aged 65 and older) in Japan. At the initial interview, it was confirmed that the 
participants did not have any functional disabilities. Information collected from 
participants included self-reported measures of laughter frequency, medical conditions 
present, and other psychological, sociological, and demographic information. The 
researchers found that those with lower reported frequency of laughter were significantly 
more likely to have subsequent functional disabilities a year later (Hirosaki et al., 2011). 
Although I did not measure or predict functional disabilities in this study, worsening 
symptoms of FMS have been shown to be associated with increasing disability and may 
render patients unable to complete everyday tasks (see ACR, 2010). In this study, it has 
been demonstrated that laughing more for these patients results in improvements to 
positive affect and pain levels. If FMS patients are feeling better, it would intuitively 
suggest that laughing more frequently might be associated with an increased ability to 
carry out the tasks of daily living—perhaps a worthwhile topic for future investigations 
with this population.  
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 Hayashi et al. (2016) analyzed cross-sectional survey data from a large sample of 
older adults in Japan (N = 20,934). Those who reported never or almost never laughing 
per day had a significantly increased likelihood of having experienced a heart attack or 
stroke when compared to those who reported laughing daily. In Hayashi et al.’s study, 
depression was also shown to be a predictor of heart attack and stroke, but when 
depression was controlled for in the analyses, laughter frequency remained an 
independent predictor. Similarly, in this present study, depression was shown to be a 
significant predictor of decreases in positive affect, increases in negative affect, and 
increases in pain, but when depression was controlled for, laughter frequency remained 
an individually significant predictor of decreased pain and increased positive affect 
ratings. Hayashi et al. suggested that laughter frequency may be health protective in 
terms of ameliorating symptoms caused by psychological stress and that increased 
laughter frequency may also be indicative of people who enjoy “physically and or 
mentally positive lifestyles” (p. 549). They cautioned, however, that, it could also be 
possible that those who had experienced cardiovascular disease “may experience fewer 
occasions in daily life to feel cheerful” (Hayashi et al., 2016, p. 549). The same might 
also hold true for those with FMS.  
Hierarchical Analyses  
Hypothesis 1. In the first hypothesis, I investigated the influence of laughter 
frequency on participants’ positive and negative affect ratings while controlling for 
measures of depression and alexithymia. In studies with undergraduate students, it has 
been shown that more frequent laughter is significantly associated with increased 
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cheerfulness (Young, 1937). It has been shown that elicited laughter from humorous 
videos produces significant temporary improvements in positive affective states 
(Sakuragi et al., 2002), and it has been shown that forced (simulated) laughter has been 
found to significantly improve positive affect ratings (Foley et al., 2002; Neuhoff & 
Schaefer; 2002). In this study, I demonstrated that those beneficial outcomes to positive 
affect from laughter appear to also be available to those with FMS. Those who laughed 
more frequently in this study reported significantly higher ratings of overall positive 
affect.   
 However, laughter frequency was not found to have a significant relationship 
with participants’ negative affect ratings in this study. Negative affect is associated with 
adverse effects in those with FMS. Those FMS patients who report higher measures of 
positive affect also tend to report lower symptomology, whereas those reporting higher 
levels of negative affect tend to report increased symptom burden in FMS (McAllister et 
al., 2013). Pain-related negative affect has also been shown to account for a significant 
proportion of variance in pain intensity with these individuals (Staud et al., 2006). These 
patients appear to also be especially vulnerable to pain exacerbations when experiencing 
aversive emotional states (Davis et al., 2001). Davis et al. found that patients with FMS 
primed into an aversive emotional state evidenced increases in their pain levels, and those 
pain levels then remained elevated, not returning to baseline during the 10-minute 
recovery period.  
There are few recent studies regarding laughter frequency and affect in the 
literature to compare with the outcomes of this study, however, the findings by Kuiper 
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and Martin (1998) continue to be relevant to this investigation. In their three-day study 
involving community volunteers, Kuiper and Martin (1998) similarly did not show a 
direct effect of laughter frequency on negative affect ratings. However, they did find 
laughter frequency acted to moderate the effects of stressful experiences on their ratings 
of negative affect. Those who laughed more in their study did not report as much of an 
increase in their negative affect ratings as their stressors increased. However, Kuiper and 
Martin’s study was conducted with volunteers from the community, not with chronic pain 
patients, and their participants reported laughing more frequently on average (18 times 
per day) than the participants in this study (3.97). It could be that with the pain and other 
symptoms being experienced by this group of participants, that the frequency of laughter 
was not quite enough to also produce improvements in negative affect ratings.  
Hypothesis 2. In the second hypothesis, I investigated the influence of laughter 
frequency on the participants’ perceived chronic pain levels while controlling for 
measures of depression and alexithymia. The findings of these analyses indicated that as 
overall laughter frequency increased, participants’ overall perceived chronic pain levels 
significantly decreased. This is consistent with the outcomes of other studies reviewed for 
this investigation, with both acute and chronic pain conditions. With regards to acute 
pain, laughter has been found to increase discomfort thresholds and pain tolerance 
(Dunbar et al., 2011; Mahony et al., 2001; Stuber et al., 2009; Zweyer et al., 2004). With 
regards to chronic pain, fewer studies have been conducted, but it appears that laughter 
may appear to exhibit positive effects in terms of reducing how bothersome the pain is 
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with RA patients (Herschenhorn, 1994), and in reducing the intensity of pain in older 
adults with chronic pain participating in humor therapy (Tse et al., 2010).  
 Follow-up and posthoc analyses: Hypotheses 1 and 2. In the follow-up and post 
hoc analyses, it was found that increases in morning laughter frequency (laughter 
incidence from wake-up ratings to the time of midday ratings) were shown to be 
associated with significantly higher midday and evening ratings of positive affect, as well 
as with significantly lower midday ratings of pain. However, there were no significant 
relationships observed between increased evening laughter frequency (laughter incidence 
from the midday ratings to the evening ratings) and evening positive affect ratings or 
evening pain ratings. Based on these outcomes, it appears study participants benefited 
most from increased laughter frequency earlier in the day, and those benefits to positive 
affect were sustained from the morning to the evening ratings.  
It was observed in the analyses that participants tended to report higher pain 
levels in their evening ratings, along with lower positive affect and higher negative affect 
ratings compared to their midday ratings. It is possible that they were fatigued in the 
evenings, or that their increased evening symptomology could have led to a decreased 
ability to benefit as much from episodes of laughter in the afternoon and evening. 
Although levels of fatigue were not measured in this study, Reilly and Littlejohn (1993) 
assessed fibromyalgia patients (N = 17) in the morning and then again in the evening, and 
found that participants reported worsened fatigue (as well as pain) in the evening ratings 
compared to the morning ratings. The authors also reported that their participants 
reported that “they felt at their best around mid-day” (Reilly & Littlejohn, 1993, p. 237), 
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and concluded that FMS symptoms tend to become more prominent toward the evening. 
This appears to be consistent with this study’s outcomes. Study findings were significant 
at the midday ratings, but the only significant finding for the evening ratings was the 
sustained increase in positive affect related to morning laughter frequency. It would be 
interesting to know if fatigue was an influencing factor in this study’s results, and it 
might be something to consider adding to the analyses for future studies.  
Additionally, as discussed in the second chapter, Zautra, Fasman, et al. (2005) 
suggested that those with FMS tend to have trouble sustaining positive affect, and as such 
they may not have enough positive affect stores to mediate the effects of increasing pain 
and stress. They may also have difficulty drawing from the positive affect stores they do 
have when experiencing aversive states related to increased pain or stress (Furlong et al., 
2010). In this study, increases in morning laughter were related to sustained 
improvements in evening positive affect ratings—indicating that participants were able to 
shore up their positive affect reserves. Despite evening increases in pain and in negative 
affect ratings, morning laughter frequency continued to be significantly associated with 
higher evening positive affect ratings. This suggests that these participants had long 
lasting stores of positive affect that did appear to mediate the increases in evening pain 
and negative affect. As such, it appears that direct interventions geared toward improving 
positive affect states and increasing the available stores of positive affect in these 
individuals may assist them in being able to sustain positive affect to buffer against 
increasing levels of pain or negative affect related to other stressors.   
152 
 
Another consideration is the extended duration of this study. It is possible that 
over time, participants may have become tired of completing the assessments, and that 
perhaps they were less diligent in recording laughter frequency and less thoughtful in 
completing their daily assessments. Okifuji, Bradshaw, Donaldson, and Turk (2011) 
asked FMS patients to document eight symptom measures 3 times per day for 30 days. 
They found that after 1 week, participants were more likely to begin missing measures. 
With longer duration of the study, more measures were missed. Based on their outcomes, 
the Okifuji et al. (2011) concluded that the ideal length of time for symptom reporting is 
likely to be 1 week in duration. If this study is to be replicated, it might be worthwhile to 
change the reporting time frame to 1 week only.   
 Dynamic model of affect. The findings of this study do appear to provide support 
for the tenets of the dynamic model of affect theory. According to the principles of this 
model, it is predicted that if individuals experience episodes of positive affect during the 
time they are experiencing increased pain or stress, the positive emotions (in this case, the 
positive emotional state of laughter) should act to moderate pain-related negative 
emotions. The developers of this model suggested that experiencing (and being able to 
sustain) positive affective states is important in being able to reduce the impact of 
aversive emotional states caused by increased pain (Zautra et al., 2001; Zautra, Fasman, 
et al., 2005), which in turn is expected to increase their ability to recover from episodes 
of heightened pain and stress (Davis et al., 2004). Though this study’s outcomes did not 
show a significant direct effect of laughter frequency on negative affect, it was shown 
that increased laughter frequency was significantly associated with increases in overall 
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positive affect. This indicates that increased laughter did appear to produce improvements 
in positive affect for this group of FMS patients, and those improvements were sustained 
from midday ratings to evening ratings.  
Pain theories. Findings of these analyses appear to support the influence of 
psychological factors on the experience of pain in individuals with FMS. As suggested by 
Melzack and Wall (1965), in their gate control theory of pain, rather than a simple 
stimulus-response type of relationship, some pain experiences may also be influenced by 
the individual’s attention, memories, and emotional state. In these cases, the individual 
might be able to alter his or her pain experience through distraction techniques or other 
types of strategies geared toward exerting some control over the pain (Melzack & Wall, 
1965). Because increased laughter frequency was associated with lower pain levels in this 
sample, this might provide some evidence that laughter could be an effective strategy (or 
distraction) for ameliorating some of the discomfort associated with FMS pain.   
Similarly, within the neuromatrix theory of pain theory (Melzack, 1999b; 
Melzack, 2005), it was proposed that the pain experience could be subject to being 
altered by many types of influences and stimuli. These potential influences include the 
sensory, cognitive, and affective dimensions (Melzack, 2005). In this particular study, it 
appears that the activation of the affective dimension was associated with reductions in 
pain. As overall laughter frequency increased, overall positive affect increased, and 
overall pain levels decreased. In this way, laughter frequency appears to have influenced 
positive affect rating scores, which may have then served to modulate the pain 
experienced by these individuals. McAllister (2015) suggested that treatments geared 
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toward reducing pain severity in chronic pain patients should target various dimensions 
of the pain experience in the neuromatrix. This would ideally include a comprehensive, 
interdisciplinary approach—including conventional treatments, physical therapy, and 
health psychologist and cognitive therapist interventions.  
Limitations 
As discussed in the first chapter, because this study did not take place in a 
rigorously controlled laboratory setting in which extraneous variables could be 
minimized, it is possible that there were other confounds that could have influenced this 
study’s results. There also could have been unknown events or experiences in the 
participants’ lives that exerted effects on their ratings and on their frequency of laughter.  
Additionally, there are limitations to the generalizability of this study to other 
populations. For example, this sample was disproportionately composed of women 
(95.12%). Study results may not necessarily generalize to men with FMS. Additionally, 
because this study was conducted solely with FMS patients, results may not easily 
generalize to other chronic pain patients, or to patients with other medical conditions. 
Also, as discussed in the first chapter, study results may not even be easily generalizable 
to the larger population of FMS patients. This study’s participants were all volunteers and 
there may be intrinsic differences between those FMS patients who chose to volunteer for 
the study and those who did not. There could be variances in personality traits, or it could 
be that those who did not choose to participate may have been more symptomatic than 
those who volunteered for the study, making it more difficult for them to fulfill the 
requirements of the study. As such, it might be useful for future researchers to consider 
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methods that could potentially target a larger population of FMS patients with various 
symptom profiles—perhaps through the use of a simple survey that is less burdensome 
for participants to complete. Indeed, several prospective participants in this study 
believed they were volunteering to complete a survey, and when they were instructed in 
what was expected of them for this two-week long investigation, they did not continue 
with the study.   
 It is also possible that results might have been influenced by participants’ implicit 
expectations that they would experience reductions in pain and improvements in 
emotional states if they laughed more frequently. For example, Mahony et al. (2001) 
showed videos to their participants (the content of the videos was either relaxing or 
funny), and then applied blood pressure cuffs to participants in order to elicit acute pain. 
They found that both control participants (no priming) as well as those who had been 
primed to expect their discomfort thresholds to increase evidenced increases in pain 
thresholds. Mahony et al. (2001) concluded that it might be attributed to the existing 
implicit expectations the control group participants already had regarding the effects of 
relaxation or humor. However, as discussed above, if this were the case in this study, it 
seems that their negative affect ratings would also have been affected by laughter 
frequency. This also does not explain why laughter frequency was associated with lower 
pain ratings in the afternoon, but not in the evening ratings.  It seems that if implicit 
expectations were influencing the results, they would have influenced all measures.   
Another potential limitation to the study may be the nature of the way the data 
were gathered. Participants found it necessary to interrupt their activities and document 
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each time they laughed. It could be that some laughter incidents were missed or recorded 
after the fact, increasing the risk that the data may not have been precisely accurate. 
Future researchers may consider other options for tracking laughter, such as employing 
simple clicker counters that are less disruptive or using a recording device to capture 
laughter in real time. It may also have been beneficial to use computer applications or 
Smart Phone Apps to complete and submit the daily measures as they were taken.  
Recommendations for Future Research 
 As I have mentioned above, future researchers might consider investigating how 
frequently FMS patients laugh in general as compared to samples of patients with other 
types of chronic pain, to patients with other types of medical conditions, as well as to 
samples of healthy volunteers. Based on this study’s results, it appears FMS patients 
laugh relatively infrequently (3.97 times per day, on average). It would be interesting to 
learn whether this holds true for a larger sample of FMS patients. Adding fatigue as a 
measurable variable in future studies might also be useful. It would be interesting to 
know whether and how fatigue impacts FMS patients’ affect ratings as well as their levels 
of pain, along with considering the role of laughter frequency. Also, it might be 
worthwhile to conduct a similar study, but shortening the time frame to 1 week of data 
collection.  
Because it is not known whether strength or duration of laughter episodes may 
have played a role in this study’s findings, for a potential future follow-on study I would 
also be interested in analyzing whether that data captured by participants on their laughter 
logs intensity or duration of laughter had any influence on their outcome measures. Also, 
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because negative affect ratings in this sample were largely unaffected by laughter 
frequency, efforts to target negative affect ratings with this population might also be an 
interesting topic to research in future investigations. If interventions are found that are 
associated with a decrease in negative affect that might also assist in bringing about 
decreases in symptomology for these patients.      
 Finally, since this study relied on participants simply recording each episode of 
laughter as it occurred naturally in their everyday lives, it might be useful in future 
studies to conduct a formal laughter intervention with this population. This more 
controlled, laboratory approach to this topic could help us understand how deliberate 
increases in laughter frequency influence affect and pain in this population.   
Implications 
Positive Social Change 
The outcomes of this study have the potential to be associated with various levels 
of positive social change. At the individual level, if laughing more frequently can lead to 
improvements in positive affect and pain, these decreases in symptomology can, over 
time, potentially lead to improvements in overall mood, increased productivity in daily 
activities, and perhaps even enhanced interpersonal relationships and increased 
involvement in community events. The better FMS patients feel, the more likely they will 
be to participate more in their lives. Laughing more is also something they can do with 
their family, thereby having more fun and improving relationships. It may also mean 
fewer days missed from work, or the ability to more fully participate in longer work 
hours, which would enhance their economic position. Even a slight improvement brought 
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about by a self-care strategy such as laughing more frequently may have the effect of 
reducing visits to medical providers, thereby decreasing health care costs. Something as 
simple as laughter could make a meaningful impact (no matter how small) in these 
individuals’ lives, those of their friends, family, and coworkers, and in the field of health 
care. Finally, it may also have implications for future research. Because of what has been 
observed in this study’s outcomes, other researchers may be influenced to conduct further 
investigations. As more and more is learned about the potential effects and influences of 
laughter, the results can be used to foster more study or to be put into practice in the 
health care arena. For instance, laughter yoga, shown to have promise as a treatment 
modality in research (Sakuragi et al., 2002), could be implemented more widely as part of 
a comprehensive, interdisciplinary plan of care. Those implementing the treatments could 
gather pre and post data on participants in order to provide evidence-based outcomes. If 
such programs appear to produce beneficial outcomes for patients, the more likely it will 
be that laughter interventions will be more formally (and widely) used within medical 
settings.   
Recommendations for Practice   
This study paves the way for research involving more formal applications of 
laughter with FMS patients. This research could also represent a step forward toward the 
acceptance of laughter therapy as an alternative treatment modality as part of an 
interdisciplinary team approach to care with these patients. If nothing else, it provides 
some support for the beneficial effects of laughter for pain and temporary emotional 
states in those with FMS. Providers could encourage their FMS patients to seek out 
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frequent laughter opportunities. This might mean participating in activities such as 
watching some of their favorite humorous videos, spending time with friends, or even 
attending formal laughter workshops.  
Conclusion 
In this study, I set out to investigate whether the positive benefits of laughter 
observed with acute pain and in other health conditions also held true for those with the 
chronic pain and affective difficulties characteristic of FMS. Indeed, the findings of this 
investigation do appear to support the assertions that increased laughter frequency is 
associated with improvements in pain levels and affective states in those with FMS. It is 
hoped that this knowledge might inspire and encourage FMS patients to seek out reasons 
to laugh, and to laugh more often. Because conventional treatment typically does not 
ameliorate all symptoms, it is important for FMS patients to have a set of alternative 
strategies to help boost their treatment’s effectiveness. Some may find laughter to be a 
helpful strategy added to their interventional toolbox. It is also hoped that 
interdisciplinary health care teams might consider encouraging laughter (whether that be 
individually or as part of formal laughter interventions) as part of a comprehensive 
treatment and self-care plan. Finally, it is hoped that researchers continue adding to this 
foundation of knowledge with regards to laughter and its potential health effects.  
160 
 
References 
Ablin, J. N., Cohen, H., Neumann, L., Kaplan, Z., & Buskila, D. (2008). Coping styles in 
fibromyalgia: Effect of co-morbid posttraumatic stress disorder. Rheumatology 
International, 28(7), 649-656. doi:10.1007/s00296-007-0496-1 
Aguglia, A., Salvi, V., Maina, G., Rossetto, I., & Aguglia, E. (2011). Fibromyalgia 
syndrome and depressive symptoms: Comorbidity and clinical correlates. Journal 
of Affective Disorders, 128(3), 262-266. doi:10.1016/j.jad.2010.07.004  
Alnigenis, M. N., Bradley, J. D., Wallick, J., & Emsley, C. L. (2001). Massage therapy in 
the management of fibromyalgia: A pilot study. Journal of Musculoskeletal Pain, 
9(2), 55-67. doi:10.1300/J094v09n02_05   
American College of Rheumatology. (2010). Fibromyalgia. Retrieved from 
http://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-
Conditions/Fibromyalgia  
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental 
disorders (4th ed.), Washington, DC: Author. 
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental 
disorders (4th ed., text rev.), Washington, DC: Author. 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 
disorders (5th ed.). Arlington, VA: American Psychiatric Publishing. 
Amital, D., Fostick, L., Polliack, M. L., Segev, S., Zohar, J., Rubinow, A., & Amital, H. 
(2006). Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: Are 
they different entities? Journal of Psychosomatic Research, 61(5), 663-669. 
161 
 
doi:10.1016/j.jpsychores.2006.07.003 
Anas, M., & Akhouri, D. (2013). Positive and negative affect in depressed and normal 
adults. Journal of Indian Health Psychology, 8(1), 61-68. Retrieved from 
http://globalvisionpub.com/globaljournalmanager/pdf/1380177380.pdf 
Arnold, L. M., Crofford, L. J., Mease, P. J., Burgess, S. M., Palmer, S. C., Abetz, L., & 
Martin, S. A. (2008). Patient perspectives on the impact of fibromyalgia. Patient 
Education and Counseling, 73(1), 114-120. doi:10.1016/j.pec.2008.06.005 
Arnold, L. M., Hudson, J. I., Hess, E. V., Ware, A. E., Fritz, D. A., Auchenbach, M. B., 
… Keck, Jr., P. E. (2004). Family study of fibromyalgia. Arthritis & Rheumatism, 
50(3), 944-952. doi:10.1002/art.20042 
Babu, A. S., Mathew, E., Danda, D., & Prakash, H. (2007). Management of patients with 
fibromyalgia using biofeedback: A randomized control trial. Indian Journal of 
Medical Sciences, 61(8), 455-461. doi:10.1043/0019-5359.33710 
Bagby, R. M., Ayearst, L. E., Morariu, R. A., Watters, C., & Taylor, G. J. (2013). The 
internet administration version of the 20-Item Toronto Alexithymia Scale. 
Psychological Assessment. Advance online publication. doi:10.1037/a0034316 
Bagby, R. M., Parker, J. D., & Taylor, G. J. (1993). The twenty-item Toronto 
Alexithymia Scale—I. Item selection and cross-validation of the factor structure. 
Journal of Psychosomatic Research, 38(1), 23-32. doi:10.1016/0022-
3999(94)90005-1 
Bagby, R. M., Taylor, G. J., & Parker, J. D. (1994). The Twenty-Item Toronto 
Alexithymia Scale—II. Convergent, discriminant, and concurrent validity. 
162 
 
Journal of Psychosomatic Research, 38(1), 33-40. doi:10.1016/0022-
3999(94)90006-X 
Baker, T. A., Buchanan, N. T., & Corson, N. (2008). Factors influencing chronic pain 
intensity in older Black women: Examining depression, locus of control, and 
physical health. Journal of Women’s health, 17(5), 869-878. 
doi:10.1089/jwh.2007.0452  
Barker, K. K. (2008). Electronic support groups, patient-consumers, and medicalization: 
The case of contested illness. Journal of Health and Social Behavior, 49(1), 20-
36. doi:10.1177/002214650804900103 
Barlow, J., Wright, C., Sheasby, J., Turner, A., & Hainsworth, J. (2002). Self-
management approaches for people with chronic conditions: A review. Patient 
Education and Counseling, 48(2), 177-187. doi:10.1016/S0738-3991(02)00032-0 
Bartley, E. J., Rhudy, J. L., & Williams, A. E. (2009). Experimental assessment of 
affective processing in fibromyalgia. Journal of Pain, 10(11), 1151-1160. 
doi:10.1016/j.jpain.2009.04.008 
Bazzichi, L., Giacomelli, C., Rossi, A., Sernissi, F., Scarpellini, P., Consensi, A., & 
Bombardieri, S. (2012). Fibromyalgia and sexual problems. Reumatismo, 64(4), 
261-267. doi:10.4081/reumatismo.2012.261 
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). BDI-II Manual. San Antonio, TX: 
Pearson. 
Bellato, E., Marini, E., Castoldi, F., Barbasetti, N., Mattei, L., Bonasia, D. E., & Blonna, 
D. (2012). Fibromyalgia syndrome: Etiology, pathogenesis, diagnosis, and 
163 
 
treatment. Pain Research and Treatment, 2012, 1-17. doi:10.1155/2012/426130 
Bennett, H. J. (2003). Humor in medicine. Southern Medical Journal, 96(12), 1257-1561. 
doi:10.1097/01.SMJ.0000066657.70073.14 
 Bennett, M. P., & Lengacher, C. A. (2006). Humor and laughter may influence health. I. 
History and background. Evidence-Based Complementary and Alternative 
Medicine, 3(1), 61-63. doi:10.1093/ecam/nek015 
Bennett, M. P., Zeller, J. M., Rosenberg, L., & McCann, J. (2003). The effect of mirthful 
laughter on stress and natural killer cell activity.  Alternative Therapies in Health 
& Medicine, 9(2), 38-44. Retrieved from http://www.alternative-therapies.com  
Bennett, R. M. (2009). Science of fibromyalgia. National Fibromyalgia Association. 
Retrieved from 
http://fmaware.org/site/PageServerccdf.html?pagename=fibromyalgia_science 
Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J., & Matallana, L. (2007). An internet 
survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders, 8(1), 
27-37. doi:10.1186/1471-2474-8-27 
Berger, A., Dukes, E., Martin, S., Edelsberg, J., & Oster, G. (2007). Characteristics and 
healthcare costs of patients with fibromyalgia syndrome. International Journal of 
Clinical Practice, 61(9), 1498-1508. doi:10.1111/j.1742-1241.2007.01480.x  
Berger, A., Sadosky, A., Dukes, E. M., Edelsberg, J., Zlateva, G., & Oster, G. (2010). 
Patterns of healthcare utilization and cost in patients with newly diagnosed 
fibromyalgia. American Journal of Managed Care, 16(5, Supp.), S126-S137. 
Retrieved from http://www.ajmc.com/ 
164 
 
Berk, L. S., Felten, D. L., Tan, S. A., Bittman, B. B., & Westengard, J. (2001). 
Modulation of neuroimmune parameters during the eustress of humor-associated 
mirthful laughter. Alternative Therapies in Health and Medicine, 7(2), 62-76. 
Retrieved from http://www.alternative-therapies.com 
Berk, L. S., & Tan, S. A. (2006). [beta]-Endorphin and HGH increase are associated with 
both the anticipation and experience of mirthful laughter [Abstract]. Journal of 
the Federation of American Societies for Experimental Biology, 20(4), A382. 
Abstract retrieved from http://www.fasebj.org 
Bernardy, K., Füber, N., Klose, P., & Häuser, W. (2011). Efficacy of hypnosis/guided 
imagery in fibromyalgia syndrome- A systematic review and meta-analysis of 
controlled trials. BMC Musculoskeletal Disorders, 12(1), 133-143. 
doi:10.1186/1471-247412-133 
Bertini, M., Iani, L., De Santo, M., Scaramuzzi, C., Petramala, L., Cotesta, D., . . . 
Letizia, C. (2010). Stress-moderating effects of positive emotions: Exposure to 
humorous movies during hemodialytic sessions decreases blood levels of stress 
hormones. Journal of Chinese Clinical Medicine, 5(2), 61-70. Retrieved from 
http://www.cjmed.net/ 
Brattberg, G. (1999). Connective tissue massage in the treatment of fibromyalgia. 
European Journal of Pain, 3(3), 235-245. doi:10.1016/S1090-3801(99)90050-2 
Broderick, J. E., & Vikingstad, G. (2008). Frequent assessment of negative symptoms 
does not induce depressed mood. Journal of Clinical Psychology in Medical 
Settings, 15(4), 296-300. doi:10.1007/s10880-008-9127-6 
165 
 
Brutsche, M. H., Grossman, P., Müller, R. E., Wiegand, J., Pello, Baty, F., & Ruch, W. 
(2008). Impact of laughter on air trapping in severe chronic obstructive lung 
disease. International Journal of Chronic Obstructive Pulmonary Disease, 3(1), 
185-192. Retrieved from http://www.dovepress.com/international-journal-of-
chronic-obstructive-pulmonary-disease-journal 
Burckhardt, C. S., Clark, S. R., & Bennett, R. M. (1991). The Fibromyalgia Impact 
Questionnaire: Development and validation. Journal of Rheumatology, 18(5), 
728-733. Retrieved from http://www.jrheum.com 
Buskila, D., Atzeni, F., & Sarzi-Puttini, P. (2008). Etiology of fibromyalgia: The possible 
role of infection and vaccination. Autoimmunity Reviews, 8(1), 41-43. 
doi:10.1016/j.autrev.2008.07.023  
Buskila, D., Neumann, L., Sibirski, D., & Shvartzman, P. (1997). Awareness of 
diagnostic and clinical features of fibromyalgia among family physicians. Family 
Practice, 14(3), 238-241. doi:10.1093/fampra/14.3.238 
Cacioppo, J. T., & Petty, R. E. (1982). The need for cognition. Journal of Personality and 
Social Psychology, 42(1), 116-131. doi:10.1037//0022-3514.42.1.116 
Cash, E., Salmon, P., Weissbecker, I., Rebholz, W. N., Bayley-Veloso, R., Zimmaro, L. 
A., …Sephton, S. E. (2015). Mindfulness meditation alleviates fibromyalgia 
symptoms in women: Results of a randomized clinical trial. Annals of Behavioral 
Medicine, 49(3), 319-330. doi:10.1007/s12160-014-9665-0  
Castro-Sánchez, A., Matarán-Peñarrocha, G. A., Granero-Molina, J., Aguilera-Manrique, 
G., Quesada-Rubio, J. M., & Moreno-Lorenzo, C. (2011). Benefits of massage-
166 
 
myofascial release therapy on pain, anxiety, quality of sleep, depression, and 
quality of life in patients with fibromyalgia. Evidence-Based Complementary and 
Alternative Medicine, 2011, 1-9. doi:10.1155/2011/561753  
Centers for Disease Control and Prevention (CDC). (2011). Fibromyalgia. Retrieved 
from http://www.cdc.gov/arthritis/basics/fibromyalgia.htm 
Choy, E., Perrot, S., Leon, T., Kaplan, J., Petersel, D., Ginovker, A., & Kramer, E. 
(2010). A patient survey of the impact of fibromyalgia and the journey to 
diagnosis. BioMed Central Health Services Research, 10(1), 102-110. 
doi:10.1186/1472-6963-10-102  
Christie, W., & Moore, C. (2005). The impact of humor on patients with cancer. Clinical 
Journal of Oncology Nursing, 9(2), 211-218. doi:10.1188/05.CJON.211-218 
Conte, H. R., Ratto, R., & Karasu, T. B. (1996). The Psychological Mindedness Scale: 
Factor structure and relationship to outcome of psychotherapy. Journal of 
Psychotherapy Practice and Research, 5(3), 250-259. Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/journals/1745/ 
Crawford, J. R., & Henry, J. D. (2004). The positive and negative affect schedule 
(PANAS): Construct validity, measurement properties and normative data in a 
large non-clinical sample. British Journal of Psychology, 43(3), 245-265. 
doi:10.1348/0144665031752934  
Creswell, J. W. (2012). Educational research: Planning, conducting, and evaluating 
quantitative and qualitative research (4th ed.). Boston, MA: Pearson 
Crofford, L. J., & Clauw, D. J. (2002). Fibromyalgia: Where are we a decade after the 
167 
 
American College of Rheumatology classification criteria were developed? 
Arthritis & Rheumatism, 46(5), 1136-1138. doi:10.1002/art.10217  
Curtis, K., Osadchuk, A., & Katz, J. (2011). An eight-week yoga intervention is 
associated with improvements in pain, psychological functioning and 
mindfulness, and changes in cortisol levels in women with fibromyalgia. Journal 
of Pain Research, 4, 189-201. doi:10.2147/JPR.S22761 
Da Silva, G., Lorenzi-Filho, G., & Lage, L. V. (2007). Effects of yoga and the addition of 
tui na in patients with fibromyalgia. Journal of Alternative and Complementary 
Medicine, 13(10), 1107-1113. doi:10.1089/acm.2007.0615 
Davis, M. C., Thummala, K., & Zautra, A. J. (2014). Stress-related clinical pain and 
mood in women with chronic pain: Moderating effects of depression and positive 
mood induction. Annals of Behavioral Medicine (February, 2014). 
doi:10.1007/s12160-013-9583-6 
Davis, M. C., Zautra, A. J., & Reich, J. W. (2001). Vulnerability to stress among women 
in chronic pain from fibromyalgia and osteoarthritis. Annals of Behavioral 
Medicine, 23(3), 215-226. Retrieved from 
http://www.sbm.org/publications/annals-of-behavioral-medicine 
Davis, M. C., Zautra, A. J., & Smith, B. (2004). Chronic pain, stress, and the dynamics of 
affective differentiation. Journal of Personality, 72(6), 1133-1159. 
doi:10.1111/j.1467-6494.2004.00293.x 
DeLeo, J. A. (2006). Basic science of pain. Journal of Bone and Joint Surgery, 88(supp. 
2), 58-62. doi:10.2106/JBJS.E.01286 
168 
 
Dolgoff-Kaspar, R., Baldwin, A., Johnson, M. S., Edling, N., & Sethi, G. K. (2012). 
Effect of laughter yoga on mood and heart rate variability in patients awaiting 
organ transplantation: A pilot study. Alternative Therapies, 18(4), 53-58. 
Retrieved from http://www.alternative-therapies.com 
dos Santos, E. B., Quintans, L. J., Jr., Fraga, B. P., Macieira, J. C., & Bonjardim, L. R. 
(2012). An evaluation of anxiety and depression symptoms in fibromyalgia. 
Revista da Escola de Enfermagem- Universidade de São Paulo, 46(3), 589-594. 
Retrieved from http://www.ee.usp.br/reeusp/ 
Dreyer, L., Kendall, S., Danneskiold-Samsøe, B., Bartels, E. M., & Bliddal, H. (2010). 
Mortality in a cohort of Danish patients with fibromyalgia. Arthritis & 
Rheumatism, 62(10), 3101-3108. doi:10.1002/art.27623 
Dunbar, R. I., Baron, R., Frangou, A., Pearce, E., van Leeuwin, E. J., Stow, J., . . . van 
Vugt, M. (2011). Social laughter is correlated with an elevated pain threshold. 
Proceedings of the Royal Society B: Biological Sciences. 
doi:10.1098/rspb.2011.1373 
Evans, C. J., Parthan, A., & Le, K. (2006). Economic and humanistic burden of 
fibromyalgia in the USA. Expert Review of Pharmacoeconomics & Outcomes 
Research, 6(3), 303-314. doi:10.1586/14737167.6.3.303  
Evren, B., Evren, C., & Guler, M. H. (2006). Clinical correlates of alexithymia in patients 
with fibromyalgia. Pain Clinic, 18(1), 1-9. doi:10.1163/156856906775249857 
Farrar, J. T., Young, J. P., Jr., LaMoreaux, L., Werth, J. L., & Poole, R. M. (2001). 
Clinical importance of changes in chronic pain intensity measured on an 11-point 
169 
 
numerical pain rating scale. Pain, 94(2), 149-158. doi:10.1016/S0304-
3959(01)00349-9  
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009). Statistical power analyses 
using G*Power 3.1: Tests for correlation and regression analyses. Behavior 
Research Methods, 41(4), 1149-1160. doi:10.3758/BRM.41.4.1149 
Field, A. (2013). Discovering Statistics Using SPSS, 4th ed. Thousand Oaks, CA: Sage 
Publications. 
Finan, P. H., Zautra, A. J., & Davis, M. C. (2009). Daily affect relations in fibromyalgia 
patients reveal positive affective disturbance. Psychosomatic Medicine, 71(4), 
474-482. doi:10.1097/PSY.0b013e31819e0a8b 
Fitzcharles, M.-A., & Boulos, P. (2003). Inaccuracy in the diagnosis of fibromyalgia: 
Analysis of referrals. Rheumatology, 42(2), 263-267. 
doi:10.1093/rheumatology/keg075 
 Foley, E., Matheis, R., & Schaefer, C. (2002). Effect of forced laughter on mood. 
Psychological Reports, 90(1), 184. doi:10.2466/pr0.2002.90.1.184 
Friedberg, F., Leung, D. W., & Quick, J. (2005). Do support groups help people with 
chronic fatigue syndrome and fibromyalgia? A comparison of active and inactive 
members. Journal of Rheumatology, 32(12), 2416-2420. Retrieved from 
http://www.jrheum.org 
Furlong, L. V., Zautra, A., Puente, C. P., López-López, A., & Valero, P. B. (2010). 
Cognitive-affective assets and vulnerabilities: Two factors influencing adaptation 
to fibromyalgia. Psychology and Health, 25(2), 197-212. 
170 
 
doi:10.1080/08870440802074656 
 Ganz, F. D., & Jacobs, J. M. (2014). The effect of humor on elder mental and physical 
health. Geriatric Nursing, 35(3), 205-211. doi:10.1016/j.gerinurse.2014.01.005  
Garg, N., & Deodhar, A. (2012). New and modified fibromyalgia diagnostic criteria. 
Journal of Musculoskeletal Medicine, 29(1), 1-4. Retrieved from 
http://www.musculoskeletalnetwork.com 
Glombiewski, J. A., Sawyer, A. T., Gutermann, J., Koenig, K., Rief, W., & Hofmann, S. 
G. (2010). Psychological treatments for fibromyalgia: A meta-analysis. Pain, 
151(2), 280-295. doi:10.1016/j.pain.2010.06.011 
González, E., Elorza, J., & Failde, I. (2010). Fibromyalgia and psychiatric comorbidity: 
Their effect on the quality of life patients. Actas Españolas de Psiquiatría, 38(5), 
295-300. Retrieved from http://actaspsiquiatria.es/ 
Gross, J. J. (1998). The emerging field of emotion regulation: An integrative review. 
Review of General Psychology, 2(3), 271-299. Retrieved from 
http://www.apa.org/journals/gpr/ 
Hassett, A. L., Cone, J. D., Patella, S. J., & Sigal, L. H. (2000). The role of 
catastrophizing in the pain and depression of women with fibromyalgia syndrome. 
Arthritis & Rheumatism, 43(11), 2493-2500. doi:10.1002/1529-
0131(200011)43::<AID-ANR17>3.0.CO;2-W  
Hassett, A. L., Simonelli, L. E., Radvanski, D. C., Buyske, S., Savage, S. V., & Sigal, L. 
H. (2008). The relationship between affect balance style and clinical outcomes in 
fibromyalgia. Arthritis & Rheumatism, 59(6), 833-840. doi:10.1002/art.23708 
171 
 
Häuser, W., Klose, P., Langhorst, J., Moradi, B., Steinbach, M., Schiltenwolf, M., & 
Busch, A. (2010). Efficacy of different types of aerobic exercise in fibromyalgia 
syndrome: A systematic review and meta-analysis of randomised controlled trials. 
Arthritis Research & Therapy, 12(3), R79-R92. doi:10.1186/ar3002  
Häuser, W., Kosseva, M., Üceyler, N., Klose, P., & Sommer, C. (2011). Emotional, 
physical, and sexual abuse in fibromyalgia syndrome: A systematic review with 
meta-analysis. Arthritis Care & research, 63(6), 808-820. doi:10.1002/acr.20328    
Häuser, W., & Wolfe, F. (2012). Diagnosis and diagnostic tests for fibromyalgia 
(syndrome). Reumatismo, 64(4), 194-205. doi:10.4081/reumatismo.2012.194 
Haviland, M. G., Morton, K. R., Oda, K., Fraser, G. E. (2010). Traumatic experiences, 
major life stressors, and self-reporting a physician-given fibromyalgia diagnosis. 
Psychiatry Research, 177(3), 335-341. doi:10.1016/j.psychres.2009.08.017 
Hayashi, K., Kawachi, I., Ohira, T., Kondo, K., Shirai, K., & Kondo, N. (2016). Laughter 
is the best medicine? A cross-sectional study of cardiovascular disease among 
older Japanese adults. Journal of Epidemiology, 26(10), 546-552. 
doi:10.2188/jea.JE20150196   
Hayashi, T., Tsujii, S., Iburi, T., Tamanaha, T., Yamagami, K., Yamagami, R., … 
Murakami, K. (2007). Laughter up-regulates the genes related to NK cell activity 
in diabetes. Biomedical Research, 28(6), 281-285. doi:10.2220/biomedres.28.281  
Hayashi, T., Urayama, O., Hori, M., Sakamoto, S., Nasir, U. M., Iwanaga, S., … 
Murakami, K. (2007). Laughter modulates prorenin receptor gene expression in 
patients with type 2 diabetes. Journal of Psychosomatic Research, 62(6), 703-706. 
172 
 
doi:10.1016/j.jpsychores.2007.01.010   
Herschenhorn, S. (1994). The impact of focused laughter therapy on chronic pain in 
young women with rheumatoid arthritis (Doctoral dissertation). Order No. 
9510856. Retrieved from ProQuest Dissertations and Theses Global database. 
Hirosaki, M., Ishimoto, Y., Kasahara, Y., Sakamoto, R., Ishine, M., Wada, T., 
…Matsubayashi, K. (2011). Laughter as a predictor of subsequent disability in 
community-dwelling elderly in Japan. Journal of Epidemiology and Community 
Health, 65 (supp. 1), A464. doi:10.1136/jech.2011.142976q.5 
Howard, K. J., Mayer, T. G., Neblett, R., Perez, Y., Cohen, H., & Gatchel, R. J. (2010). 
Fibromyalgia syndrome in chronic disabling occupational musculoskeletal 
disorders. Journal of Occupational and Environmental Medicine, 52(12), 1186-
1191. doi:10.1097/JON.0b013e3181fc838d 
Hsu, M. C., Schubiner, H., Lumley, M. A., Stracks, J. S., Clauw, D. J., & Williams, D. A. 
(2010). Sustained pain reduction through affective self-awareness in 
fibromyalgia: A randomized controlled trial. Journal of General Internal 
Medicine, 25(10), 1064-1070. doi:10.1007/s11606-010-1418-6 
Huber, A., Suman, A. L., Biasi, G., & Carli, G. (2009). Alexithymia in fibromyalgia 
syndrome: Associations with ongoing pain, experimental pain sensitivity and 
illness behavior. Journal of Psychosomatic Research, 66(5), 425-433. 
doi:10.1016/j.jpsychores.2008.11.009 
Institutional Review Board for Social & Behavioral Sciences: University of Virginia. 
(2012). Retention of research records and destruction of data. Retrieved from 
173 
 
http://www.virginia.edu/vpr/irb/sbs/resources_guide_data_retention.html 
Iversen, M. D., Hammond, A., & Betteridge, N. (2010). Self-management of rheumatic 
diseases: State of the art and future perspectives. Annals of the Rheumatic 
Diseases, 69(6), 955-963. doi:10.1136/ard.2010.129270 
Jensen, M. P., & McFarland, C. A. (1993). Increasing the reliability and validity of pain 
intensity measurement in chronic pain patients. Pain, 55(2), 195-203. 
doi:10.1016/0304-3959(93)90148-I 
Johnson, P. (2002). The use of humor and its influences on spirituality and coping in 
breast cancer survivors. Oncology Nursing Forum, 29(4), 691-695. 
doi:10.1188/02.ONF.691-695  
Jones, G. T., Power, C., & Macfarlane, G. J. (2009). Adverse events in childhood and 
chronic widespread pain in adult life: Results from the 1958 British Birth Cohort 
Study. Pain, 143(1-2), 92-96. doi:10.1016/j.pain.2009.02.003 
Jones, K. D., Kindler, L. L., & Liptan, G. L. (2011). Self-management in fibromyalgia. 
Journal of Clinical Rheumatology & Musculoskeletal Medicine, 000(000), 1-10. 
Retrieved from http://www.slm-rheumatology.com 
Juuso, P., Skär, L., Olsson, M., & Söderberg, S. (2011). Living with a double burden: 
Meanings of pain for women with fibromyalgia. International Journal of 
Qualitative Studies on Health and Well-Being, 6(3), 1-9. 
doi:10.3402/qhw.v613.7244 
 Kano, M., Hamaguchi, T., Itoh, M., Yanai, K., & Fukudo, S. (2007). Correlation 
between alexithymia and hypersensitivity to visceral stimulation in human. Pain, 
174 
 
132(3), 252-263. doi:10.1016/j.pain.2007.01.032 
Kelley, G. A., Kelley, K. S., & Jones, D. L. (2011). Efficacy and effectiveness of exercise 
on tender points in adults with fibromyalgia: A meta-analysis of randomized 
controlled trials. Arthritis, 2011, Article ID 125485, 1-10. 
doi:10.1155/2011/125485  
Kerns, R. D., Sellinger, J., & Goodin, B. R. (2011). Psychological treatment of chronic 
pain. Annual Review of Clinical Psychology, 7(1), 411-434. doi:10.1146/annurev-
clinpsy-090310-120430 
Kim, S. H., Kim, Y. H., Kim, H. J., Lee, S.-H., & Yu, S. O. (2009). The effect of laughter 
therapy on depression, anxiety, and stress in patients with breast cancer 
undergoing radiotherapy. Journal of Korean Oncology Nursing, 9(2), 155-162. 
Retrieved from http://www.koreamed.org 
Kim, S. H., Kook, J. R., Kwon, M., Son, M. H., Ahn, S. D., & Kim, Y. H. (2015). The 
effects of laughter therapy on mood state and self-esteem in cancer patients 
undergoing radiation therapy: A randomized controlled trial. Journal of 
Alternative and Complementary Medicine, 21(4), 217-222. 
doi:10.1089/acm.2014.0152  
Kimata, H. (2004). Effect of viewing a humorous vs. nonhumorous film on bronchial 
responsiveness in patients with bronchial asthma. Physiology & Behavior, 81(4), 
681-684. doi:10.1016/j.physbeh.2004.03.010  
Kimata, H. (2007a). Increase in dermicidin-derived peptides in sweat of patients with 
atopic eczema caused by a humorous video. Journal of Psychosomatic Research, 
175 
 
62(1), 57-59. doi:10.1016/j.jpsychores.2006.05.006  
Kimata, H. (2007b). Laughter elevates the levels of breast-milk melatonin. Journal of 
Psychosomatic Research, 62(6), 699-702. doi:10.1016/j.jpsychores.2006.12.007 
Kimata, H. (2009). Viewing a humorous film decreases IgE production by seminal B 
cells from patients with atopic eczema. Journal of Psychosomatic Research, 
66(2), 173-175. doi:10.1016/j,jpsychores.2008.06.006  
Kleinman, N., Harnett, J., Melkonian, A., Lynch, W., Kaplan-Machlis, B., & Silverman, 
S. L. (2009). Burden of fibromyalgia and comparisons with osteoarthritis in the 
workforce. Journal of Occupational and Environmental Medicine, 51(12), 1384-
1393. doi:10.1097/JOM.0b013e3181bb808b  
Ko, H.-J., & Youn, C.-H. (2011). Effects of laughter therapy on depression, cognition and 
sleep among the community-dwelling elderly. Geriatrics & Gerontology 
International, 11(3), 267-274. doi:10.1111/j.1447-0594.2010.00680.x 
Kong, M., Shin, S. H., Lee, E., & Yun, E. K. (2014). The effect of laughter therapy on 
radiation dermatitis in patients with breast cancer: A single-blind prospective pilot 
study. OncoTargets and Therapy, 7, 2053-2059. doi:10.2147/OTT.S72973   
Kuiper, N. A., & Martin, R. A. (1998). Laughter and stress in daily life: Relation to 
positive and negative affect. Motivation and Emotion, 22(2), 133-153. Retrieved 
from http://www.springer.com/psychology/journal/11031   
Lachaine, J., Beauchemin, C., & Landry, P.-A. (2010). Clinical and economic 
characteristics of patients with fibromyalgia. Clinical Journal of Pain, 26(4), 284-
290. doi:10.1097/AJP.0b013e3181cf599f  
176 
 
Langhorst, J., Klose, P., Musial, F., Irnich, D., & Häuser, W. (2010). Efficacy of 
acupuncture in fibromyalgia syndrome—a systematic review with a meta-analysis 
of controlled clinical trials. Rheumatology, 49(4), 778-788. 
doi:10.1093/rheumatology/kep439 
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A.,… 
Wolfe, F. (2008). Estimates of the prevalence of arthritis and other rheumatic 
conditions in the United States: Part II. Arthritis & Rheumatism, 58(1), 26-35. 
doi:10.1002/art.23176 
Lebowitz, K. R., Suh, S., Diaz, P. T., & Emery, C. F. (2011). Effects of humor and 
laughter on psychological functioning, quality of life, health status, and 
pulmonary functioning among patients with chronic obstructive pulmonary 
disease: A preliminary investigation. Heart & Lung: The Journal of Acute and 
Critical Care, 40(4), 310-319. doi:10.1016/j.hrtlng.2010.07.010 
Lempp, H. K., Hatch, S. L., Carville, S. F., & Choy, E. H. (2009). Patients’ experiences 
of living with and receiving treatment for fibromyalgia syndrome: A qualitative 
study. BMC Musculoskeletal Disorders, 10, 124-134. doi:10.1186/1471-2474-10-
124 
Lengacher, C. A., Bennett, M. P., Kip, K. E., Keller, R., LaVance, M. S., Smith, L. S., & 
Cox, C. E. (2002). Frequency of use of complementary and alternative medicine 
in women with breast cancer. Oncology Nursing Forum, 29(10), 1445-1452. 
doi:10.1188/02.ONF.1445-1452 
Loeser, J. D., Butler, S. H., Chapman, C. R., & Turk, D. C. (2001). Bonica’s 
177 
 
Management of Pain (3rd ed.; Electronic Version). Retrieved from the Walden 
Library Books database. 
Lönnqvist, J.-E., Paunonen, S., Verkasalo, M., Leikas, S., Tuulio-Henriksson, A., & 
Lönnqvist, J. (2007). Personality characteristics of research volunteers. European 
Journal of Personality, 21(8), 1017-1030. doi:10.1002/per.655  
Mahony, D. L., Burroughs, W. J., & Hieatt, A. C. (2001). The effects of laughter on 
discomfort thresholds: Does expectation become reality? Journal of General 
Psychology, 128(2), 217-226. doi:10.1080/00221300109598909 
Mahony, D. L., Burroughs, W. J., & Lippman, L. G. (2002). Perceived attributes of 
health-promoting laughter: A cross-generational comparison. Journal of 
Psychology, 136(2), 171-181. doi:10.1080/00223980209604148 
Makino, S., Jensen, M. P., Arimura, T., Obata, T., Anno, K., Iwaki, R.,… Hosoi, M. 
(2013). Alexithymia and chronic pain: The role of negative affectivity. Clinical 
Journal of Pain, 29(4), 354-361. doi:10.1097/AJP.0b013e3182579c63 
Maletic, V., & Raison, C. L. (2009). Neurobiology of depression, fibromyalgia, and 
neuropathic pain. Frontiers in Bioscience, 14(1), 5291-5338. doi:10.2741/3598 
Martin, R. A., & Kuiper, N. A. (1999). Daily occurrence of laughter: Relationships with 
age, gender, and Type A personality. Humor, 12(4), 355-384. 
doi:10.1515/humr.1999.12.4.355 
Martínez, M. P., Sánchez, A. I., Miró, E., Lami, M. J., Prados, G., & Morales, A. (2014). 
Relationships between physical symptoms, emotional distress, and pain appraisal 
in fibromyalgia: The moderator effect of alexithymia. Journal of Psychology: 
178 
 
Interdisciplinary and Applied, 00(0), 1-26. doi:10.1080/00223980.2013.844673 
Martinez-Lavin, M. (2012). Fibromyalgia: When distress becomes (un)sympathetic pain. 
Pain Research and Treatment, 2012, 1-6. doi:10.1155/2012/981565 
Matsuzaki, T., Nakajima, A., Ishigami, S., Tanno, M., & Yoshino, S. (2006). Mirthful 
laughter differentially affects serum pro- and anti-inflammatory cytokine levels 
depending on the level of disease activity in patients with rheumatoid arthritis. 
Rheumatology, 45(2), 182-186. doi:10.1093/rheumatology/kei081 
McAllister, M. (2015). Neuromatrix of pain: What is the neuromatrix of pain? Institute 
for Chronic Pain. Retrieved from 
http://www.instituteforchronicpain.org/understanding-chronic-pain/what-is-
chronic-pain/neuromatrix-of-pain 
McAllister, S. J., Vincent, A., Hassett, A. L., Whipple, M. O., Oh, T. H., Benzo, R. P., & 
Toussaint, L. L. (2013). Psychological resilience, affective mechanisms and 
symptom burden in a tertiary-care sample of patients with fibromyalgia. Stress 
Health (Dec 2013). doi:10.1002/smi.2555 
McCrae, R. R., & John, O. P. (1992). An introduction to the five factor model and its 
applications. Journal of Personality, 60(2), 175-215. doi:10.1111/j.1467-
6494.1992.tb00970.x 
McMahon, L., Murray, C., Sanderson, J., & Daiches, A. (2012). “Governed by the pain”: 
Narratives of fibromyalgia. Disability & Rehabilitation, 34(16), 1358-1366. 
doi:10.3109/09638288.2011.645114 
Mease, P. (2005). Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, 
179 
 
outcome measures, and treatment [Abstract]. Journal of Rheumatology, 75, 6-21. 
Retrieved from http://www.jrheum.org 
Mease, P., Arnold, L. M., Choy, E. H., Clauw, D. J., Crofford, L. J., Glass, J. M., . . . 
Williams, D. A. (2009). Fibromyalgia syndrome module at OMERACT 9: 
Domain construct. Journal of Rheumatology, 36(10), 2318-2329. 
doi:10.3899/jrheum.090367 
Melzack, R. (1993). Pain: Past, present, and future. Canadian Journal of Experimental 
Psychology, 47(4), 615-629. doi:10.1037/h0078871 
Melzack, R. (1999a). From the gate to the neuromatrix. Pain, 82(Supp. 6), S121-S126. 
doi:10.1016/S0304-3959(99)00145-1 
Melzack, R. (1999b). Pain—an overview. Acta Anaesthesiologica Scandinavica, 43(9), 
880-884. doi:10.1034/j.1399-6576.1999.430903.x 
Melzack, R. (2001). Pain and the neuromatrix in the brain. Journal of Dental Education, 
65(12), 1378-1382. Retrieved from http://www.jdentaled.org/ 
Melzack, R. (2005). Evolution of the neuromatrix theory of pain. The Prithvi Raj lecture: 
Pain Practice, 5(2), 85-94. doi:10.1111/j.1533-2500.2005.05203.x  
Melzack, R. (2008). The future of pain. Nature Reviews. Drug Discovery, 7(8), 629. 
doi:10.1038/nrd2640   
Melzack, R., & Wall, P. (1965). Pain mechanisms: A new theory. Science, 150(3699), 
971-979. doi:10.1126/science.150.3699.971 
Menzies, V., Taylor, A. G., & Bourguignon, C. (2006). Effects of guided imagery on 
outcomes of pain, functional status, and self-efficacy in persons diagnosed with 
180 
 
fibromyalgia. Journal of Alternative and Complementary Medicine, 12(1), 23-30. 
doi:10.1089/acm.2006.12.23 
Merskey, H. (2008). Social influences on the concept of fibromyalgia. CNS Spectrums, 
13(3, Supp. 5), 18-21. Retrieved from http://www.cnsspectrums.com/default.aspx 
Merskey, H., & Bogduk, N. (Eds.). (1994). Classification of chronic pain: Descriptions 
of chronic pain syndromes and definitions of pain terms. Seattle, WA: IASP 
Press. Retrieved from http://www.iasp-
pain.org/files/Content/ContentFolders/Publications2/FreeBooks/Classification-of-
Chronic-Pain.pdf 
Mist, S. D., Firestone, K. A., & Jones, K. D. (2013). Complementary and alternative 
exercise for fibromyalgia: A meta-analysis. Journal of Pain Research, 6, 247-260. 
doi:http://dx.doi.org/10.2147/JPR.S32297 
Mora-Ripoll, R. (2010). The therapeutic value of laughter in medicine.  Alternative 
Therapies in Health and Medicine, 16(6), 56-64. Retrieved from 
http://www.alternative-therapies.com 
Mora-Ripoll, R. (2011). Potential health benefits of simulated laughter: A narrative 
review of the literature and recommendations for future research. Complementary 
Therapies in Medicine, 19(3), 170-177. doi:10.1016/j.ctim.2011.05.003 
Myers, I. B., McCaulley, M. H., Quenk, N. L., & Hammer, A. L. (1998). The MBTI® 
manual: A guide to the development and use of the Myers-Briggs Type Indicator 
(3rd ed.). Palo Alto, CA: Consulting Psychologists Press.    
Nasir, U. M., Iwanaga, S., Nabi, A. H., Urayama, O., Hayashi, K., Hayashi, T.,… Suzuki, 
181 
 
F. (2005). Laughter therapy modulates the parameters of renin-angiotensin system 
in patients with type 2 diabetes. International Journal of Molecular Medicine, 
16(6), 1077-1081. Retrieved from http://www.spandidos-publications.com/ijmm/ 
 National Fibromyalgia Association (NFA). (2009). About fibromyalgia. Retrieved from 
http://www.fmaware.org  
Neuhoff, C. C., & Schaefer, C. (2002). Effects of laughing, smiling, and howling on 
mood. Psychological Reports, 91(8), 1079-1080. doi:10.2466/PRO.91.8.1079-
1080 
Okifuji, A., Bradshaw, D. H., Donaldson, G. W., & Turk, D. C. (2011). Sequential 
analyses of daily symptoms in women with fibromyalgia syndrome. Journal of 
Pain, 12(1), 84-93. doi:10.1016/j.jpain.2010.05.003 
Oncu, J., Iliser, R., & Kuran, B. (2013). Do new diagnostic criteria for fibromyalgia 
provide treatment opportunity to those previously untreated? Journal of Back and 
Musculoskeletal Rehabilitation, 26, 437-443. doi:10.3233/BMR-130403 
Ozcetin, A., Ataoglu, S., Kocer, E., Yazycy, S., Yildiz, O., Ataoglu, A., & Ycmeli, C. 
(2007). Effects of depression and anxiety on quality of life of patients with 
rheumatoid arthritis, knee osteoarthritis, and fibromyalgia syndrome. West Indian 
Medical Journal, 56(2), 122-129. doi:10.1590/S0043-31442007000200004   
Palacio, A., Uribe, C. L., Li, H., Hanna, J., Deminski, M., Alvir, J.,… Sanchez, R. 
(2010). Financial and clinical characteristics of fibromyalgia: A case-control 
comparison. American Journal of Managed Care, 16(5), S118-S125. Retrieved 
from http://www.ajmc.com/ 
182 
 
Pallant, J. (2010). SPSS Survival Manual (4th ed.). New York, NY: McGraw-Hill. 
Paquet, C., Kergoat, M.-J., & Dubé, L. (2005). The role of everyday emotion regulation 
on pain in hospitalized elderly: Insights from a prospective within-day 
assessment. Pain, 115(3), 355-363. doi:10.1016/j.pain.2005.03.024 
Parker, J. D., Bagby, R. M., Taylor, G. J., Endler, N. S., & Schmitz, P. (1993). Factorial 
validity of the 20-item Toronto Alexithymia Scale. European Journal of 
Personality, 7(4), 221-232. doi:10.1002/per.2410070403   
Parker, J. D., Taylor, G. J., & Bagby, R. M. (2003). The 20-item Toronto Alexithymia 
Scale. III. Reliability and factorial validity in a community population. Journal of 
Psychosomatic Research, 55(3), 269-275. doi:10.1016/S0022-3999(02)00578-0   
Peres, J. F., Gonçalves, A. L., & Peres, M. F. (2009). Psychological trauma in chronic 
pain: Implications of PTSD for fibromyalgia and headache disorders. Current 
Pain and Headache Reports, 13(5), 350-357. doi:10.1007/s11916-009-0057-2 
Peterson, E. L. (2007). Fibromyalgia—management of a misunderstood disorder. Journal 
of the American Academy of Nurse Practitioners, 19(7), 341-348. 
doi:10.1111/j.1745-7599.2007.00235.x 
Phillips, L. J., & Stuifbergen, A. K. (2010). The relevance of depressive symptoms and 
social support to disability in women with multiple sclerosis or fibromyalgia. 
International Journal of Rehabilitation Research, 33(2), 142-150. 
doi:10.1097/MRR.0b013e3283310cce 
Prins, M. A., Woertman, L., Kool, M. B., & Geenen, R. (2006). Sexual functioning of 
women with fibromyalgia. Clinical and Experimental Rheumatology, 24(5), 555-
183 
 
561. Retrieved from http://www.clinexprheumatol.org/ 
 Raphael, K. G., Janal, M. N., Nayak, S., Schwartz, J. E., & Gallagher, R. M. (2004). 
Familial aggregation of depression in fibromyalgia: A community-based test of 
alternate hypotheses. Pain, 110(1), 449-460. Retrieved from 
http://www.journals.elsevier.com/pain/ 
Reilly, P. A., & Littlejohn, G. O. (1993). Diurnal variation in the symptoms and signs of 
the fibromyalgia syndrome. Journal of Musculoskeletal Pain, 1(3-4), 237-243. 
doi:10.1300/J094v01n03-25 
Rico-Villademoros, F., Calandre, E. P., Rodriguez-López, C. M., García-Carrillo, J., 
Ballesteros, J., Hidalgo-Tallón, J., & García-Leiva, J. M. (2012). Sexual 
functioning in women and men with fibromyalgia. Journal of Sexual Medicine, 
9(2), 542-549. doi:10.1111/j.1743-6109.2011.02513.x  
Riley, J. L., Robinson, M. E., & Price, D. D. (2000). The stages of pain processing across 
the adult lifespan. Journal of Pain, 1(2), 162-170. doi:10.1016/S1526-
5900(00)90101-9  
Rodero, B., Casanueva, B., Luciano, J. V., Gili, M., Serrano-Blanco, A., & García-
Campayo, J. (2011). Relationship between behavioural coping strategies and 
acceptance in patients with fibromyalgia syndrome: Elucidating targets of 
interventions. BioMed Central Musculoskeletal Disorders, 12(143), 1-9. 
Retrieved from https://www.biomedcentral.com/bmcmusculoskeletdisord 
Ruiz-Aranda, D., Salguero, J. M., & Fernández-Berrocal, P. (2010). Emotional regulation 
and acute pain perception in women. Journal of Pain, 11(6), 564-569. 
184 
 
doi:10.1016/j.jpain.2009.09.011  
Sakuragi, S., Sugiyama, Y., & Takeuchi, K. (2002). Effects of laughing and weeping on 
mood and heart rate variability. Journal of Physiological Anthropology and 
Applied Human Science, 21(3), 159-165. doi:10.2114/jpa.21.159 
Saliba, A., & Ostojic, P. (2014). Personality and participation: Who volunteers to 
participate in studies. Psychology, 5(3), 230-243. doi:10.4236/psych.2014.53034 
Salminen, J. K., Saarijärvi, S., Äärelä, E., Toikka, T., & Kauhanen, J. (1998). Prevalence 
of alexithymia and its association with sociodemographic variables in the general 
population of Finland. Journal of Psychosomatic Research, 46(1), 75-82. 
doi:10.1016/S0022-3999(98)00053-1  
Sanchez, R. J., Uribe, C., Li, H., Alvir, J., Deminiski, M., Chandran, A., & Palacio, A. 
(2011). Longitudinal evaluation of health care utilization and costs during the first 
three years after a new diagnosis of fibromyalgia. Current Medical Research & 
Opinion, 27(3), 663-671. doi:10.1185/03007995.2010.550605  
Schmidt, S., Grossman, P., Schwarzer, B., Jena, S., Naumann, J. (2011). Treating 
fibromyalgia with mindfulness-based stress reduction: Results from a 3-armed 
randomized controlled trial. Pain, 152(2), 361-369. 
doi:10.1016/j.pain.2010.10.043 
Sephton, S. E., Salmon, P., Weissbecker, I., Ulmer, C., Floyd, A., Hoover, K., & Studts, 
J. L. (2007). Mindfulness meditation alleviates depressive symptoms in women 
with fibromyalgia: Results of a randomized clinical trial. Arthritis & Rheumatism, 
57(1), 77-85. doi:10.1002/art.22478  
185 
 
Sicras-Mainar, A., Rejas, J., Navarro, R., Blanca, M., Morcillo, A., Larios, 
R.,…Villarroya, C. (2009). Treating patients with fibromyalgia in primary care 
settings under routine medical practice: A claim database cost and burden of 
illness study.  Arthritis Research & Therapy, 11(2), R54-R67. doi:10.1186/ar2673 
Sifneos, P. E. (1973). The prevalence of ‘alexithymic’ characteristics in psychosomatic 
patients. Psychotherapy and Psychosomatics, 22(2-6), 255-262. 
doi:10.1159/000286529 
Sim, J., & Madden, S. (2008). Illness experience in fibromyalgia syndrome: A 
metasynthesis of qualitative studies. Social Science & Medicine, 67(1), 57-67. 
doi:10.1016/j.socscimed.2008.03.003 
Skorupska, E., Bednarek, A., & Samborski, W. (2013). Tender points and trigger 
points—Differences and similarities. Journal of Musculoskeletal Pain, 21(3), 
269-275. doi:10.3109/10582452.2013.827773  
Spaeth, M. (2009). Epidemiology, costs, and the economic burden of fibromyalgia. 
Arthritis Research & Therapy, 11(3), 117-118. doi:10.1186/ar2715 
Staud, R., Price, D. D., Robinson, M. E., & Vierck, C. J., Jr. (2004). Body pain area and 
pain-related negative affect predict clinical pain intensity in patients with 
fibromyalgia. Journal of Pain, 5(6), 338-343. doi:10.1016/j.jpain.2004.05.007  
Staud, R., Vierck, C. J., Robinson, M. E., & Price, D. D. (2006). Overall fibromyalgia 
pain is predicted by ratings of local pain and pain-related negative affect—
possible role of peripheral tissues. Rheumatology, 45(11), 1409-1415. 
doi:10.1093/rheumatology/kel121 
186 
 
Steinweg, D. L., Dallas, A. P., & Rea, W. S. (2011). Fibromyalgia: Unspeakable 
suffering: A prevalence study of alexithymia. Psychosomatics, 52(3), 255-262. 
doi:10.1016/j.psym.2010.12.022  
Stevens, J. P. (2009). Applied multivariate statistics for the social sciences (5th ed.). 
Mahwah, NJ: Routledge Academic.  
Stuber, M., Hilber, S. D., Mintzer, L. L., Castaneda, M., Glover, D., & Zeltzer, L. (2009). 
Laughter, humor, and pain perception in children: A pilot study. Evidence Based 
Complementary and Alternative Medicine, 6(2), 271-276. 
doi:10.1093/ecam/nem097 
Sueiro, B. F., Estévez, S. I., Ayán, C., Cancela, J. M., & Martin, V. (2008). Potential 
benefits of non-pharmacological therapies in fibromyalgia. Open Rheumatology 
Journal, 2, 1-6. Retrieved from http://www.benthamscience.com/open/torj/ 
Sugawara, J., Tarumi, T., & Tanaka, H. (2010). Effect of mirthful laughter on vascular 
function. American Journal of Cardiology, 106(6), 856-859. 
doi:10.1016/j.amjcard.2010.05.011 
Sullivan, M. J., Bishop, S. R., & Pivik, J. (1995). The Pain Catastrophizing Scale: 
Development and validation. Psychological Assessment, 7(4), 524-532. 
doi:10.1037/1040-3590.7.4.524 
Svebak, S. (1974). A theory of sense of humor. Scandinavian Journal of Psychology, 
15(1), 99-107. doi:10.1111/j.1467-9450.1974.t600561.x 
Svebak, S., Kristoffersen, B., & Aasarød, K. (2006). Sense of humor and survival among 
a county cohort of patients with end-stage renal failure: A two-year prospective 
187 
 
study. International Journal of Psychiatry in Medicine, 36(3), 269-281. 
doi:10.2190/EFDR-CMDW-X8MH-WKUD 
Takeda, M., Hashimoto, R., Kudo, T., Okochi, M., Tagami, S., Morihara, T.,… Tanaka, 
T. (2010). Laughter and humor as complementary and alternative medicines for 
dementia patients. BMC Complementary and Alternative Medicine, 10(1), 28-34. 
doi:10.1186/1472-6882-10-28   
Tang, N. K., Salkovskis, P. M., Hodges, A., Wright, K. J., Hanna, M., & Hester, J. 
(2008). Effects of mood on pain responses and pain tolerance: An experimental 
study in chronic back pain patients. Pain, 138(2), 392-401. 
doi:10.1016/j.pain.2008.01.018 
Terhorst, L., Schneider, M. J., Kim, K. H., Goozdich, L. M., & Stilley, C. S. (2011). 
Complementary and alternative medicine in the treatment of pain in fibromyalgia: 
A systematic review of randomized controlled trials. Journal of Manipulative and 
Physiological Therapeutics, 34(7), 483-496. doi:10.1016/j.jmpt.2011.05.006 
Theadom, A., Cropley, M., & Humphrey, K.-L. (2007). Exploring the role of sleep and 
coping in quality of life in fibromyalgia. Journal of Psychosomatic Research, 
62(2), 145-151. doi:10.1016/j.jpsychores.2006.09.013 
Thieme, K., Turk, D. C., & Flor, H. (2004). Comorbid depression and anxiety in 
fibromyalgia syndrome: Relationship to somatic and psychosocial variables. 
Psychosomatic Medicine, 66(6), 837-844. 
doi:10.1097/01.psy.0000146329.63158.40 
Toda, M., Kusakabe, S., Nagasawa, S., Kitamura, K., & Morimoto, K. (2007). Effect of 
188 
 
laughter on salivary endocrinological stress marker chromogranin A. Biomedical 
Research, 28(2), 115-118. doi:10.2220/biomedres.28.115 
Tooyserkani, M. A., Besharat, M. A., & Koochi, S. (2011). The moderating role of 
positive and negative affects on the relationship between alexithymia and 
experience of pain in chronic pain patients. Procedia – Social and Behavioral 
Sciences, 30, 154-158. doi:10.1016/j.sbspro.2011.10.030 
Traska, T. K., Rutledge, D. N., Mouttapa, M., Weiss, J., & Aquino, J. (2011). Strategies 
used for managing symptoms by women with fibromyalgia. Journal of Clinical 
Nursing, 21(5-6), 626-635. doi:10.1111/j.1365-2702.2010.03501.x 
Tsao, J. C. (2007). Effectiveness of massage therapy for chronic, non-malignant pain: A 
review. Evidence-Based Complementary and Alternative Medicine, 4(2), 165-179. 
doi:10.1093/ecam/nel109 
Tse, M. M., Lo, A. P., Cheng, T. L., Chan, E. K., Chan, A. H., & Chung, H. S. (2010). 
Humor therapy: Relieving chronic pain and enhancing happiness for older adults. 
Journal of Aging Research, 2010, 1-9. doi:10.4061/2010/343574 
Turk, D. C., Swanson, K. S., & Tunks, E. R. (2008). Psychological approaches in the 
treatment of chronic pain patients—When pills, scalpels, and needles are not 
enough. Canadian Journal of Psychiatry, 53(4), 213-223. Retrieved from 
http://publications.cpa-apc.org/browse/sections/0 
Uguz, F., Ҫiҫek, E., Salli, A., Karahan, A. Y., Albayrak, I., Kaya, N., & Uğurlu, H. 
(2010). Axis I and axis II psychiatric disorders in patients with fibromyalgia. 
General Hospital Psychiatry, 32(1), 105-107. 
189 
 
doi:10.1016/j.genhosppsych.2009.07.002    
Van Der Laan. (2013). Rehab measures: Numeric Pain Rating Scale. Retrieved from 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=891 
van Middendorp, H., Lumley, M. A., Jacobs, J. W., Bijlsma, J. W., & Geenen, R. (2010). 
The effects of anger and sadness on clinical pain reports and experimentally-
induced pain thresholds in women with and without fibromyalgia. Arthritis Care 
& Research, 62(10), 1370-1376. doi:10.1002/acr.20230   
van Middendorp, H., Lumley, M. A., Jacobs, J. W., van Doornen, L. J., Bijlsma, J. W., & 
Geenen, R. (2008). Emotions and emotional approach and avoidance strategies in 
fibromyalgia. Journal of Psychosomatic Research, 64(2), 159-167. 
doi:10.1016/j.jpsychores.2007.08.009 
Verbunt, J. A., Pernot, D. H., & Smeets, R. J. (2008). Disability and quality of life in 
patients with fibromyalgia. Health and Quality of Life Outcomes, 6(1), 1-8. 
doi:10.1186/1477-7525-6-8 
Verkaik, R., Busch, M., Koeneman, T., Van den Berg, R., Spreeuwenberg, P., & Francke, 
A. L. (2014). Guided imagery in people with fibromyalgia: A randomized clinical 
trial of effects on pain, functional status, and self-efficacy. Journal of Health 
Psychology, 19(5), 678-688. doi:10.1177/1359105313477673 
Wagner, J.-S., DiBonaventura, M. D., Chandran, A. B., & Cappelleri, J. C. (2012). The 
association of sleep difficulties with health-related quality of life among patients 
with fibromyalgia. BioMed Central Musculoskeletal Disorders, 13(1), 199-208. 
doi:10.1186/1471-2474-13-199 
190 
 
Walter, M., Hänni, B., Haug, M., Amrhein, I., Krebs-Roubicek, E., Müller-Spahn, F., & 
Savaskan, E. (2007). Humour therapy in patients with late-life depression or 
Alzheimer’s disease: A pilot study. International Journal of Geriatric Psychiatry, 
22(1), 77-83. doi:10.1002/gps.1658 
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2015). 
Fibromyalgia diagnosis: A review of the past, present and future. Expert Review 
of Neurotherapeutics, 15(6), 667-679. doi:10.1586/14737175.2015.1046841   
Watson, D., Clark, L. A., & Tellegen, A. (1988). Development and validation of brief 
measures of positive and negative affect: The PANAS scales. Journal of 
Personality and Social Psychology, 54(6), 1063-1070. doi:10.1037//0022-
3514.54.6.1063 
Weisenberg, M., Raz, T., & Hener, T. (1998). The influence of film-induced mood on 
pain perception. Pain, 76(3), 365-375. doi:10.1016/S0304-3959(98)00069-4  
White, L. A., Robinson, R. L., Yu, A. P., Kaltenboeck, A., Samuels, S., Mallett, D., & 
Birnbaum, H. G. (2009). Comparison of health care use and costs in newly 
diagnosed and established patients with fibromyalgia. Journal of Pain, 10(9), 
976-983. doi:10.1016/j.jpain.2009.03.012 
Willoughby, S. G., Hailey, B. J., Mulkana, S., & Rowe, J. (2002). The effect of 
laboratory-induced depressed mood state on responses to pain. Behavioral 
Medicine, 28(1), 23-31. doi:10.1080/08964280209596395  
Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Häuser, W., Katz, R. 
S.,… Winfield, J. B. (2011). Fibromyalgia criteria and severity scales for clinical 
191 
 
and epidemiological studies: A modification of the ACR preliminary diagnostic 
criteria for fibromyalgia. Journal of Rheumatology, 38(6), 1113-1122. 
doi:10.3899/jrheum.100594  
Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Katz, R. S., Mease, P.,… 
Yunus, M. B. (2010). The American College of Rheumatology preliminary 
diagnostic criteria for fibromyalgia and measurement of symptom severity. 
Arthritis Care & Research, 62(5), 600-610. doi:10.1002/acr.20140 
Wolfe, F., Hassett, A. L., Walitt, B., & Michaud, K. (2011). Mortality in fibromyalgia: A 
study of 8,186 patients over 35 years. Arthritis Care & Research, 63(1), 94-101. 
doi:10.1002/acr.20301 
Wolfe, F., Häuser, W., Walitt, B. T., Katz, R. S., Rasker, J. J., & Russell, A. S. (2014). 
Fibromyalgia and physical trauma: The concepts we invent. Journal of 
Rheumatology, 41(9), 1-9. doi:10.3899/jrheum.140268     
Wolfe, F., & Michaud, K. (2009). Outcome and predictor relationships in fibromyalgia 
and rheumatoid arthritis: Evidence concerning the continuum versus discrete 
disorder hypothesis [Abstract]. Journal of Rheumatology, 36(4), 831-836. 
doi:10.3899/jrheum.080897  
Wolfe, F., Ross, K., Anderson, J., Russell, I. J., & Hebert, L. (1995). The prevalence and 
characteristics of fibromyalgia in the general population. Arthritis & Rheumatism, 
38(1), 19-28. doi:10.1002/art.1780380104 
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. 
L.,… Sheon, R. P. (1990). The American College of Rheumatology 1990 criteria 
192 
 
for the classification of fibromyalgia. Arthritis and Rheumatism, 33(2), 160-172. 
doi:10.1002/art.1780330203 
Woolfolk, R. L., Allen, L. A., & Apter, J. T. (2012). Affective-cognitive behavioral 
therapy for fibromyalgia: A randomized controlled trial. Pain Research and 
Treatment, 2012, 1-6. doi:10.1155/2012/937873 
Young, P. T. (1937). Laughing and weeping, cheerfulness and depression: a study of 
moods among college students. Journal of Social Psychology, 8(3), 311-334. 
doi:10.1080/00224545.1937.9920012 
Zautra, A. J., Fasman, R., Parish, B. P., & Davis, M. C. (2007). Daily fatigue in women 
with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Pain, 128(1-2), 128-
135. doi:10.1016/j.pain.2006.09.004 
Zautra, A. J., Fasman, R., Reich, J. W., Harakas, P., Johnson, L. M., Olmsted, M. E., & 
Davis, M. C. (2005). Fibromyalgia: Evidence for deficits in positive affect 
regulation. Psychosomatic Medicine, 67(1), 147-155. Retrieved from 
http://www.psychosomaticmedicine.org 
Zautra, A. J., Johnson, L. M., & Davis, M. C. (2005). Positive affect as a source of 
resilience for women in chronic pain. Journal of Consulting and Clinical 
Psychology, 73(2), 213-220. doi:10.1037/0022-006X.73.2.212 
Zautra, A., Smith, B., Affleck, G., & Tennen, H. (2001). Examinations of chronic pain 
and affect relationships: Applications of a dynamic model of affect. Journal of 
Consulting and Clinical Psychology, 69(5), 786-795. doi:10.1037//0022-
006X.69.5.786 
193 
 
Zweyer, K., Velker, B., & Ruch, W. (2004). Do cheerfulness, exhilaration, and humor 
production moderate pain tolerance? A FACS study. Humor, 17(1/2), 85-119. doi: 
10.1515/humr.2004.009  
 
  
194 
 
Appendix A: Release of Information 
Authorization to Use or Disclose PHI for Research Purposes 
The top portion of this form (above the dotted line) should be completed by the 
researcher.  A copy of the form should be given to the research participant for his/her 
personal records. 
 
Research Participant Name: ___________________________________ 
Phone: _______________ 
Address: ______________________________________________________________ 
Discloser of Information: ______________________ 
Recipient of Information: Deidre Molchan, MA 
Means of disclosing information (i.e., verbal, written, etc.):  Verbal, written, or 
electronic 
Information to be disclosed:     
School district/educational data 
Mental Health/psychological data 
Legal data   
Chemical dependency/abuse data 
Medical data  
Other (specify) Diagnosis Confirmation 
____________________________________________________    
Reason for the Release:  This information is being released/obtained for the purpose of 
Researcher confirming fibromyalgia syndrome diagnosis.  
 
--------------------------------------------------------------------------------------------------------- 
Authorization Provided by Research Participant:   
I understand that this authorization permits the release of information between the two 
parties named above.   
 
I understand that I have the right to refuse to sign this release form. 
 
I understand that upon release, this information will be kept confidential; my identity will 
be concealed and data will not be re-disclosed outside of the specified individuals or 
agencies.  
 
I understand a photocopy of this release will be as effective as the original. 
 
I understand this authorization will be in effect for 12 months from the date signed unless 
cancelled by me in writing.  Upon receipt of the written cancellation, this release will be 
void.  
 
______________________________________________________________________ 
Signature                                                                                                             Date 
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______________________________________________________________________ 
Witness              Date    
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Appendix B: TAS-20  
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Appendix C: Demographic Questionnaire 
ID #:_________   _____Female  ____Male 
Date: ________________       
 
Fibromyalgia Syndrome 
Demographic Information Form 
 
Marking Instructions: Please complete the choice which best reflects your experience.  
 
1. How old are you? _______ 
 
2. What is your ethnicity? _________________________ 
 
3. You are: 
�1 Married/Partnered 
�2 Single 
�3 Divorced 
�4 Widowed 
�5 Other: ______________________________ 
 
4. If you are married/partnered, do you live with your spouse? 
�1 Yes 
�2 No 
 
5a. Do you have any children? 
�1 Yes 
�2 No 
 
5b. How many children do you have? ____________ 
 
5c. How old are they? ________________________ 
 
5d. If your children are grown, where do they live? __________________ 
 
6. What is the highest grade you completed in school? (Check one) 
�1 8th grade or less 
�2 Some High School 
�3 High school graduate 
�4 Some college 
�5 College graduate 
�6 Post graduate work 
 
7. Are you currently employed? 
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�1 Yes 
�2 No 
 
7a. If you are employed, are you working: 
�1 Full-time 
�2 Part-time 
�3 Self-employed 
�4 Never worked outside the home 
 
7b. What is your occupation (if retired, what was your occupation)? 
____________________ 
 
7c. If you are retired, when did you retire? ______________ 
 
8. What is your average yearly family income? (Check one) 
�1 < $15,000: 
�2 $15,000-29,000: 
�3 $30,000-44,000: 
�4 $45,000-59,000: 
�5 $60,000-74,000: 
�6 $75,000-89,000 
�7 $90,000-114,000 
�8 $115,000-129,000 
�9 $130,000-200,000 
�10 $201,000-500,000 
�11 $501,000-1,000,000 
�12  > $1,000,000  
 
9. When were you first diagnosed with fibromyalgia syndrome?  
______________________ 
 
10a. As a result of your fibromyalgia syndrome diagnosis, have you had a change in 
income? 
�1 Yes 
�2 No 
 
10b. If yes, have you had: 
�1 Increased Income 
�2 Decreased Income 
�3 No change in Income 
 
11a. Are you taking any medications for symptom management?  
�1 Yes 
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�2 No 
 
11b. If yes, please list the medications and dosages below: 
 
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
12a. Have you engaged in any alternative therapies or activities as an adjunct to 
conventional medical treatment for fibromyalgia symptom management?  
�1 Yes 
�2 No 
 
12b. If yes, please list those alternative therapies or activities  
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
 
13a. Have you been diagnosed with other medical conditions in addition to 
fibromyalgia syndrome?  
�1 Yes 
�2 No 
 
13b. If yes, please list those diagnoses  
�_________________________ 
 
�_________________________ 
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�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
�_________________________ 
 
 
14a. Have you ever seen a mental health professional to help you cope with your 
fibromyalgia symptoms? 
�1 Yes 
�2 No 
 
14b. If yes, what type of mental health professional was it? 
�1 Psychologist 
�2 Psychiatrist 
�3 Social worker 
�4 MFCC 
�5 Other 
 
14c. If yes, for how long did you see this person? ________ 
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Appendix D: Positive and Negative Affect Schedule (PANAS) 
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Appendix E: Pain Intensity—Numeric Rating Scale (PI-NRS) 
Retrieved 10 May 2015, from 
http://www.painedu.org/downloads/nipc/pain%20assessment%20scales.pdf 
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Appendix F: DLR  
ID#_______________ 
Daily Laughter Record 
 (Martin & Kuiper, 1999; adapted with permission) 
Day____ (1 – 14)         Date__________________ 
Laughter 
Occurrence 
Time Stimulus 
M= Mass 
Media  
S= 
Spontaneous 
Situation 
J= Joke 
E= Event 
Strength of 
Laughter 
1 = silent 
chuckle/forceful 
exhale or snort 
2 = a little bit of 
laughter 
3 = a lot of 
laughter 
 
Who 
Caused the 
Laughter? 
S = Self 
O = Other 
(family, 
friend, pets, 
etc.) 
Were 
Others 
Present? 
Y or N. 
1  
 
    
2  
 
    
3  
 
    
4  
 
    
5  
 
    
6  
 
    
7  
 
    
8  
 
    
9  
 
    
10  
 
    
11  
 
    
12  
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Appendix G: Emergency Guidance 
Emergency Guidance 
It is unlikely, and not anticipated, that you will experience any increased distress 
or worsening mood issues due to your participation in this study. However, if your 
symptoms worsen during the course of the study and you feel as if you are at significant 
risk of harming yourself or others, please call 911 or go to your nearest emergency room. 
If the need is less emergent, please contact your primary care physician as soon as 
possible or schedule an appointment with a local community mental health center. 
Alternatively, you may consider reaching out to one of the telephone or online chat 
hotlines listed below, or you may also contact the researcher, Deidre Molchan, at XXX-
XXX-XXXX or via email at XXX@waldenu.edu.  
Crisis Hotlines: 
National Hopeline Network 
(800) SUICIDE 
National Suicide Prevention Lifeline 
(800) 273-TALK (8255) 
Online Crisis Hotlines with Chat Function: 
http://www.suicidepreventionlifeline.org/GetHelp/LifelineChat.aspx 
http://www.crisischat.org/ 
*Hotline information retrieved from http://psychcentral.com/lib/common-hotline-phone-
numbers/   
Participants Outside of the United States: 
UK or Ireland: http://www.samaritans.org 
Other Countries: Befrienders International—Helplines for over 40 countries. 
http://www.befrienders.org 
 
 
